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Summary 
 
Background 
Primary immune thrombocytopenia (ITP) is an autoimmune disease involving autoantibody-mediated platelet 
destruction, suboptimal platelet production, and T-cell-mediated platelet lysis. These processes cause a decreased 
peripheral blood platelet count (< 150 ! 109/L), resulting in an increased susceptibility to bleeding events. While the 
course of primary ITP is often acute (< 6 months) among children, it is generally chronic in adults. Despite a marked 
increase in epidemiological research over the past decade, unresolved questions remain with regard to disease 
pathogenesis, treatment effectiveness, and co-morbid burden among adults with primary ITP.   
 
Objectives  
1. To launch a registry for adults with primary ITP in the United Kingdom (UK) 
2. To evaluate associations of candidate single nucleotide polymorphisms (SNPs) with primary ITP    
3. To assess the effectiveness of 111In-labelled platelet studies in predicting outcomes from splenectomy  
4. To document health-related lifestyle concerns among patients  
5. To gauge the effectiveness of Helicobacter pylori (H. pylori) eradication in elevating platelet counts 
6. To characterise associations of primary ITP with both arterial and venous thromboembolic events (TEs)   
 
Data sources 
1. The UK Adult ITP Registry (17 centres, 327 patients) 
2. The UK Adult ITP Registry-affiliated, 111In-Labelled Platelet Study Database (117 centres, 256 patients) 
3. The Wellcome Trust Case-Control Consortium (WTCCC) 1958 British Birth Cohort (3,000 individuals) 
4. The General Practice Research Database (GPRD) (500+ centres, 4 million+ patients) 
5. The UK ITP Support Association Health-Related Lifestyle Survey (790 patients) 
6. Systematic reviews of published epidemiological studies 
 
Methods and Results 
SNP Study 
Caucasian patients from the UK Adult ITP Registry were gender-matched (1:3) with healthy controls from the 
WTCCC 1958 British Birth Cohort. Six functional candidate SNPs in cytokine or cytokine receptor genes were measured 
in cases and retrieved for controls from the European Genome-phenome Archive. Associations were evaluated using 
logistic regression models. A statistically significant per allele odds ratio (OR) of 1.34 (95% confidence interval [CI], 1.03-
1.75) was observed for TNFA -308 g>a, implicating increased disease susceptibility among carriers of the rare allele. 
 
111In Study 
The effectiveness of autologous 111In-labelled platelet sequestration studies in predicting short (1-3 months), 
medium (6-12 months), and long-term (last follow-up) complete response (CR; count < 100 ! 109/L) to splenectomy in 
patients with primary ITP was evaluated using multivariable logistic regression models. Significant adjusted (gender, age at 
splenectomy, and mean platelet lifespan) ORs were uncovered for short (7.47 [95% CI, 1.89-29.43], medium (4.85 [95% 
CI, 1.04-22.54]) and long-term (5.39 [95% CI, 1.34-21.65]) CR in patients with purely or predominantly splenic versus 
mixed or hepatic splenic platelet sequestration, highlighting the utility of platelet sequestration studies as an adjunct 
predictive tool prior to splenectomy. 
 
H. pylori Eradication Study 
A systematic literature review was conducted of studies evaluating the effects of H. pylori eradication on platelet 
count in patients with primary ITP. Twenty-five studies were identified, encompassing 696 evaluable patients. The 
weighted mean complete response (count > 100 ! 109/L) and overall response (platelet count > 30 ! 109/L) were 42.7% 
(95% CI, 31.8%-53.9%) and 50.3% (95% CI, 41.6%-59.0%), respectively. Observed responses were higher in countries with 
a higher prevalence of H. pylori infection and in patients with milder thrombocytopenia. These findings support the benefits 
of H. pylori detection and eradication in patients with primary ITP.  
 
Health-Related Lifestyle Study 
A 43-question, closed-field questionnaire was used to identify health-related lifestyle concerns among patient 
members of the UK Adult ITP Support Association. Completed surveys were returned by 790 (44.7%) members, with 
nearly one-third of adults reporting having an elective surgery delayed due to a low platelet count and experiencing 
difficulty in obtaining travel insurance. Notably, 12.5% of all patients reported “always” or “often” missing work or school 
due to fatigue. These results highlight several promising avenues for future health-related quality of life (HRQoL) research.   
 
Thromboembolic Event Studies 
Using the GPRD, 1,070 adults with primary ITP were matched (1:4) with 4,280 ITP-free controls by age, gender, 
practice, and observation time. Comparative risks of TEs were assessed using Cox proportional hazards models. Over a 
median time of 47.6 months (range: 3.0-192.5 months), adjusted hazard ratios of 1.58 (95% CI, 1.01-2.48) and 1.37 (95% 
CI, 0.94-2.00) were found for venous and arterial TEs, respectively. A similar investigation was conducted comparing age 
and sex-stratified incidence rates of TEs among patients in the UK Adult ITP Registry with population-based estimates for 
the general adult population, yielding significant standardised rate ratios of 2.43 (95% CI, 1.01-5.83) and 2.45 (95% CI, 
1.48-4.06) for venous and arterial TEs, respectively. These results collectively highlight an increased risk of venous and 
arterial TEs in adults with primary ITP. 
 
Conclusions 
Primary ITP is a pro-inflammatory (i.e., TH-1-mediated), pro-thrombotic disease in adults. Available evidence 
supports testing for and eradication of H. pylori infection in patients with primary ITP and the utility of autologous 111In-
labelled platelet sequestration studies in identifying patients likely to respond to splenectomy. The development of a 
prospective, international registry will help assemble the sample sizes needed for promising further research, namely 
genome-wide disease association studies and investigations into the effects of the eradication of strain-specific H. pylori 
infection on platelet count, the precise relative risk of non-response to splenectomy in patients with mixed or hepatic 
platelet sequestration, and the associations of TEs with primary ITP in antiphospholipid antibody-negative. 
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Preface 
The aim of this thesis was to further current understanding of primary immune 
thrombocytopenia (ITP) pathogenesis, treatment effectiveness, and co-morbid burden 
among adults. Results from investigations evaluating health-related lifestyle concerns among 
patients, the utility of a prognostic radioisotope test prior to splenectomy, the effectiveness 
of Helicobacter pylori (H. pylori) eradication in platelet count elevation, and primary ITP 
associations with both single nucleotide polymorphisms (SNPs) and thromboembolic events 
(TEs) are presented in 9 chapters. This thesis is the result of my own work and includes 
nothing done in collaboration except where specifically indicated (see Acknowledgements).  
The majority of data used in the aforementioned investigations was derived from the 
United Kingdom (UK) Adult ITP Registry, a repository of clinical data and biological samples 
of adult patients with primary ITP, which I developed and launched under the supervision of 
Dr. Drew Provan as part of my doctoral studies. Principle funding for the Registry was 
provided by GlaxoSmithKline (GSK). The pharmaceutical company had recently developed a 
thrombopoietin-agonist (eltrombopag) for the treatment of primary ITP and was interested 
in securing additional epidemiological data on the disease in the adult population. As will be 
discussed at length in Chapter 9 of this thesis, industry sponsorship of research is a 
necessary, albeit inherently problematic, reality of academic medicine. Cognizant of the 
potential influence of GSK on the research presented herein, I affirm that the Registry-
specific analyses were designed independently by me and that the conclusions reached from 
the data generated were mine alone.  
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Chapter 1: Introduction 
 
Summary 
Primary immune thrombocytopenia (ITP) is a relatively rare autoimmune 
disease characterised by autoantibody-mediated platelet destruction, T-cell-mediated 
platelet lysis, and suboptimal platelet production in the absence of a demonstrable 
cause, leading to decreased peripheral blood platelet counts (< 150 ! 109/L) or 
thrombocytopenia. The disease typically runs a chronic (> 6 months) course in 
adults and exhibits considerable phenotypic heterogeneity. Thus, although one-
fourth of patients are asymptomatic at diagnosis (i.e., diagnosed incidentally), clinically 
relevant morbidity, including major haemorrhage, is not uncommon. Despite a surge 
in research over the past decade, considerable epidemiological questions remain 
concerning primary ITP pathogenesis, treatment effectiveness, and co-morbid burden 
in adults. This thesis aimed to advance current understanding in these areas by 
characterising associations of primary ITP with both candidate single nucleotide 
polymorphisms (SNPs) and thromboembolic events, by assessing the utility of 
autologous 111In-labelled platelet sequestration studies prior to splenectomy, and by 
gauging the effectiveness of eradication therapy in elevating platelet counts in H. 
pylori-infected patients. 
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
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Background 
Primary immune thrombocytopenia (ITP) is an autoimmune disease 
characterised by autoantibody-mediated platelet destruction, T-cell-mediated platelet 
lysis, and suboptimal platelet production in the absence of a demonstrable cause.1,2 
These processes result in a decreased peripheral blood platelet count (i.e., 
thrombocytopenia), defined as less than 150 ! 109/L.3-5* The course of primary ITP in 
children is typically acute (< 6 months3-5*),6 whereas among adults it is predominantly 
chronic.7 The clinical manifestations of the disease are heterogeneous. While 
approximately one-fourth of adult patients are asymptomatic at diagnosis (i.e., 
incidentally diagnosed), petechiae, purpura, and mucosal bleeds are not uncommon.8,9 
The past decade has witnessed a marked increase in research into the disease, 
fuelled in part by the successful development and testing of novel therapeutic agents. 
However, despite these efforts, considerable gaps in our understanding of primary 
ITP pathogenesis, treatment effectiveness, and co-morbid disease burden remain.2  
 
Clinical Definition 
Primary ITP is clinically defined by the presence of thrombocytopenia in the 
absence of demonstrable pathogenic, therapeutic, systemic (autoimmune diseases or 
malignancies), or congenital causes. As such, primary ITP can only be diagnosed 
through thorough clinical evaluation, which both past3,4 and present guidelines2 
recommend be based upon a detailed history, physical examination, full blood count 
(FBC), and blood film examination. These investigations may direct clinicians toward 
alternate diagnoses; a comprehensive history, for example, may identify a dietary 
cause of thrombocytopenia10 while a blood film may reveal a MHY9-related disorder 
(Figure 1-1).  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* A panel of internationally recognised ITP specialists have recently recommended that the definitions 
of thrombocytopenia and chronic disease be changed to less than 100 ! 109/L and greater than one 
year, respectively. They have further recommended that the formal name of the disease be changed 
from idiopathic thrombocytopenic purpura to primary immune thrombocytopenia to highlight its 
autoimmune aetiology and heterogeneous clinical manifestations. See Rodeghiero F, Stasi R, Gernsheimer 
T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura 
of adults and children: report from an international working group. Blood. 2009;113:2386-2393. 
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Owing to potentially significant differences in management, particular care 
must be given to distinguishing primary ITP from hepatitis-C (HCV) and human 
immunodeficiency virus (HIV)-induced thrombocytopenias. Screening for these two 
conditions is therefore recommended for all patients during initial work-up.2 Bone 
marrow aspiration and trephine biopsy are further advised for elderly (> 60 years 
old at presentation) patients due to their elevated risk of myelodysplastic syndromes 
(MDS) and haematological malignancies.2-4 Finally, as systemic autoimmune diseases 
(e.g., systemic lupus erythematosus [SLE]) may initially manifest as isolated 
thrombocytopenias, periodic revaluation of the diagnosis of primary ITP is 
necessary.11  
 
 
 
 
 
 
     
      
      (a)                                         (b)                                          (c) 
 
Figure 1-1: Blood films of a healthy donor (a) and patients with primary ITP (b) 
and May-Hegglin Anomaly (c).  A reduction in platelets (view arrows) is evident in a blood 
film of a patient with primary ITP in comparison with that of a healthy donor. May-Hegglin anomaly, a 
congenital thrombocytopenic disease, may be distinguished from primary ITP by the presence of giant 
platelets on a blood film. Films (a) and (c) adapted from Lichtman’s Atlas of Hematology,14 film (b) courtesy 
of Dr. Drew Provan.   
 
Patients in whom the onset of thrombocytopenia is coupled with the 
concurrent or sequential development autoimmune haemolytic anaemia (AIHA) 
comprise a disease subclass known as Evans syndrome.†13 Higher rates of morbidity 
and mortality have been observed in adult patients with Evans syndrome compared 
to those with isolated thrombocytopenia.14  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
† Some ITP specialists class AIHA and Helicobacter pylori (H. pylori) infection-associated ITP as 
secondary ITP. See Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and 
clinical diversity. Blood. 2009;113:6511-6521. However, as conclusive evidence has not yet emerged 
linking the thrombocytopenia to the pathogenesis of these conditions, they are considered specialised 
cases of primary ITP for the purposes of this thesis.!
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Pathogenesis  
Traditional Model: Autoantibody-Mediated Destruction by the Reticuloendothelial System 
Almost 60 years have passed since Harrington et al.’s15 classic experiment in 
which blood samples from patients with primary ITP were injected into compatible, 
healthy volunteers, resulting in an immediate reduction in platelet count (Figure 1-2). 
These findings prompted Harrington to hypothesise the existence of an anti-platelet 
factor in the globulin fraction of plasma of patients with primary ITP. Through the 
work of McMillan et al.,16 Dixon et al.,17 and van Leeuwen et al.,18 this factor was 
successfully isolated and identified as anti-platelet autoantibody. Studies have 
subsequently shown that adult patients with primary ITP most commonly exhibit 
autoantibodies to platelet glycoprotein (GP)IIb/IIIa and GPIb/IX, though those to 
GPIa/IIa, GPIV, and GPV have also been observed.1,19 The chief class of these 
antibodies is immunoglobulin (Ig)G, namely the complement-fixing IgG1 and IgG3 
isotypes.20,22  
  
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
Figure 1-2: Results from Harrington et al.’s classic 1951 experiment.  Blood from 
patients with primary ITP was injected into healthy volunteers‡, resulting in a marked reduction in 
platelet count within hours. Adapted from Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. 
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab 
Clin Med. 1951;38:1-10. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
‡ Patients with inoperable neoplasms also served as controls in the study.  
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The discovery of anti-platelet autoantibodies was paralleled by observations 
of shortened mean platelet lifespan (MPLS) in patients with primary ITP relative to 
healthy individuals. Harker,22 for example, used allogeneic, 51chromium (51Cr)-labelled 
platelets to document a MPLS of 0.3 ± 0.4 days in 16 patients with primary ITP 
versus 9.9 ± 0.6 days in 15 healthy controls. The combination of these findings led 
investigators to propose autoantibody-mediated, peripheral platelet destruction by 
the reticuloendothelial system (RES) as the underlying mechanism of disease in 
primary ITP, the traditional model of primary ITP pathogenesis.   
 
Revised Model: Increased Destruction & Suboptimal Production & Defective Regulation 
 The adequacy of the traditional model, however, was challenged when 
allogeneic platelets were substituted with autologous platelets in radioisotopic 
studies. Using autologous 111Indium (111In)-labelled platelets, Ballem et al.23 reported 
that platelet turnover, a proxy for platelet production, was decreased§ in 7 of 17 
(41.2%) untreated patients with primary ITP in comparison with 15 healthy controls. 
A higher MPLS was further noted in patients with primary ITP than in previous 
investigations. To explore this discrepancy, Ballem et al. examined the results of 4 
patients for whom both allogeneic and autologous platelet radioisotopic studies had 
been performed. A significant difference in MPLS (autologous: 3.6 ± 1.4 days vs. 
allogeneic: 1.2 ± 1.2 days; p = 0.017) was observed, leading to speculation that the 
results of earlier investigations may have been biased by alloimmunisation.23,24 
Subsequent findings of impaired in vitro megakaryocytopoiesis following the addition 
of plasma from adults and children with primary ITP have further underscored the 
role of suboptimal platelet production in primary ITP pathogenesis.25,26  
 Recent studies have uncovered an even greater diversity of mechanisms in 
primary ITP. Noting that prior investigations were unable to detect anti-platelet 
autoantibodies in 30% to 50% of diagnosed patients,27,28 Olsson et al.29 questioned 
whether T-cell-mediated cytotoxicity constituted an alternate pathogenic pathway. 
They found evidence in support of this theory in the form of increased expression of 
genes associated with cell-mediated immunity and elevated rates of in vitro platelet 
destruction by CD14-CD19- mononuclear cells (T cells and natural killer cells) in 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§ More than 2 standard deviations lower than the mean platelet turnover seen in healthy controls. 
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patients with active primary ITP compared with both patients with remitted primary 
ITP and healthy controls.29  
This report was followed by observations implicating defective T regulatory 
cells (Tregs) in the loss of self-tolerance and, thus, disease onset in patients with 
primary ITP. While Yu et al.30 found no difference in the number of circulating Tregs 
in 17 patients with chronic primary ITP and 16 age-matched, healthy controls, they 
noted a statistically significant (p < 0.05), twofold decrease of Treg 
immunosuppressive activity in vitro.30 A revised mechanistic model of primary ITP 
must then encompass not only autoantibody-mediated platelet destruction and 
suboptimal platelet production, but also T-cell-mediated platelet lysis and impaired 
self-tolerance, mechanisms that may or may not occur in tandem within an individual 
patient.     
 
Cytokine Profiles in Primary ITP: A Th-1 Disease 
Cytokines are powerful messenger proteins of low molecular weight and 
serve as critical effectors of the aforementioned mechanisms. Under the Mosmann-
Coffman31 model of T-helper (Th) cells, immunological homeostasis is maintained 
through the balance of cytokines secreted by Th1 cells, which promote pro-
inflammatory, cell-mediated and complement-fixing IgG isotype responses, and Th2 
cells, which elicit immediate-type hypersensitivity, augmenting humoral defense. 21,32,33 
Past investigations have demonstrated Th1 polarisation in primary ITP. Wang et al.34 
reported a significantly (p = 0.002) higher Th1/Th2 ratio among 20 adults with active 
chronic primary ITP than in 20 healthy adult volunteers. Panistas et al.35 further 
demonstrated an inverse correlation (r2 = 0.251, p = 0.017) of this ratio with platelet 
count when evaluating 11 healthy adult controls and 21 adult patients with chronic 
primary ITP. Finally, in an investigation of 34 children with chronic or acute primary 
ITP, Semple et al.36 were unable to detect any levels of interleukin (IL)-4 or IL-6, 
prototypical Th2 cytokines. While these data highlight primary ITP as a pro-
inflammatory TH1 disease, the potential genetic contribution to this imbalance 
remains unclear.  
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Elements of a Perfect Storm: Genetic Susceptibility and an Environmental Trigger 
It is generally accepted among immunologists that while genetic susceptibility 
may be necessary, it is not sufficient for the development of autoimmune disease 
within an individual. Ermann and Fathman,37 for instance, note that concordance for a 
autoimmune disease is less than 50% among monozygotic twins. It has therefore 
been widely postulated that an environmental trigger (e.g., an infection) must also be 
present to initiate the autoimmune pathway via such mechanisms as molecular 
mimicry or Treg inhibition.38 
 
                  
Figure 1-3: The aetiology of autoimmune disease is multi-factorial. It is hypothesised 
that the onset of autoimmune disease requires both a genetic predisposition to immune dysregulation 
and an environmental trigger to initiate pathogenesis. Adapted from Ermann J, Fathman CG. Autoimmune 
diseases: genes, bugs and failed regulation. Nat Immunol. 2001;2:759-761. 
 
One such hypothesised trigger of primary ITP is Helicobacter pylori (H. pylori) 
infection. In a 1998 letter in The Lancet, Gasbarrini et al.39 reported that 11 of 18 
patients with ITP evaluated at their institution tested positive for H. pylori infection. 
At 2 and 4 months following the administration of triple-therapy,** a statistically 
significant increase in platelet counts from baseline was observed only in patients in 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
** Triple-therapy is the standard treatment for H. pylori infection and consists of a proton pump 
inhibitor and two classes of antibiotics.  
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whom H. pylori was eradicated (N = 8).39 Furthermore, 6 (75.0%) of these patients 
were no longer found have detectable anti-platelet autoantibodies.39 A host of single-
centre trials have been conducted following the publication of this study;40-43 further 
assessment of their aggregate results is warranted.  
 
Descriptive Epidemiology 
 The descriptive epidemiology of primary ITP in adults remains poorly 
investigated. A systematic review of autoimmune diseases conducted by Jacobson et 
al.44 in 1997 found no population-based studies of primary ITP in the medical 
literature. Such studies either directly evaluate or are representative of all individuals 
within a defined geographic region and are therefore critical for accurate measures 
of disease frequency.  
A total of 6 population-based studies, 3 in the United Kingdom (UK),45-47 2 in 
the United States (US),48,49 and 1 in Denmark,8 have since been conducted and 
published in peer-reviewed journals (Table 1-1). The number of new cases, or 
incidence,†† of primary ITP was estimated by 48,45-47 of these investigations. As shown 
in Table 1-2, Schoonen et al.46 and Abrahamson et al.47 utilised comparable 
classification codes to identify adult patients with primary ITP in the General Practice 
Research Database (GPRD), a repository of clinical data on over 4 million patients 
across 500 Primary Care centres in the UK. They reported an incidence rate of 
between 3.847 and 3.946 per 100,000 adult person-years. To capture the frequency of 
the disease most likely to require active clinical management, Frederiksen et al.8 and 
Neylon et al.45 restricted their disease populations to patients with platelet counts 
below 50 ! 109/L, documenting an annual incidence of 2.64 and 1.6 per 100,000 
adults, respectively. All four studies noted a sharp rise in the incidence with 
increasing age and a moderate female preponderance (female-to-male ratio range: 
[1.2-1.7]:1) consistent with other autoimmune diseases.50 By contrast, population-
based studies have captured incidence rates of 0.15 per 100,000 person-years51 for 
acquired haemophilia and 0.45 per 100,000 person-years52 for idiopathic thrombotic 
thrombocytopenic purpura (TTP). These estimates collectively suggest that primary 
ITP, though rare, is nevertheless among the more commonly experienced 
autoimmune haematological diseases in adults.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
†† Use of the term incidence rate is conventionally limited to measures of frequency in which the 
denominator is at risk person-time (e.g., person-years). 
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 The lower annual incidence observed in Neylon et al.’s study is likely a result 
of their requirement of a bone marrow aspirate and trephine biopsy in all patients 
for diagnostic confirmation. However, the possibility of ethnic and geographic 
differences cannot be excluded. A paucity of data exists on the subject. In a 2005 
review, Terrell et al.53 were only able to secure 6 US studies with 10 or more 
patients with primary ITP identified by race. The data were suggestive of a possible 
lower prevalence, or number of new and existing cases,‡‡ of primary ITP among 
African-Americans. This hypothesis was further explored by Landgren et al.,54 who 
failed to detect a disparity between white and African-American male veterans, an 
admittedly non-population-based cohort. To date, no systematic comparative 
investigation has been published on international differences in the incidence or 
prevalence of primary ITP in adults. 
Estimation of the prevalence of chronic primary ITP among adults has proven 
particularly challenging owing to uncertain accuracy of ascertainment methods within 
non-disease-specific databases. Segal and Powe48 and Feudjo-Tepie et al.49 both used 
the International Classification of Diseases (ICD)-9 287.3 code in health insurance 
claims in the US to derive estimates of this parameter. The diagnostic accuracy of 
the code in such a setting had been subject to a prior validation study, which 
documented a sensitivity and specificity§§ of 84% and 66% in outpatients and 100% 
and 89% in inpatients respectively when compared with hospital medical records.55  
To exclude patients with acute disease, Segal and Powe and Feudjo-Tepie et 
al. required entry of 2 distinct ICD-9 287.3 codes separated by great than 30 and 
180 days, respectively.48,49 As Segal and Powe did not provide an overall prevalence 
of primary ITP among adults, their age-specific estimates were pooled using a 
DerSimonian and Laird random-effects meta-analysis, yielding an overall prevalence 
of 10.0 per 100,000 adults (Table I-I) over one year. Although this estimate appears 
considerably different from that reported by Fuedjo-Tepie et al., 24.1 per 100,00 
adults,49 the latter prevalence encompassed 5-year period and included patients over 
65 years of age. Segal and Powe’s estimate would prove more comparable were one 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
‡‡ Prevalence can be measured at a given time (point) or over a specified interval (period). 
§§ The terms sensitivity and specificity refer to the probability of correct classification of patients with 
and without disease respectively, in this instance patients with and without primary ITP.  
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to account for incident cases of primary ITP in adults over an additional 4-year 
period:*** 20.6 per 100,000 adults. 
Table 1-2: Population-Based Studies on Primary ITP in Adults 
Authors  
(Publication Year) 
Country Data Source Criteria Frequency 
Estimate 
Incidence Rate of Primary ITP (95% Confidence Interval) Per 100,000 Person-Years: Unadjusted 
Schoonen et al.46 
(2008) 
UK General Practice  
Research Database 
• Age: > 18 years 
 
• Read codes: 42P2.11, 42P..00, 42PZ.00, 
D313.11, D313.12, D313000, D313012; 
OXMIS††† codes: 2871C, L_146N 
 
• Period: First code between 1990-2005 
3.8  
(3.6-4.1)  
Abrahamson et al.47  
(2009) 
UK General Practice 
Research Database 
• Age: " 18 years 
 
• Read codes: 42P2.11, D313.11, D313.12, 
D313000, D313012; OXMIS codes: 2871C 
 
• Period: First code between 1992-2005 
3.9  
(3.6-4.1)  
Annual Incidence of Primary ITP (95% Confidence Interval) Per 100,000 Persons Per Year: Unadjusted 
Frederiksen et al.8 
(1999) 
Denmark Retrospective Cohort 
County of Funen 
• Age: " 15 years; count‡‡‡ < 50 ! 109/L 
 
• American Society of Hematology3 criteria 
 
• Period: April 1973 – December 1995 
2.64  
(2.29-2.98) 
Neylon et al.45 
(2003) 
UK Prospective Cohort 
Northern Health Region 
• Age: > 16 years; count < 50 ! 109/L 
 
• American Society of Hematology3 criteria, 
bone marrow aspirate & trephine biopsy 
 
• Period: January 1993 – December 1999  
1.6 
(N/A)§§§ 
Period Prevalence of Chronic, Primary ITP (95% Confidence Interval) Per 100,000 Persons: Unadjusted 
Segal et al.48 
(2006) 
USA Medical Care Database 
Maryland Health  
Care Commission 
• Age:  18 < X < 65 years  
 
• ICD-9# code: 287.3; " 2 codes separated by  
> 30 days  
 
• Period: 2002 
10.0**** 
(5.4-14.7) 
Fuedjo-Tepie et al.49 
(2008) 
USA Integrated Healthcare  
Information  
System Database 
• Age > 18 years 
 
• ICD-9 code: 287.3; " 2 codes separated by  
> 6 months  
 
• Period: January 2002 – December 2006; 
continuous enrolment in 2004 required; first 
code $ 2004, second code " 2004 
24.1  
(23.4-24.8) 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
*** Assuming a conservative annual incidence of 2.64 per 100,000 adults (Frederiksen et al.), 10.6 
incident cases of primary ITP would be expected over a four-year period.   
††† OXMIS: Oxford Medical Information System; ICD: International Classification of Diseases 
‡‡‡ Frederiksen et al. additionally reported incidence rates using a threshold of less than 100 ! 109/L. 
§§§ Neylon et al. did not provide a 95% confidence interval.  
**** Segal et al. did not provide an overall prevalence of primary ITP among adults in their study but 
instead reported the following age-specific estimates: 19-24 years: 4.1 (2.0-7.3), 25-34 years: 9.3 (5.8-
14.0), 35-54 years: 11.0 (9.1-13.0), 55-64 years: 16.0 (13.0-20.0) per 100,000 adults over one year. 
These estimates were pooled using a Der-Simonian and Laird random-effects meta-analysis.   
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Bleeding Manifestations 
 The principal bleeding manifestations of primary ITP are petechiae and 
purpura, or pinpoint haemorrhages and ecchymoses, which result from vessel 
rupture or leakage (Figure 1-4[a]). Mucosal haemorrhages such as epistaxis, gum 
bleeds, and menorrhagia are also commonly observed, albeit with decreased 
frequency. The incidence of major bleeding events (e.g., intracranial haemorrhage 
[Figure 1-4(b)]) among adults with primary ITP is perceived to be low, with a long-
term observational study estimating a 1.6%45 cumulative incidence of fatal 
haemorrhage over a median interval of 5 years (range: 0.5-6.5 years).  
The platelet count remains the best-known predictor of bleeding events in 
primary ITP. Portielje et al.9 reported no such events in patients with moderate 
thrombocytopenia (> 30 x 109/L) when evaluating 152 consecutive adults with 
primary ITP over a median time of 9.4 years (range: 0.2-22.6 years). Similarly, in a 
retrospective study of 208 patients spanning a median period of 7.7 years (4.0-12.6 
years), Stasi et al.7 observed bleeding events in only 5 (5.7%) patients with a 
presenting count greater than 50 ! 109/L.  
 
                       
 
 
 
        
 
 
 
 
                                
                                     (a)                                                                           (b) 
 
Figure 1-4: Images of cutaneous bleeding (a) and an intracranial haemorrhage 
from a computerised tomography (CT) scan (b). Petechiae and purpura are commonly 
observed in adult patients with primary ITP. The risk of intracranial haemorrhage, however, is low. 
Images courtesy of Dr. Drew Provan 
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Although an increased risk of major bleeding events among patients with 
severe thrombocytopenia (< 30 x 109/L) has been well documented,7-9,56 both its 
magnitude and distribution remain controversial. In a meta-analysis of cohort studies 
on primary ITP, Cohen et al.56 estimated an incidence rate of 0.0162 to 0.0389 fatal 
haemorrhages per severely thrombocytopenic patient-year, which translates to a 
seemingly high 10-year cumulative risk of 16.2% to 38.9%. Porteilje et al.9 reported a 
comparable incidence rate of fatalities, 0.019 per patient-year, but noted that 
bleeding events and infection contributed equally to cause of death within their 
cohort  
The risk of major haemorrhage in this population, moreover, appears 
heterogeneous. Frederiksen et al., for example, reported no episodes of severe†††† 
bleeding in 16 patients with platelet counts persistently below 50 x 109/L over a 
median of 24 months.8 Additionally, numerous anecdotal reports of asymptomatic 
patients with platelet counts less than 20 x 109/L abound. A highly sensitive 
instrument capable of identifying individuals in whom such events are likely to occur 
would therefore prove of considerable benefit in the management of adult patients 
with primary ITP. 
 
Disease Management  
First-Line Treatments: Corticosteroids, Intravenous Immunoglobulin, and Anti-D 
Prednisolone‡‡‡‡ remains the most common first-line treatment for patients 
with primary ITP.1,57 In a retrospective study of 208 adults with primary ITP over a 
median time of 7.7 years (range: 4.0-12.6 years), Stasi et al.7 observed a complete 
remission (platelet count > 120 ! 109/L, one month following the discontinuation of 
therapy) in 47 (38.8%) patients initially receiving this treatment. However, responses 
were maintained in only 11 (8.6%) patients at last follow-up.7 Multiple observational 
studies have documented a comparable decline in long-term success among initial 
responders to prednisolone.3 Dexamethasone and methylprednisolone comprise 
additional members of the corticosteroid family that have been recommended as 
possible first-line treatments for the management of primary ITP by an international 
panel of clinical specialists.2 Although these therapeutic agents have been shown to 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
†††† Frederiksen et al. did not define severe bleeding.  
‡‡‡‡ Prednisone is activated to prednisolone in the liver. For the purposes of this thesis, the term 
prednisolone shall encompass both prednisolone and prednisone.  
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elicit an initial response§§§§ in 80.0% to 89.2% of adult patients in clinical trials, a 
substantial drop off in long-term response has been observed with them as well58-61 
Intriguingly, no randomised-controlled trials (RCTs) have been conducted to 
evaluate the effectiveness of corticosteroids with respect to non-treatment in adults 
with primary ITP.  
The side effects of long-term administration of corticosteroids have been 
well documented in the medical literature and include weight gain, cataracts, 
hypertension, diabetes, and osteoporosis (among others).2 These risks are generally 
well known to patients with primary ITP, who often report that the treatment for 
the disease is worse than the disease itself.62 Therefore, it has now been 
recommended that corticosteroids be slowly tapered and stopped in adult patients 
who have not shown a response within 4 weeks of the initiation of treatment.2  
The remaining first line treatments for primary ITP include intravenous 
immunoglobulin (IVIg) and, in Rh(D)-positive patients, anti-D, which have been 
hypothesised to work in part via Fc-receptor blockade.21 Imbach et al.63 first 
demonstrated the efficacy of IVIg as a primary ITP treatment in a RCT of 108 
previously untreated children with acute disease; comparable responses (platelet 
counts > 100 ! 109/L) were noted in patients receiving IVIg (39 [83.0%]) and 
prednisolone (36 [76.6%]). Meanwhile, in a more recent study of 28 Rh(D)-positive, 
non-splenectomised adults with primary ITP, Cooper et al.64 reported that 12 
(42.8%) patients were able to maintain platelet counts above 30 ! 109/L without 
treatment for at least 6 months following anti-D therapy. Both agents are fast acting, 
with an estimated time to peak response of 1-3 days, and may therefore be effective 
in emergency situations.2  
 
Second-Line Treatments: Splenectomy, Rituximab, Thrombopoietin Agonists, and More 
 Splenectomy has historically been the most common second-line treatment 
for adult patients with primary ITP who are either unresponsive to or require 
unacceptably high doses of corticosteroids.57,65 In a systematic review of 135 case-
series, Kojouri et al.65 observed a complete response***** at last follow-up in two-
thirds of adult patients with primary ITP. Indeed, surgery is considered by some ITP 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§§§§ An initial response was defined as a platelet count above 50 ! 109/L by Alpdogan et al. and Cheng 
et al. and above by 100 ! 109/L by Mazzuconi et al. and Von Dem Borne et al.  
***** A complete response was defined as a platelet count above 150 x 109/L, or as defined in the study 
and at least 100 x 109/L, and no ITP-specific treatment 30 days post-splenectomy. 
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clinical specialists the only curative treatment for the disease.66 However, the 
procedure is not without risk, including intrabdominal haemorrhage,67 
thromboembolic events,68 and opportunistic post-splenectomy infections.69 
Knowledge of these risks, together with a recognised non-response to treatment 
among one-third of adult patients with primary ITP and limited long-term data on 
long-term relapse,††††† demonstrate the potential utility of identifying a pre-surgical 
predictor of success. Although a number of variables have been proposed, they have 
been largely met with scepticism in the absence of sufficient observational data.65  
Table 1-3: First and Second-Line Treatments for Primary ITP2  
Treatment Recommended Dosing 
First-Line Treatments (In Alphabetical Order) 
Anti-D‡‡‡‡‡ 50-75 µg/kg 
Dexamethasone 40 mg/day ! 4 days/2-3 weeks ! 1-4 cycles 
Intravenous Immunoglobulin (IVIg) 
0.4 g/kg/day ! 5 days or 
1 g/kg/day ! 1-2 days 
Methylprednisolone 30 mg/kg/day ! 7 days 
Prednisolone 0.5-2 mg/kg/day ! 2-4 weeks 
Second-Line Treatments (In Alphabetical Order) 
Azathioprine 1-2 mg/kg/day 
Cyclophosphamide 
Orally: 1-2 mg/kg ! 7 weeks or 
Intravenously: 0.3-1 g/m2/day ! 1-3 days/2-4 weeks 
Cyclosporine 
5 mg/kg/day ! 6 days then 
2.5-3 mg/kg/day 
Danazol 200 mg b.d.§§§§§ 
Dapsone 75-100 mg/day 
Mycophenolate 100 mg b.d. 
Rituximab 375 mg/m2/week ! 4 weeks 
Splenectomy N/A 
TPO****** receptor agonist: eltrombopag 25-75 mg/day 
TPO receptor agonist: romiplostim 1-10 µg/kg/week 
Vinca alkaloid: vinblastine 10 mg/week ! 3 weeks 
Vinca alkaloid: vincristine 1-2 mg/week ! 3-6 weeks 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
††††† The median follow-up time in Kojouri et al.’s systematic review was 2.8 years (0.3-12.8 years). 
‡‡‡‡‡ Intravenously administered anti-D 
§§§§§ Twice daily  
****** Thrombopoietin 
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Recent additions to the second-line treatment arsenal include rituximab and 
the recently approved thrombopoietin (TPO) receptor agonists, romiplostim and 
eltrombopag. The latter treatments stimulate platelet production by megakaryocytes 
while rituximab, a chimeric monoclonal anti-CD20 antibody, has been shown to 
improve Treg numbers and function through B cell depletion.70-72  
A host of immunosuppressive, antibacterial, and anti-mitotic agents comprise 
the remaining second-line treatments for patients with primary ITP. A full listing of 
first and second-line treatments and their recommended dosing are shown in Table 
1-3.  
 
Treating the Patient and not the Platelet Count 
ITP clinical specialists have increasingly advocated a less interventional 
approach to managing the disease.73 This shift may be attributable to population-
based findings of a low incidence of major bleeding events in patients with primary 
ITP8,45 and to the side effects of long-term use of immunosuppressive therapies. In an 
observational study of 152 consecutive adults with primary ITP over a median 
follow-up time of 9.4 years (range: 0.2-22.6 years), for example, Portielje et al.9 noted 
that more patients died from infection (N = 4) than bleeding (N = 2).  
Accordingly, current treatment guidelines recommend against efforts to 
normalise platelet counts in adults and children with primary ITP but instead favour 
securing patient-specific platelet counts at which the bleeding risk is believed 
minimal.2 Evidence suggests that patients may nevertheless continue to be 
excessively treated. Bolton-Maggs and Moon74 uncovered a notable discrepancy 
between reported and recommended75 practices in an audit of the management of 
paediatric primary ITP in the UK. Of a total of 427 cases evaluated, they 
documented inappropriate administration of IVIg in 86 children with clinically mild or 
asymptomatic disease. Additionally, while only 39 (26.2%) children with primary ITP 
exhibited wet bleeding at presentation, 353 (82.7%) had been hospitalised for a 
median duration of 3 days (range: 1-30 days). A large-scale audit of the management 
of primary ITP in adults has yet to be published though data suggest that guideline-
discrepant practice is likely. In a retrospective, multi-centre investigation of 186 
adults with primary ITP, for instance, Aledort et al.76 observed that 87 (46.7%) 
patients had been diagnosed incidentally, yet 165 (88.7%) had been administered 
treatment. As Corrigan Jr.77 aptly noted in an editorial accompanying Bolton-Maggs 
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and Moon’s study, these data collectively indicate a continued tendency for 
“clinicians to be focusing on the platelet count and not the patient.” 
 
Quality of Life & Health-Related Lifestyle 
Patients with primary ITP have historically been subject to considerable 
lifestyle restrictions, typically instigated by clinicians in the absence of data on disease 
progression. Despite the publication and dissemination of research highlighting a 
generally low risk of major haemorrhage, anecdotal reports patients and ITP clinical 
specialists suggest that potentially excessive limitations (e.g., advice against airline 
travel and minimum-contact sports) persist. Investigation into the potential impact of 
these restrictions; of highly visible, if largely benign, bleeding manifestations; and of 
patient concerns over possible treatment side-effects78 and often experienced 
fatigue79 has only recently begun.  
Emerging research in the field of health-related quality of life (HRQoL) has 
highlighted the considerable burden faced by patients with primary ITP. In a 2007 
study, Zhou et al.80 found significantly lower (p < 0.01) quality of life scores in 236 
adults with primary ITP compared with 1,688 healthy adult controls across 6 of 8 
evaluable categories†††††† in the Short-Form (SF)-36, a non-disease specific, HRQoL 
questionnaire. Using the same instrument, McMillan et al.81 further reported lower 
aggregate scores among 73 adults with primary ITP than in patients with 
hypertension, arthritis, or cancer. These investigations have coincided with 
successful efforts to develop and validate the ITP-Patient Assessment Questionnaire 
(ITP-PAQ)82 and the Kids’ ITP Tools (KIT),83,84 instruments that will ultimately enable 
a more robust comparative evaluation of treatment modalities. 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
†††††† The eight categories of the SF-36 are 1) physical functioning, 2) role limitations due to physical 
problems, 3) role limitations due to emotional problems, 4) body pain, 5) social functioning, 6) general 
health perception, 7) mental health, and 8) energy vitality. Zhou et al. noted statistically significant 
differences between adult patients with primary ITP and healthy adult controls in all but the latter two 
categories. 
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Thesis Objectives & Structure 
While detailing the considerable progress that has been made since 
Harrington et al.’s foundational study, the aforementioned discussion further 
highlights unresolved questions concerning pathogenesis, treatment effectiveness, 
and co-morbid disease burden in adult patients with primary ITP. In an effort to 
collate the necessary materials to tackle these questions, I aimed to develop, initiate, 
and expand a National disease registry as part of my doctoral studies. This work was 
carried out under the supervision of Dr. Drew Provan, an internationally recognised 
adult ITP specialist at The Royal London Hospital.     
 
Thesis Objectives 
Data from the UK Adult ITP Registry, the Wellcome Trust Case-Control 
Consortium (WTCCC) 1958 British Birth Cohort, the GPRD, and peer-reviewed 
published studies were used to meet the following objectives of this thesis.  
 
Disease Pathogenesis 
I. To characterise associations of functional, candidate single nucleotide 
polymorphisms (SNPs) in cytokine or cytokine receptor genes with primary 
ITP in the Caucasian adult population. 
 
Treatment Effectiveness 
2. To assess the utility of autologous 111Indium (111In)-labelled platelet 
sequestration studies in patients with primary ITP prior to possible 
splenectomy. 
 
3. To evaluate the effectiveness of eradication therapy in elevating platelet 
counts in H. pylori-infected, adult patients with primary ITP. 
 
Co-Morbid Disease Burden 
4. To document health-related lifestyle concerns among patients with primary 
ITP. 
 
5. To characterise associations of primary ITP among adults with both 
arterial and venous thromboembolic events (TEs).  
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Thesis Outline 
Chapter 2 describes the methodology of the establishment and operation 
of the UK Adult ITP Registry and the demographics, test results, and co-morbid 
disease prevalence of its participants at the time of diagnosis. Chapter 3 details an 
investigation into the associations of 6 functional candidate SNPs in cytokine or 
cytokine receptor genes with primary ITP onset among Caucasian adults and with H. 
pylori infection status and disease severity in Caucasian adult patients with primary 
ITP. Chapter 4 presents a retrospective study on the effectiveness of autologous 
111In-tropolone labelled platelet sequestration studies in predicting short, medium, 
and long-term outcomes from splenectomy in patients with primary ITP. Chapter 
5 reports a literature-based meta-analysis on the effects of eradication of H. pylori 
infection in patients with primary ITP. Chapter 6 highlights health-related lifestyle 
concerns among patients with primary ITP. Chapters 7 and 8 present studies on 
the relative risk of arterial and venous TEs in adults with and without primary ITP 
using data from the GPRD and the UK Adult ITP Registry, respectively. Chapter 9 
summarises the findings of the thesis, discusses the strengths and limitations of the 
analyses performed, and highlights ongoing research and promising avenues for 
future investigation. Appendix 1 lists the publications that I authored during my 
doctoral studies. Appendix 2 details the talks that I have given in conjunction with 
my work on the UK Adult ITP Registry and the projects that I have tackled with Dr. 
Provan to communicate research findings to patients with primary ITP. Appendix 
3 shows the health-related lifestyle questionnaire created by the ITP Support 
Association, and Appendix 4 presents the proposal I authored to secure funding 
from GSK for the development of the UK Adult ITP Registry.  
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Chapter 2: The development, initiation, and operation of the 
United Kingdom Adult ITP Registry 
 
Summary 
The United Kingdom Adult ITP Registry is an active, linked-anonymised, 
repository of longitudinal clinical data (demographics, bleeding events, ITP-specific 
treatments, laboratory results, and co-morbid conditions) and biological specimens 
(whole blood [~EDTA] or saliva [Oragene Saliva Kit]) on adults (! 16 years) with 
primary ITP. This chapter details the development and structure of the Registry, 
concluding with an overview of the baseline (i.e., at the time of diagnosis) 
demographics and co-morbid disease profile of its participants. By March 2010, 
comprehensive clinical data spanning a median post-diagnosis observation time of 5.6 
years (inter-quartile range: 2.4-9.2 years) was available for 327 adults with primary 
ITP from 17 centres across the United Kingdom. The mean age of this cohort was 
42.9 ± 19.2 years, and a female-to-male ratio of 1.7:1 was observed. Among patients 
for whom information was available, 41.5% had been secondarily referred (i.e., 
referred to their enrolling centre by a haematologist and not a general practitioner), 
and 81.5% were Caucasian. The median baseline platelet count was 31 x 109/L (inter-
quartile range: 9-80 x 109/L). These results are illustrative of a largely successful 
effort to launch a national registry, which now stands as one of the richest databases 
on primary ITP in the world.  
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Introduction 
As discussed in Chapter 1, considerable questions remain with regard to disease 
pathogenesis, treatment effectiveness, and co-morbid burden in adults with primary ITP. 
Exploration of these queries requires a representative picture of patients with the disease 
and its clinical management over time. However, owing to the limited incidence (annual 
incidence: 1.6-2.4 per 100,000 adults)1,2* and prevalence (5-year period prevalence: 20.6-24.1 
per 100,000 adults)3,4 of the disease in the general adult population it is likely that the 
formation of such a picture will only follow the development of a registry or a systematic, 
multi-centre compilation of clinical data and biological material from adult patients with 
primary ITP.  
 
History 
 Over the course of the 1990s, The Royal London Hospital emerged as the largest 
referral centre for adults with primary ITP in the UK. This growth was overseen by 
Professor Adrian Newland, who in the year 2000 recruited Dr. Drew Provan, then a 
haematology consultant at Southampton General Hospital, to direct and expand research 
into the disease. While a registry for children with primary ITP had already been initiated,† 
Dr. Provan observed that a similar registry for adults did not yet exist. He therefore 
spearheaded efforts for its creation, submitting to the London Research Ethics Committee 
(REC) in early 2002 a proposal for the “Establishment of a UK Registry for adults with 
idiopathic thrombocytopenic purpura (ITP) and investigation of the role of cytokine gene 
polymorphisms in the pathogenesis and natural history of autoimmune thrombocytopenia 
(idiopathic thrombocytopenic purpura) in adults.” The Registry was approved in August 
2002 (London REC: 02/02/58) and was operational until June 2005, when Dr. Provan left 
The Royal London Hospital for a medical directorship with GlaxoSmithKline (GSK).  
During this time, the Registry had been successfully populated with the names of 734 
adults with primary ITP in the UK. This cohort was comprised of 332 consecutive patients 
from Barts and The London NHS Trust (i.e., The Royal London Hospital or St. 
Bartholomew’s Hospital) between January 1997 and June 2005 and 402 patients from 
collaborating hospitals between August 2002 and June 2005. Although blood samples (whole 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* When using a platelet count threshold of less than 50 ! 109/L to define thrombocytopenia. 
† The International Cooperative ITP Study Group, led by Professor Paul Imbach at the University Children’s 
Hospital Basel UKBB (Basel, Switzerland) pioneered Registry work within the field of ITP and had by 2001 
already conducted a comprehensive analysis on newly diagnosed children. See Kuhne T, Imbach P, Bolton-Maggs 
PH, Berchtold W, Blanchette V, Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an 
observational study. Lancet. 2001;358:2122-2125.  
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blood, ~EDTA) had been secured from approximately 40% of these patients for subsequent 
DNA analyses, collation of clinical data on Registry participants had been extremely limited. 
Furthermore, work on the project had come to a virtual halt in Dr. Provan’s absence. In July 
2006, Dr. Provan returned to The Royal London Hospital and, with the aim of rekindling his 
research programme, was put in touch with me, a recently graduated M.Phil. student in 
epidemiology at the University of Cambridge, by Dr. Jamie Robinson, then head of oncology 
epidemiology at GSK.   
 
Objective 
 Given the existing infrastructure and active encouragement from the ITP Support 
Association, Dr. Provan and I concurred that there was sufficient promise to seek to 
develop, initiate, and operate a revised Registry for adult patients with primary ITP in the 
UK.  
 
Methods 
Research Funding 
 GSK was at this time nearing completion of a phase III trial of eltrombopag, an oral 
TPO receptor agonist, in adults with primary ITP. As interim results suggested that the drug 
was effective in stimulating platelet production in these patients,5 the company was actively 
exploring how to fulfil its requirements for licensing approval from US and European 
regulators (e.g., the Food and Drug Administration [FDA] and the European Medicines 
Agency [EMA], respectively). Recognising an overlap of interest in the timely collection of 
epidemiological information on primary ITP in adults, I drafted a grant proposal (Appendix 
3) to secure the necessary resources to launch the revised Registry in exchange for the 
preparation of a series of reports on disease pathogenesis, treatment effectiveness, and co-
morbid disease burden in adults with primary. Importantly, a stipulation was made that any 
agreement be predicated on written affirmation of Dr. Provan’s continued ownership of 
Registry data and his autonomy over their use in published work.‡   
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
‡ The benefits and drawbacks of our research having formal ties to a pharmaceutical company are discussed at 
length in Chapter 9. 
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Registry Structure 
The revised Registry was structured to serve as a repository of biological material 
(15 mL whole blood [~EDTA] or saliva [Oragene Saliva Kit]) and longitudinal data on adults 
(" 16 years) who had been diagnosed with primary ITP in accordance with guidelines 
published by the British Committee for Standards in Haematology (BCSH).6 Patients who 
had been diagnosed as children but in whom the disease persisted in adulthood were eligible 
for inclusion.  
Clinical data collected for the Registry included demographics, bleeding events, ITP-
specific treatments, co-morbid conditions, and laboratory test results. A full list of data fields 
captured is shown in the case report form (CRF) in Figure 2-1.  
 
 
 
I. Demographic Information 
A. Key Dates:   
1. Registration Date               ______/_____/_____ 
                                                        Day            Month         Year 
2. Diagnosis Date                   ______/_____/_____ 
                                                                                                                                               Day            Month         Year 
3. Date of Last Clinic Visit      ______/_____/_____ 
                                                                                                                                               Day            Month          Year 
B. Patient Information:   
4. Surname         _______________________________ 
 
5. Forename(s)   _______________________________ 
 
6. Gender                                    male   female 
 
7. Date of Birth                      ______/_____/_____ 
                                                        Day             Month         Year 
8. Address  _______________________________                                                                                                                    
                                                           Address Line 1                                                 
             _______________________________                                                                                                                                              
                                                          Address Line 2                      
             _______________________________                                                                        
                                                             City/Town                       
             _______________________________                                                                                                                             
                                                            Post Code 
 
 
 
Figure 2-1(a): Case Report Form-Part 1 of 6.  
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C. Hospital & Consultant Information:  
9. Hospital Name              _______________________________  
 
10. Departmental Address  _______________________________                                                                                                                    
                                                                                                  Address Line 1                                 
                                                                            _______________________________                                                                                                                                   
                                                                                                                                                                       Address Line 2                   
                                                                            _______________________________                                                                                                                                              
                                                                                                                                                                         City/Town       
                                                                           _______________________________                                                            
                                                                                                                                                                         Post Code 
11. Consultant Name         _______________________________ 
 
II. Clinical Information  
 
A. Patient Weight (Time of Diagnosis):  
 
12. ____________kg 
 
B. Platelet Counts: 
 
13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1(b): Case Report Form-Part 2 of 6.  
Date (day/month/year) Count (!109/L) 
  
  
  
  
C.    Bleeding Events:  
        Location Occurrence Presentation Date(s) 
14. 
 
Cutaneous Bleeds  ____/____/____ 
____/____/____ 
15. Bleeds from the Oral Cavity  ____/____/____ 
____/____/____ 
16. Epistaxis  ____/____/____ 
____/____/____ 
17. Uterine Bleeds  ____/____/____ 
____/____/____ 
18.  Haematuria  ____/____/____ 
____/____/____ 
19.  Gastrointestinal Bleeds  ____/____/____ 
____/____/____ 
20.  Intracranial Haemorrhage   ____/____/____ 
____/____/____ 
21. Muscle Bleeds  ____/____/____ 
____/____/____ 
22. Joint Bleeds  ____/____/____ 
____/____/____ 
23. Subconjunctival Bleeds  ____/____/____ 
____/____/____ 
24. Retinal Bleeds  ____/____/____ 
____/____/____ 
  !
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Figure 2-1(c): Case Report Form-Part 3 of 6. Newer agents were evaluated alongside older 
therapies (e.g., protein A immunoadsortion and interferon) for ITP.  
 
D. Treatments: 
        Treatment Administered Date(s) Dosage(s) Course 
25. Prednisolone  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
26. IVIg  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
27. Splenectomy  
Laparoscopic  
___/___/___   
28. 
 
Anti-D  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
29. Methylprednisolone  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
30. Dexamethasone  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
31. Danazol  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
32. Dapsone  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
33. Azathioprine  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
34. Cyclophosphamide  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
35. Vinca Alkaloids  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
36. Mycophenolate  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
37. Plasmapheresis  ___/___/___ 
___/___/___ 
  
38. Protein A Immunoadsorption  ___/___/___ 
___/___/___ 
  
39. Interferon  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
40. Cyclosporine  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
41. Rituximab  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
42. Platelet Transfusion  ___/___/___ 
___/___/___ 
_______ 
_______ 
 
43. Red Blood Cell Transfusion  ___/___/___ 
___/___/___ 
_______ 
_______ 
 
44. H. pylori Treatment  ___/___/___ 
___/___/___ 
  
45. Vitamin C Supplements  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
46. Other  ___/___/___ 
___/___/___ 
_______ 
_______ 
________ 
________ 
  !
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Figure 2-1(d): Case Report Form-Part 4 of 6. Recorded co-morbid conditions included commonly 
reported side effects of corticosteroids, thromboembolic events, and malignancies. 
E. Co-Morbid Conditions 
        Condition Occurrence Diagnosis Date 
47. 
 
Cataracts  ____/____/____ 
48. Osteoarthritis  ____/____/____ 
 
49. Type-II Diabetes  ____/____/____ 
 
50. Hypertension   ____/____/____ 
 
51. Peptic Ulcers  ____/____/____ 
 
52. H. pylori Infection  ____/____/____ 
 
53. Renal Failure/Impairment  ____/____/____ 
 
54. Chronic Liver Disease  ____/____/____ 
 
55. Myocardial Infarction  ____/____/____ 
56.  Ischaemic Stroke   ____/____/____ 
57. Transient Ischaemic Attack  ____/____/____ 
58. Unstable Angina   ____/____/____ 
59. Deep Vein Thrombosis   ____/____/____ 
60. Pulmonary Embolism  ____/____/____ 
61. Splenomegaly  ____/____/____ 
62. Thyroid Disease  ____/____/____ 
 
63. Depression/Anxiety  ____/____/____ 
 
64. Miscarriage  ____/____/____ 
 
65. Cushing’s Syndrome  ____/____/____ 
66. Candida Infection  ____/____/____ 
67. Pneumonia  ____/____/____ 
68. Other Autoimmune Disease  ____/____/____ 
69. Haematological Malignancy  ____/____/____ 
70. Solid Tumour/Malignancy  ____/____/____ 
71. Photoxicity  ____/____/____ 
  !
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Figure 2-1(e): Case Report Form-Part 5 of 6. 
F. Biochemical Information (Time of Diagnosis):    Serum Level 
 
72. Alanine Transaminase (ALT)          ____________ 
73. Aspartate Transaminase (AST)          ____________ 
74. Alkaline Phosphatase (ALP)           ____________ 
75. Bilirubin             ____________ 
G. Haematological Information (Time of Diagnosis Except Where Noted): 
 Performed Result 
 
76. 
 
Blood Group 
                                            Rh(D) 
                               
    A       B     A/B     O            +        - 
 
77. 
 
Mean Platelet Volume (MPV) 
  
________________________ 
 
78. 
 
Red Blood Cells (RBC) 
  
________________________ 
 
79. 
 
White Blood Cells (WBC) 
  
________________________ 
 
80. 
 
Haemoglobin (Hb) 
  
________________________ 
 
81.   
 
Haemoglobin (Hb)  [Last] 
  
________________________ 
 
82. 
 
Neutrophils 
  
________________________ 
 
83. 
 
Neutrophils [Last] 
  
________________________ 
 
84. 
 
Direct Agglutination Test (DAT) 
 
 
 
                
             Positive     Negative 
 
85. 
 
Marrow Aspirate 
 
 
 
Conclusion:__________________ 
                   
 
86. 
 
Trephine Biopsy  
 
 
 
Conclusion:__________________ 
H. Immunological Information (Time of Diagnosis) 
 
 Performed Serum Level 
 
87. 
 
IgG 
 
 
 
__________ 
 
88. 
 
IgA 
 
 
 
__________ 
 
89. 
 
IgM 
 
 
 
__________ 
 
90. 
 
Anti-nuclear Antibodies (ANA) 
 
 
 
__________ 
  !
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Figure 2-1(f): Case Report Form-Part 6 of 6. 
 
 As illustrated in Figure 2-2, data were retrospectively extracted at the time of 
patient registration and will be prospectively collected at annual intervals thereafter until 
censoring (i.e., discharge from clinic or loss to follow-up) or Registry closure.   
 
       
Figure 2-2: An overview of follow-up intervals in the UK Adult ITP Registry. At 
registration, a retrospective extraction of patient hospital medical records was performed for life-long co-
morbidities, laboratory test results at diagnosis, and post-diagnosis bleeding events, platelet counts, and 
treatments. Prospective follow-up will be conducted at annual intervals thereafter. 
I. Coagulation Information (Time of Diagnosis) 
 Performed Serum Level/Percentage Time/Ratio 
91. Prothrombin (PT) Ratio    __________ 
92. Activated Partial  
Prothrombin Time (APPT) 
  __________ 
 
93. 
 
Lupus Anticoagulant 
 
 
 
__________ 
 
 
94.  
 
IgG-Anticardiolipin Antibodies  
 
 
 
__________ 
 
 
95.  
 
IgM-Anticardiolipin Antibodies  
 
 
 
__________ 
 
 
96.  
 
Reticulocyte Percentage 
 
 
 
__________ 
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Ethics 
 Applications for the approval to operate the aforestructured Registry were 
submitted to the Institute of Cell and Molecular Science (ICMS) at Barts and The London 
School of Medicine and Dentistry in March 2007, to the Joint Research Office at Barts and 
The London National Health Service (NHS) Trust in May 2007, and to the London REC in 
July 2007.  
 
Patient Recruitment 
A three-tiered strategy for recruitment was adopted, with a primary focus on 
securing comprehensive clinical data for past participants (i.e., patients who had enrolled in 
the original Registry). Owing to substantive parallels between the original and revised 
Registries and the non-sensitive nature of proposed novel data collection, a request was 
made to the London REC for the automatic inclusion of past participants into the revised 
Registry. Written requests for clinical data were made to haematologists from collaborating 
centres while direct extraction of hospital medical records was performed by the Registry 
team at Barts and The London NHS Trust.  
 By late 2006, the Department of Nuclear Medicine at St. Bartholomew’s Hospital 
remained one of only three centres in the UK to offer autologous 111In-labelled platelet 
sequestration studies for patients with primary ITP. These studies are hypothesised to be an 
accurate predictor of the likelihood of success from splenectomy. Their efficacy has, 
however, been questioned by many ITP specialists, most prominently by Kojouri et al.7 in a 
2004 systematic review. To contribute to the body of evidence fuelling this ongoing debate, 
efforts were secondly made to enrol in the Registry all adult patients with primary ITP who 
had undergone testing since inception of the service in March 1994. Due to the combination 
of the size of this cohort and limited available resources, limited, splenectomy-specific data 
collection (Figure 2-3) was pursued for these patients. 
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Figure 2-3: Autologous 111In-labelled platelet sequestration study follow-up form. Data 
collection was kept to a minimum to maximise response rates. 
 
 
  
Autologous 
111
In-Labelled Platelet Sequestration Study Follow-Up Request 
UK Adult ITP Registry 
                         
Dear Dr. 
 
We hope that this message finds you well. Your patient with primary ITP underwent an Autologous 111In-Labelled 
Platelet Sequestration Study prior to possible splenectomy. As part of an audit of our results, we are keen to know 
whether your patient had a splenectomy and, if so, what his/her platelet response following splenectomy was.   
 
The data gathered over the course of this audit will be used to assess both the diagnostic precision of indium 
labelled platelet scanning and the utility of the extension of this technology to other centres. If possible, could you 
please complete this short form and fax or post it back to us? We thank you very much for your help on this 
request.  
 
Patient name & DOB:  
 
 
 
Consultant haematologist:  
  
 
Was a splenectomy performed?      Yes/No       Date:
  
 
If no, please briefly give a reason: 
 
 
Pre-surgery-specific-treatment        Date: 
platelet count (!109/L):                      
 
 
Platelet count 1-3 months post                   Date: 
post-surgery (!109/L) 
          
   
Platelet count 6-12 months                                                                             Date:                                                 
post-surgery (!109/L) 
 
 
Latest platelet count (!109/L):  Date: 
 
 
Was the patient receiving ITP-treatment at         Yes/No   
the time of the latest platelet count?      
 
If so, please specify:   
 
 
Yours Sincerely, 
 
                                Dr Drew Provan              Mr Ameet Sarpatwari 
       Chief Investigator & Consultant Haematologist                         Study Coordinator & Epidemiologist 
DOB needed:  
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Thirdly, the Registry was opened to new patients throughout the UK. To streamline 
the process for hospitals to obtain local approval, applications were made for the Registry 
to be both site-specific assessment (SSA)-exempt and included in the United Kingdom 
Clinical Research Network (UKCRN) Portfolio Database, a collection of studies eligible for 
infrastructural support (i.e., National Health Service [NHS] funding) from the National 
Institute for Health Research (NIHR). Advertisements for the launch of the Registry were 
made in The Platelet, the newsletter of the ITP Support Association and the British Society for 
Haematology (BSH) Bulletin; personal invitations to join the Registry were additionally sent to 
over 100 haematologists. 
 
Data Collection 
 Extraction of hospital medical records for participants from Barts and The London 
NHS Trust were conducted by two-person teams led by trained epidemiologists. Physical 
records were first reviewed in full with the help of a research assistant.§ Data for extraction 
were tagged and orally relayed for direct entry into an electronic database, enabling cross-
verification of recorded information. Catalogued clinical correspondence and electronic 
medical records were subsequently searched for additional data.  
 Collaborating centres were free to devise their own protocols, with data transfer 
taking place via paper-based submission or an encrypted, online database developed in 
partnership with Dendrite Clinical Systems.    
 
 
 
 
 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§ Fourth or 5th-year medical or dental students from Barts and The London School of Medicine and Dentistry. 
A full list of past and present research assistants may be found at 
http://www.ukitpregistry.com/UKITPContactpage/page20/page20.html. !!!
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Results 
Registry Development 
 Timelines for projects pertaining to the development and operation of the Registry 
are shown in Figure 2-4. Briefly, £267,875 in funding was secured from GSK in December 
2006 and used to assemble a research team (i.e., a data manager, a PhD student, and 
research assistants).** Extraction of hospital medical records at Barts and The London NHS 
Trust and active recruitment of collaborating centres were initiated following final ethical 
approval of the Registry an as SSA-exempt study in October 2007 (London REC: 
07/H0718/57) and completion of the online database (http://host-dendrite.com/itpr) in 
November 2008, respectively. The Registry was adopted as a UKCRN Portfolio study†† in 
July 2008 and is scheduled to operate until October 2017. Data collection for the first series 
of analyses was concluded in March 2010.     
 
Figure 2-4: Project timeline and key events in the development of the UK Adult ITP 
Registry. The Registry was formally launched in November 2008 and will continue to enrol collaborating 
centres and participants until closure in October 2017.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
** NB: The one-year molecular scientist post was funded by the ITP Support Association.  
†† http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=4961 
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Registry Centres and Participants 
 Four patient cohorts were assembled (Figure 2-5). During the extraction process it 
was noted that over half of the hospital medical records of Barts and The London patients 
not seen since 1999 had been lost or destroyed. A post-hoc decision was therefore made to 
restrict this cohort (Barts and The London Cohort) to consecutive adults with primary ITP 
attending haematology clinics between January 2000 and June 2005, resulting in a catchment 
population of 223 patients. These patients were coupled in the Registry with 104 patients 
from 16 collaborating NHS Trusts across the UK; 50 of these patients had been enrolled 
under the original Registry (Old External Cohort) and 54 under the revised Registry (New 
External Cohort). By January 2009, 265 patients with primary ITP had undergone 
autologous 111In-labelled platelet sequestration studies at St. Bartholomew’s Hospital 
(Autologous 111In-Labelled Platelet Sequestration Study Cohort). As data collected on these 
patients were limited and used for splenectomy-related analyses alone, they were not 
included in the following description of Registry participants.    
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Figure 2-5: Overview of participant cohorts comprising the UK Adult ITP Registry. The 
core Registry entailed consecutive patients with primary ITP seen by a haematologist at Barts and The London 
NHS Trust between January 2000 and June 2005 (Barts and The London Cohort) and adults with primary ITP 
enrolled by collaborating centres under the original (Old External Cohort) and revised (New External Cohort) 
Registries.  
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In total, 327 adults with primary ITP were retrospectively followed for a median 
time of 5.6 years (inter-quartile range: 2.4-9.2 years). Table 2-1 details the baseline (i.e., at 
the time of diagnosis) characteristics of the Registry population. The mean age of 
participants was 42.9 ± 19.2 years, and a female-to-male ratio of 1.7:1 was observed. Among 
patients for whom information was available, 41.5% had been secondarily referred (i.e., 
referred to their enrolling centre by a haematologist and not a general practitioner), and 
81.5% were Caucasian. The median baseline platelet count was 31 x 109/L (inter-quartile 
range: 9-80 x 109/L). Of 93 patients who were screened for anticardiolipin (IgG and IgM) and 
lupus anticoagulant antibodies at baseline, 18 (19.4%) tested positive for at least one of 
these classes of antiphospholipid antibodies. 
 Table 2-2 shows the baseline prevalence of co-morbid diseases among Registry 
participants. Prior TEs had been experienced by 19 patients (5.8%; 95% CI, 3.5%-8.9%), with 
16 patients (4.9%; 95% CI, 2.8%-7.8%) having suffered an arterial TE and 4 (1.2%; 95% CI, 
0.3%-3.1%) a venous TE.  
A relatively a high percentage of patients (4.9%; 95% CI, 2.8%-7.8%) had a pre-
existing or concurrently incident autoimmune disease at the time of primary ITP diagnosis, 
with 4 patients (1.2%; 95% CI, 0.3%-3.1%) meeting diagnostic criteria (i.e., primary ITP and 
AIHA) for Evans syndrome. The true prevalence of autoimmune disease in the population 
was likely even higher. However, as autoantibody testing was not routinely performed in 
patients with hypo- or hyperthyroidism (3.1%; 95% CI, 1.5%-5.6% and 1.8%; 95% CI, 0.7%-
4.0%; respectively), it was not possible to determine whether these conditions were 
autoimmune in nature.  
Secondarily referred patients were on average younger (mean age: 36 ± 17 vs. 46 ± 
19, p < 0.001) and more thrombocytopenic (mean count: 29 ± 33 vs. 64 ± 50, p < 0.001) at 
baseline than their primarily referred counterparts.   
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Table 2-1: Baseline Characteristics of Registry Participants‡‡ 
Variable Number of 
Participants 
Mean (SD) or 
Percentage 
Socio-Demographic Variables 
Age at diagnosis (years) 318 42.9 (19.2) 
Sex   
    Female 206 63.0% 
    Male 121 37.0% 
Haematologist referral   
    No 144 44.0% 
    Yes 137 41.9% 
    Unknown 46 14.1% 
Ethnicity   
    Caucasian 207 81.5% 
    South Asian 27 10.6% 
    African 15 5.9% 
    Other 5 2.0% 
Smoking status   
    Never 88 63.8% 
    Current 25 18.1% 
    Former 25 18.1% 
Haematological Variables 
Platelet count (/nl) 229 47 (46) 
Red Blood Cell (RBC) count (/pL) 113 4.37 (0.73) 
Haemoglobin (g/dL) 132 13 (2) 
Neutrophil count (/nl) 100 5.0 (6.9) 
White Blood Cell (WBC) count (/nL) 125 6.9 (2.7) 
Immunological Variables 
Total IgG (mg/dL) 80 1264 (514) 
Total IgA (mg/dL) 80 224 (105) 
Total IgM (mg/dL) 80 165 (191) 
Anticardiolipin Antibody-IgG  102  
    Negative 96 94.1% 
    Positive 6 5.9% 
Anticardiolipin Antibody-IgM 102  
    Negative 97 95.1% 
    Positive 4 3.9% 
    Borderline 1 1.0% 
Lupus Anticoagulant  95  
    Negative 84 88.4% 
    Positive 10 10.5% 
    Borderline 1 1.1% 
Indium Scanning-Sequestration Pattern 57  
    Mixed or Hepatic 33 57.9% 
    Purely or Predominantly Splenic 24 42.1% 
H. pylori IgG antibody 36  
    Negative 18 50.0% 
    Positive 16 44.4% 
    Equivocal 2 5.6% 
Biochemical Variables 
Total Bilirubin (µmol/L) 110 11 (9) 
ALT (U/L) 106 25 (20) 
AST (U/L) 99 26 (16) 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
""!Data involves up to 327 participants.!
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Table 2-2: Baseline Prevalence of Co-morbid Conditions§§ 
Co-Morbid Disease Number of 
Participants 
Percentage (95% CI***) 
Hypertension 23 7.0 (4.5-10.4) 
Autoimmune diseases‡ 16 4.9 (2.8-7.8) 
    Autoimmune Haemolytic Anaemia 4 1.2 (0.3-3.1) 
    Reynaud’s phenomenon 2 0.6 (0.1-2.2) 
    Rheumatoid arthritis 2 0.6 (0.1-2.2) 
    Autoimmune cytopenia 2 0.6 (0.1-2.2) 
    Eczema 2 0.6 (0.1-2.2) 
    Inflammatory bowel disease 1 0.3 (0-1.7) 
    Multiple Sclerosis 1 0.3 (0-1.7) 
    Psoriasis 1 0.3 (0-1.7) 
Hypothyroidism‡ 10 3.1 (1.5-5.6) 
Renal disease 9 2.8 (1.3-5.2) 
Miscarriage††† 8 3.9 (1.7-7.5) 
Osteoarthritis 8 2.4 (1.1-4.8) 
Type 2 diabetes 8 2.4 (1.1-4.8) 
Solid tumour 8 2.4 (1.1-4.8) 
Myocardial infarction (MI) 6 1.8 (0.7-4.0) 
Unstable angina (UA) 6 1.8 (0.7-4.0) 
Hyperthyroidism‡‡‡ 6 1.8 (0.7-4.0) 
Ischaemic stroke (IS) 5 1.5 (0.5-3.5) 
Transient ischaemic attack (TIA) 4 1.2 (0.3-3.1) 
Candidiasis 4 1.2 (0.3-3.1) 
Long-bone fracture 3 0.9 (0.2-2.7) 
Deep vein thrombosis (DVT) 3 0.9 (0.2-2.7) 
Cataracts 2 0.6 (0.1-2.2) 
Liver disease 2 0.6 (0.1-2.2) 
Haematological malignancy 2 0.6 (0.1-2.2) 
Pulmonary embolism (PE) 2 0.6 (0.1-2.2) 
Peptic ulcer disease 1 0.3 (0-1.7) 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
##!Data involves up to 327 participants.!
*** Confidence interval 
††† The denominator is the total number of female participants (N = 206). 
‡‡‡ It was not possible to identify autoimmune thyroid diseases as antibody testing was not 
regularly performed for patients with thyroid disorders. 
!
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Discussion 
 The aforementioned results highlight a generally successful effort to develop and 
launch a national registry for adults with primary ITP. Multiple stumbling blocks were 
admittedly encountered during this process, including limited functionality of the online 
database. Data entry and site navigation were not straightforward, and specifications for an 
annual follow-up reporting system were never implemented by the hosting company.  
 Due in part to these limitations, fewer patients from collaborating centres were 
enrolled than had been targeted (104 patients enrolled vs. 200 patients targeted). The 
Registry nevertheless emerged as one of the largest and most comprehensive repositories 
of clinical data on adults with primary ITP in the world. I, moreover, endeavoured to learn 
from these missteps, having more explicitly discussed the needs and expectations of our 
research team in March 2010 in hiring a new data manager and contracting for the 
development of a new online database with Medical Data Solutions and Services (MDSAS), a 
company recently hired by the Department of Health to replace Dendrite in building and 
operating a National Immunoglobulin Database.  
 The limited number of patients enrolled from a subset of centres raises the spectre 
of selection bias, namely the possibility that patients who were enrolled were systematically 
different (e.g., had greater disease severity) than those were not. However, post-hoc 
subgroup analyses of baseline participant characteristics revealed that the mean age and 
platelet count did not differ significantly between participants from centres enrolling more 
than 3 patients and centres enrolling 3 or fewer patients (Table 2-3), suggesting that such 
bias was minimal, if present.   
 
Table 2-3: Subgroup Analyses of Baseline Data 
Centres Enrolling  
$  3 Patients 
Centres Enrolling  
> 3 Patients 
Variable 
Number Mean (SD) or 
% 
Number Mean (SD) or 
% 
P-
Value 
Age (Years) 23 53.2 (18.8) 79 50.9 (18.5) 0.56 
Platelet Count (! 109/L)  11 33.5 (13.5) 46 37.7 (5.5) 0.21 
Female 12 52.2% 49 60.9% 0.48 
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The percentage of South Asians in the Registry, 10.6%, was less than initially 
expected. Patients from The Royal London Hospital comprised 68.2% of the Registry 
population,§§§ and its catchment area, the borough of Tower Hamlets, is 30% Bangladeshi.**** 
Given these figures, one would expect roughly 20% of the Registry to be South Asian.†††† 
This apparent discrepancy may be explained by relative age distribution within the 
Bangladeshi and Caucasian populations. Only 14% of Caucasians in Tower Hamlets are 
between the ages of 0 and 15 years; this figure is, however, 35% among Bangladeshis.**** 
Therefore, the data likely do not implicate an ethnic disparity in the prevalence of primary 
ITP.   
 While primarily referred Registry participants may well be representative of the 
general population of adults with primary ITP, secondarily referred participants are likely 
more reflective of patients with severe disease. This assumption is supported by baseline 
data, which revealed a significantly lower mean age (36 ± 17 years vs. 46 ± 19, p < 0.001) 
and platelet count (29 ± 33 ! 109/L vs. 64 ± 50 ! 109/L, p < 0.001) among secondarily 
referred participants. The external validity of analyses from Registry data, which couples 
information from primarily and secondarily referred participants, may therefore be limited 
to the primary ITP population typically encountered at referral centres (i.e., not district 
hospitals).  
 In summary, efforts to develop, initiate, and operate the UK Adult ITP Registry have 
yielded sufficient data to begin addressing unresolved questions of pathogenesis, treatment 
effectiveness, and co-morbid disease burden among adults with primary ITP. However, 
considerable room for growth remains. Such expansion will ultimately be needed to resolve 
these questions definitively.  
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§§§ NB: Almost all of the Registry participants from Barts and The London NHS Trust were patients at The 
Royal London Hospital and not St. Bartholomew’s Hospital.  
**** Tower Hamlets Council. “Ethnicity.” Tower Hamlets. 28 May 2010 http://www.towerhamlets.gov.uk/lgsl/901-
950/916_borough_statistics/ethnicity.aspx. 
$$$$!327 (total patients) ! 0.682 (proportion of patients from The Royal London Hospital) ! 0.3 (approximate 
proportion of Bangladeshi patients at The Royal London Hospital) % 65 patients % 20%.!
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Chapter 3: Associations of functional candidate single nucleotide 
polymorphisms (SNPs) in cytokine or cytokine receptor genes with 
primary ITP in Caucasian adults 
 
Summary 
 
Although T-helper (Th)1 polarisation has been well documented in patients with 
primary ITP, the genetic contribution to this imbalance remains unclear. To address this 
question, 6 functional, candidate single nucleotide polymorphisms (SNPs) within cytokine or 
cytokine receptor genes were selected for association testing with primary ITP in Caucasian 
adults. Patients from the United Kingdom Adult ITP Registry were sex-matched (1:3) with 
healthy controls from the Wellcome Trust Case-Control Consortium 1958 British Birth 
Cohort. Variants IL10 -819 c>t, TNFA -308 g>a, TGFB1 -509 c>t, IL1A -889 c>t, IL10 -592 
c>t, and IL4R q576r were measured in samples from cases and retrieved from the European 
Genome-phenome Archive for controls. Associations were evaluated using logistic 
regression models. Overall, 206 patients with primary ITP were matched with 618 healthy 
controls. A significant, per allele odds ratio of 1.34 (95% CI, 1.03-1.75) was observed for 
TNFA -308 g>a, implicating increased disease susceptibility among Caucasian carriers of the 
rare allele. 
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Introduction 
As discussed in Chapter 1, the traditional Mosmann-Coffman1 model for the 
classification of Th cells remains a useful construct from which to evaluate the 
pathophysiology of autoimmune disease. Under this paradigm, homeostasis is maintained 
through the balance of cytokines secreted by Th1 (e.g., interferon [IFN]-&, IL-2, tumor 
necrosis factor [TNF]-', and TNF-(1) and Th2 (e.g., IL-4, Il-5, IL-6, IL-10,* and IL-13) cells.2 
While the former promote pro-inflammatory, cell-mediated and complement-fixing IgG 
isotype (IgG3 & IgG1) responses effective in the combat of intracellular pathogens, the latter 
elicit immediate-type hypersensitivity, augmenting humoral defense against extracellular 
pathogens.3,4 Crucially, Th1 and Th2 cell responses further demonstrate down regulatory 
effects on each other.5  
Although past proteomic investigations have demonstrated Th1 polarisation in both 
adults and children with primary ITP,6-8 questions remain concerning the genetic 
contribution to this imbalance. Recent studies have highlighted a non-random clustering of 
susceptibility loci for clinically distinct autoimmune diseases,9,10 implicating the existence of 
common susceptibility gene variants. However, few investigations have assessed the 
relationship of primary ITP with such polymorphisms, including copy number variations 
(CNVs), human leukocyte antigen (HLA) alleles, and SNPs.11-29 These studies are 
summarised in Tables 1 and 2. To enable comparisons of results across SNP and bi-allelic 
CNV studies, raw data from published reports were extracted and re-expressed as per rare 
allele odds ratios (ORs) with 95% CIs using logistic regression models. Pearson’s chi-square 
tests were performed for comparisons of observed and expected genotype frequencies 
under Hardy-Weinberg equilibrium (HWE). Owing to the large number of alleles evaluated, 
only significant (' = 0.05) results† were reported for HLA investigations. Importantly, no 
corrections were made for multiple testing.  
As shown in Table 1, half of all studies among adults with primary ITP evaluated 
cohorts of less than 100 patients. Furthermore, of these investigations, only 415,17,21,22 
assessed SNPs within cytokine or cytokine receptor genes, all among non-Caucasian 
populations. The primary objective of our study, therefore, was to test for associations of 
functional, candidate SNPs in cytokine or cytokine receptor genes with primary ITP among 
Caucasian adults. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
%As IL-10 is produced by both Th1 and Th2 cells, disagreement exists as to whether it can be properly 
classified as a Th2 cytokine.!
†As determined by Pearson’s chi-square or Fisher’s exact tests.!
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Table 3-1(a): Genetic Variant Studies among Adults with Primary ITP (1998-2007) 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* ASH: American Society of Hematology; CNV: copy number variation; HLA: human leukocyte antigen; HWE: Hardy-Weinberg  equilibrium; SNP: single nucleotide polymorphism; TBC: thrombocytopenia 
†Insufficient rare allele frequency prohibited logistic regression modelling; a 3x2 Fisher’s exact test was performed instead.  
‡ H. pylori-positive vs. H. pylori-negative patients & responders vs. non-responders to eradication therapy!
Author 
&  
Year 
Participant 
Ethnicity 
Primary ITP 
Cohort 
Restrictions 
Beyond 1997 ASH* 
Criteria  
Primary  
ITP  
Cohort-N  
Primary  
ITP-Free  
Cohort-N 
Gene(s)  
Evaluated 
SNP, HLA, or CNV‡ Alleles Evaluated Results 
Not Corrected for  
Multiple Testing 
HWE‡ 
(P-Value) 
Nomura et al. 
1998 
Japanese • Bone marrow aspirate  111 71 HLA-DRB1 401, 403-0408, 410, 802-804, 901 HLA-DRB1*0401: p < 0.01 N/A 
Kuwana et al. 
2000 
Japanese • TBC‡: < 50 x 109/L 
 
• Bone marrow aspirate 
83 114 HLA-DPB1 
 
HLA-DQB1 
 
HLA-DRB1,  
-DRB3, -DRB4 
DPB1-201, 202, 301, 401, 402, 501, 601, 901, 
1301, 1401, 1901; DQB1-201, 301-303, 401, 
402, 501-503, 601-604; DRB1-101, 401, 403-
407, 410, 802, 803, 901, 1001, 1101, 1102, 
1201, 1202, 1301, 1302, 1401-1403, 1405, 
1407, 1501, 1502, 1602; DRB3-101; 202; 301; 
DRB4-103 
HLA-DPB1*0201: p < 0.01 
 
 
HLA-DQB1*0501: p = 0.01 
 
 
HLA-DRB1*0101: p = 0.01 
N/A 
 
 
N/A 
 
 
N/A 
Fujimoto et al. 
2001 
Japanese • TBC: < 100 x 109/L 
 
• Bone marrow aspirate  
104 59 FCGR2A 
 
FCGR3A 
+131 h>r; rs1801274 
 
+158 v>f; rs396991 
1.18 (0.70-1.98) 
 
1.72 (1.00-2.99) 
0.50 
 
0.21 
Stanworth et al. 
2001 
Caucasian • Chronic: not defined 
 
• Bone marrow aspirate 
71 750 HLA-A 
 
HLA-B 
 
HLA-DRB1 
01, 02 
 
08 
 
03, 04, 13 
 
 
HLA-A*02: p = 0.03 
 
 
 
 
N/A 
Satoh et al. 
2004 
Japanese • TBC: < 100 x 109/L 
 
• Bone marrow aspirate 
 
84 56 IL1B 
 
 
TNFA 
 
 
TNFB1/LTA 
 
HLA-DRB1,  
-DQB1, -DPB1 
-511 c>t; rs16944 
+3953 t>c; rs1143634 
 
-238 g>a; rs361525 
-308 g>a; rs1800629 
 
+252 g>a; rs909253  
 
Data not provided 
1.32 (084-2.07) 
0.82 (0.21-3.21) 
 
0.21 (0.02-2.10) 
p = 0.10†  
 
0.55 (0.33-0.91) 
 
N/A 
0.45 
0.78 
 
0.84 
N/A 
 
0.85 
 
N/A 
Veneri et al. 
2005 
Caucasian N/A 52 N/A‡ HLA-DQB1 
 
HLA-DRB1 
02, 03, 04, 05, 06 
 
1, 3, 4, 7, 8, 910, 1001, 11, 12, 13, 14, 15, 16 
HLA-DQB1*03: p = 0.04 
 
HLA-DRB1*03: p = 0.05 
N/A 
 
N/A 
Chen et al. 
2007 
Han-Chinese • TBC: < 100 x 109/L 
 
121 128 IFNG 
 
 
IL4 
+874 a>t; rs243056 
 
 
CNV in intron 3; rp1>rp2  
ITP: 1.33 (0.78-2.27) 
Acute: 0.58 (0.20-1.69) 
 
ITP: 0.88 (0.57-1.37) 
Acute: 1.04 (0.46-2.34) 
0.63 
0.19 
 
0.74 
0.58 
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Table 3-1(b): Genetic Variant Studies among Adults with Primary ITP (2008-Present) 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§ CNV results for Breunis et al. are expressed as per rare copy effect. !
** Responders v. non-responders to H. pylori eradication therapy!
†† No a alleles observed.!
Author 
&  
Year 
Participant 
Ethnicity 
Primary ITP 
Cohort 
Restrictions 
Beyond 1997 ASH 
Criteria  
Primary  
ITP  
Cohort-N 
Primary  
ITP-Free  
Cohort-N 
Gene(s)  
Evaluated 
SNP, HLA, or CNV Alleles Evaluated Results 
Not Corrected for  
Multiple Testing 
HWE 
(P-Value) 
Breunis et al. 
2008 
Caucasian N/A 44 100 FCGR2A 
 
FCGR2B 
 
FCGR2C 
 
 
FCGR3A 
 
FCGR3B 
+131 h>r; rs1801274 
 
+232 i>t; rs1050501 
 
-386 g>c; rs3219018 
CNV in exon 3; 1/2/3 copies§ 
 
CNV in intron 1; 1/2/3 copies 
 
CNV in intron 1; 1/2/3 copies 
0.93 (0.55-1.57) 
 
0.88 (0.51-1.51) 
 
2.36 (1.14-4.85) 
1.22 (0.48-3.09) 
 
1.04 (0.25-4.32) 
 
1.22 (0.48-3.09) 
0.64 
 
0.01 
 
0.15 
N/A 
 
N/A  
 
N/A 
Chen et al. 
2008 
Han-Chinese • TBC: < 100 x 109/L 
 
119 136 DNMT3B c46359t; rs2424913 ITP: 1.15 (0.23-5.79) 
Acute: 1.98 (0.17-22.78) 
0.90 
0.92 
Xu et al. 
2008 
Han-Chinese • TBC: < 100 x 109/L 
 
118 169 CD72 CNV in intron 8; 1>2  1.41 (1.02-1.93) 0.27 
Suzuki et al. 
2008 
Japanese • H. pylori positive  
 
36 N/A** IL1B 
 
IL1RN 
 
TNFA 
 
TNFB1/LTA 
-31 t>c; rs1143627 
 
CNV in intron 2; l>s 
 
-308 g>a; rs1800629 
 
+252 g>a; rs909253 
0.71 (0.30-1.69) 
 
0.53 (0.10-2.81) 
 
p = 0.15††  
 
0.48 (0.20-1.14) 
0.32 
 
0.57 
 
N/A†† 
 
0.02 
Satoh et al. 
2009 
Japanese • Chronic: ! 0.5 years 
 
 
164 
 
H. pylori (+)  
85 
 
H. pylori (-)  
79 
75 IL1B 
 
TNFB 
 
IgG1 (Heavy Chain) 
 
IgK 
 
-511 c>t; rs16944 
 
+252 g>a; rs361525 
 
+643 g>a; unknown rsnumber 
 
+573 c>g; unknown rsnumber 
 
ITP: 1.02 (0.71-1.47) 
H. pylori: 0.80 (0.53-1.20) 
ITP: 1.18 (0.80-1.72) 
H. pylori: 1.13 (0.72-1.78) 
ITP: 1.70 (0.92-3.11) 
H. pylori: 1.05 (0.51-2.17) 
ITP: 1.15 (0.72-1.84) 
H. pylori: 0.93 (0.57-1.52) 
0.59 
0.91 
0.02 
0.69 
0.59 
0.81 
0.21 
0.93 
  !
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Table 3-2(a): Genetic Variant Studies among Children‡‡ with Primary ITP (2001-2004) 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
‡‡ Or combined results among adults and children with primary ITP that were unable to be separated!
Author 
&  
Year 
Participant 
Ethnicity 
Primary ITP 
Cohort 
Restrictions 
Beyond 1997 ASH 
Criteria  
Primary  
ITP  
Cohort-N 
Primary  
ITP-Free  
Cohort-N 
Gene(s)  
Evaluated 
SNP, HLA, or CNV Alleles Evaluated Results 
Not Corrected for  
Multiple Testing 
HWE 
(P-Value) 
Williams et al. 
1998 
Caucasian • Splenectomised  
 
29 61 FCGR2A 
 
+131 h>r; rs1801274 
 
2.81 (1.35-5.83) 0.23 
Foster et al. 
2001 
Caucasian • Chronic: ! 0.5 years 
 
37 218 IL1A 
 
IL1B 
 
IL4 
 
IL6 
 
IL10 
 
 
ILRN 
 
TNFA 
 
TNFB1/LTA 
 
FCGR2A 
 
FCGR3A 
 
FCGR3B 
-889 c>t; rs1800587 
 
+3953 t>c; rs1143634 
 
-590 g>t; rs2243250 
 
-174 c>g; rs1800795 
 
-1082 a>g; rs1800896 
-592 a>c; rs1800872 
 
CNV in intron 2; l>s §§   
 
-308 g>a; rs1800629 
 
+252 g>a; rs909253  
 
+131 h>r; rs1801274 
 
+158 v>f; rs396991 
 
na1>na2; N/A 
0.57 (0.31-1.06) 
 
0.90 (0.52-1.58) 
 
0.76 (0.37-1.55) 
 
0.98 (0.58-1.64) 
 
1.36 (0.80-2.31) 
0.89 (0.47-1.67) 
 
0.72 (0.41-1.29)  
 
0.40 (0.15-1.07) 
 
1.55 (0.96-2.47) 
 
1.42 (0.87-2.31) 
 
1.12 (0.65-1.90) 
 
0.52 (0.31-0.87) 
0.29 
 
0.08 
 
0.07 
 
0.23 
 
0.16 
0.64 
 
0.13 
 
0.02 
 
0.01 
 
0.11 
 
0.47 
 
0.39 
Carcao et al. 
2003 
Caucasian N/A 93 130 FCGR2A 
 
FCGR3A 
+131 h>r; rs1801274 
 
+158 v>f; rs396991 
1.51 (1.03-2.21) 
 
0.60 (0.40-0.90) 
0.48 
 
0.81 
Pavkovic et al. 
2003 
Caucasian N/A 60 100 CTLA4 +49 a>g; rs231775 1.23 (0.76-1.98) 0.53 
Bruin et al. 
2004 
Caucasian • TBC: < 50 x 109/L 60 N/A*** FCGR2A 
 
FCGR2B 
 
FCGR3A 
 
FCGR3B 
+131 h>r; rs1801274 
 
+232 i>t; rs1050501 
 
+158 v>f; rs396991 
 
na1>na2; N/A 
0.93 (0.40-2.15) 
 
0.16 (0.26-1.00) 
 
1.35 (0.57-3.19) 
 
1.04 (0.44-2.46) 
0.63 
 
0.57 
 
0.78 
 
0.50 
  !
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Table 3-2(b): Genetic Variant Studies among Children with Primary ITP (2005-Present) 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
§§ CNV results for Foster et al. reported using rubric put forward by Suzuki et al. (i.e., short vs. long alleles).!
*** Chronic vs. non-chronic TBC!
††† Insufficient rare allele frequency prohibited logistic regression modelling !
‡‡‡ CNV results for Breunis et al. are expressed as per rare copy effect!
Author 
&  
Year 
Participant 
Ethnicity 
Primary ITP 
Cohort 
Restrictions 
Beyond 1997 ASH 
Criteria  
Primary  
ITP  
Cohort-N 
Primary  
ITP-Free  
Cohort-N 
Gene(s)  
Evaluated 
SNP, HLA, or CNV Alleles Evaluated Results 
Not Corrected for  
Multiple Testing 
HWE 
(P-Value) 
Wu et al. 
2005 
Han-Chinese • Bone marrow aspirate 80 100 IL4 
 
 
IL6 
 
 
IL10 
CNV in intron 3; rp1>rp2 
 
 
-572 g>c; rs1800796 
 
-627 c>a; rs1800872 
 
ITP: 0.81 (0.47-1.38) 
Acute: 3.45 (1.15-10.40) 
 
ITP: 1.28 (0.81-2.00) 
Acute: 1.14 (0.60-2.20) 
 
ITP: 0.80 (0.53-1.21) 
Acute: 0.88 (0.48-1.64) 
0.61 
0.70 
 
0.79 
0.90 
 
0.57 
< 0.01 
Wu et al. 
2007 
Han-Chinese • Bone marrow aspirate 80 100 IL1B 
 
 
IL1RN 
 
+3953 t>c; rs1143634 
 
 
CNV in intron 2; 1>2   
ITP: 1.44 (0.47-4.44) 
Acute: 1.22 (0.21-7.08) 
 
ITP: 0.32 (0.10-1.02) 
Acute†††: p = 0.02 
< 0.01 
0.85 
 
0.45 
0.70 
Chen et al. 
2007 
Han-Chinese • TBC: < 100x109/L 
 
75 128 IFNG 
 
 
IL4 
+874 a>t; rs243056 
 
 
CNV in intron 3; rp1>rp2 
ITP: 1.27 (0.68-2.37) 
Acute: 0.60 (0.13-2.86) 
 
ITP: 0.84 (0.51-1.38) 
Acute: 1.30 (0.42-4.06) 
0.63 
0.78 
 
0.74 
0.31 
Breunis et al. 
2008 
Caucasian N/A 72 100 FCGR2A 
 
FCGR2B 
 
FCGR2C 
 
 
FCGR3A 
 
FCGR3B 
+131 h>r; rs1801274 
 
+232 i>t; rs1050501 
 
-386 g>c; rs3219018 
CNV in exon 3; 1/2/3 copies‡‡‡ 
 
CNV in intron 1; 1/2/3 copies 
 
CNV in intron 1; 1/2/3 copies 
1.01 (0.66-1.53) 
 
0.86 (0.46-1.62) 
 
2.02 (1.05-3.89) 
0.66 (0.30-1.41) 
 
0.41 (0.78-2.15) 
 
0.66 (0.30-1.41) 
0.64 
 
0.01 
 
0.15 
N/A 
 
N/A 
 
N/A 
Chen et al. 
2008 
Han-Chinese • TBC: < 100x109/L 
 
82 136 DNMT3B c46359t; rs2424913 ITP: 2.27 (0.50-10.42) 
Acute: 1.83 (0.18-19.13) 
0.90 
0.85 
Xu et al. 
2008 
Han-Chinese • TBC: < 100x109/L 
 
88 169 CD72 CNV in intron 8; 1>2 
 
ITP: 0.81 (0.56-1.15) 
Acute: 1.07 (0.51-2.22) 
< 0.01 
0.26 
  !
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Methods 
Study Design and Selection of Candidate SNPs 
A case-control design was adopted and 6 functional SNPs within cytokine or 
cytokine receptor genes selected on the basis of their associations with other autoimmune 
diseases in the medical literature. They are described briefly below 
 
 IL10 -819 c>t (rs1800872) & -592 c>t (rs1800871)  
IL-10 is an anti-inflammatory cytokine that inhibits Th1 cytokine production while 
promoting B cell differentiation.30 Both -819 c>t (rs1800871) and -592 c>t (rs1800871) have 
been implicated as functional SNPs. Turner et al.31 and Crilly et al.32 have documented 
decreased IL-10 production in individuals with the rare allele haplotype, ATA (SNPs: -1082 
g>a, -819 c>t, -592 c>a), Associations of this haplotype with SLE33 and rheumatoid arthritis34 
have been highlighted in the medical literature. 
 
TNFA -308 g>a (rs1800629)  
TNF-! is a pro-inflammatory cytokine with powerful cytotoxic properties.35 The 
TNF-A gene is located in the HLA class III region between the HLA-B and HLA-DRB3 loci in 
6p21.3.36 A number of polymorphisms have been described within its promoter region, 
including -308 g>a (rs1800629). The rare allele of this SNP may be tied to increased TNF-! 
levels37 and is increased in frequency among patients with rheumatoid arthritis,38 SLE,39 
inflammatory bowel disease,40 and coeliac disease.41 
 
TGFB1 -509 c>t (rs1800469)  
TGF-"1 is a dimeric cytokine that inhibits lymphocyte proliferation and activation.42 
The TGFB1 gene is located in 19q13, and 3 SNPs have been reported in its promoter region. 
Of these, -509 c>t (rs1800469) has been shown to be functionally relevant, with common 
allele homozygotes exhibiting roughly half the plasma levels of TGF-"1 as rare allele 
homozygotes.43 The SNP has recently been associated with chronic idiopathic neutropenia.44  
 
 
 
 
 
  !
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IL1A -889 c>t (rs1800587)  
The IL1A gene is one of three members of the IL-1 family (IL1A, IL1B, ILRN) located in 
2q14. IL-1! and IL-1" are pro-inflammatory cytokines involved in a wide array of host 
organism defences against infection and compete with IL-1RA, a non-signalling anti-
inflammatory molecule encoded by ILRN.45 Homozygotes for the IL1A -889 c>t (rs1800587) 
rare allele exhibit increased mRNA and protein levels of IL-1! relative to their common 
allele counterparts.46 The SNP has been reported to be associated with SLE47 and psoriatic 
arthritis.48      
 
IL4R q576r (rs1801275)  
IL-4 is an anti-inflammatory cytokine that plays a key role in humoral immunity 
though the induction of naïve T cell differentiation into Th2 cells.49 The IL-4 receptor (IL-4R) 
is a heterodimeric complex consisting of an ! and common # chain.49 In the SNP +1727 a>g 
(rs1801275), the rare allele results in the substitution of glutamine with arginine at codon 
551, leading to increased receptor activity.50 Associations of the SNP have been found with 
atopic disorders,50 SLE, and type I diabetes.51   
 
Study Subjects  
Primary ITP cases, as defined by 2003 British Committee for Standards in 
Haematology (BCSH) guidelines,52 comprised Caucasian (self-declared) adult (> 16 years) 
patients who had enrolled in the Registry and volunteered a blood sample prior to January 
1st, 2006. These cases were gender-matched at a 1:3 ratio with healthy controls otherwise 
randomly selected from the WTCCC subset of the 1958 British Birth Cohort. DNA 
samples issued to the WTCCC from the 1958 British Birth Cohort were restricted to 
Caucasians (http://www.wtccc.org.uk/info/overview.shtml).  
 
Control Data  
Encrypted genome-wide data (Illumina 1.2M chip; Essex, United Kingdom) on healthy 
controls from the WTCCC subset of the 1958 British Birth Cohort were secured online 
from the European Genome-phenome Archive (EGA, www.ebi.ac.uk/ega). Decryption and 
SNP-specific data extraction were using Bcrypt (http://bcrypt.sourceforge.net) and GTOOL 
v0.4.1 (Oxford, United Kingdom), respectively.  
 
 
  !
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Laboratory Methods 
Blood samples for cases were stored at -80°C and thawed in batches prior to DNA 
extraction. DNA was isolated from sample aliquots using a Qiagen QIAamp DNA Blood 
Mini Kit (Hilden, Germany). The quality and quantity of extracted DNA was assessed using a 
NanoDrop ND-1000 Spectrophotometer (Wilmington, Delaware).  
Assays were obtained from Applied Biosystems (Foster City, California). Reactions 
were prepared using a TaqMan Fast Universal Master Mix (2x), SNP Genotyping Assay Mix 
(40x), DNase-free water, and genomic DNA (10 ng). PCR amplification was completed using 
an ABI Prism 7900HT Sequence Detection System under the following conditions: 10 
minutes at 95°C followed by 45 cycles at 92°C for 15 seconds and at 60°C for 1 minute. 
Concordance for quality control samples was between 99% and 100% for all assays.  
 
Clinical Data 
 H. pylori infection status, disease severity and chronicity, and responses to 
splenectomy and to isolated first courses of prednisolone, IVIg, anti-D, and rituximab were 
recorded for patients for whom data were available. A platelet count less than 10 ! 109/L at 
presentation served as a surrogate marker for severe disease. Consensus guidelines by the 
International Working Group on ITP53 were used to define chronicity (> 1 year) and 
complete response (> 100 ! 109/L within specified intervals) to treatment.  
 
Statistical Analyses  
Associations of candidate SNPs with primary ITP were evaluated using logistic 
regression models of log-additive co-dominance. Results were reported as per rare allele 
odds ratios (ORs) with 95% confidence intervals (CIs). To avoid underpowered testing, a 
minimum of 23 cases, calculated using Quanto v1.2.4 (Los Angeles, California), was required 
for association analyses with clinical variables.*  
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* This threshold was formulated using the following specifications: design = unmatched case-control (1:2), 
inheritance: log-additive, rare allele frequency = 0.35, baseline risk = 0.20, and estimated OR = 3.0.!
  !
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Ethics 
The study was conducted under the auspices of the UK Adult ITP Registry, an active, 
linked-anonymised repository of hospital-based clinical data (demographics, bleeding events, 
ITP-specific treatments, laboratory results, and co-morbid conditions) and biological samples 
(whole blood, ~EDTA) of adult patients with primary ITP established to uncover 
information pertaining to disease pathogenesis, treatment effectiveness, and co-morbid 
burden. Launched in late-2007, the UK Adult ITP Registry has been approved for multi-
centre operation by the London Research Ethics Committee (Reference: 07/H0718/57) until 
mid-2017 and is sponsored by Barts and The London NHS Trust. Informed consent was 
obtained from every patient prior to enrolment, and ethical approval secured for genome-
wide SNP testing.   
 
Results 
Demographics & SNP-Primary ITP Association Results 
A total of 206 (145 females, 61 males) Caucasian adults with primary ITP were sex-
matched (1:3) with 618 (435 females, 183 males) healthy controls from the WTCCC subset 
of the 1958 British Birth Cohort. Observed genotype frequencies for the six candidate SNPs 
did not differ significantly from expected results under the assumption of HWE in healthy 
controls (Table 3-3). Per allele ORs and 95% CIs are depicted in Figure 3-1 and reveal a 
statistically significant association between TNFA -308 g>a and primary ITP (OR = 1.34 [95% 
CI, 1.03-1.75]; p = 0.03). 
 
Clinical Data, SNP- H. pylori Infection & Severity Association Results  
 Clinical data were available for 93 (45.1%) patients. The median post-diagnosis 
follow-up time was 6.0 years (range: 0.4-34.7 years). Severe disease was observed in 27 of 
76 (35.5%) patients for whom presenting counts were documented. Chronic and acute 
disease was observed in 77 (82.8%) and 12 (12.9%) patients, respectively (insufficient follow-
up prevented classification of 4 [4.3%] patients). Twenty-three (43.4%) of 53 H. pylori tests 
were positive. Patients were treated in order of frequency with prednisolone, IVIg, 
splenectomy, anti-D, and rituximab. Of the clinical variables captured, only H. pylori infection 
and disease severity met the threshold established for proceeding with analyses, and no 
significant associations were observed (Figure 3-2). 
  !
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Table 3-3: Observed Genotype Frequencies and SNP-Disease, H. pylori Infection, and Severity Association Results
SNP Disease Association SNP-H. pylori Infection Association SNP-Severity Association Gene SNP 
 rs Number 
Genotype 
Control
s 
 (%) 
Cases 
 (%) 
OR  
(95% CI) 
P 
 
Control
s 
 (%) 
Cases 
 (%) 
OR  
(95% CI) 
P 
 
Controls 
 (%) 
Cases 
 (%) 
OR  
(95% CI) 
P 
 
IL10  -592 c>a 
rs1800872 
 HWE  
p = 0.61 
 1.14  
(0.88-1.48) 
0.33 
 
HWE  
p = 0.42 
 0.97 
(0.43-2.22) 
0.95 HWE  
p = 0.62 
 1.40 
(0.65-2.98)  
0.39 
CC 382 (61.8) 119 (59.5) 17 (56.7) 13 (56.5) 33 (68.7) 17 (63.0) 
CA 205 (33.2) 66 (33.0) 10 (33.3) 8 (34.8) 13 (27.1) 7 (25.9) 
 
AA 31 (5.0) 15 (7.5) 
 
3  (4.2)  2 (8.7) 
 
2  (4.2)  3 (11.1) 
 
TNFA -308 g>a 
rs1800629 
 HWE  
p = 0.82 
 1.34  
(1.03-1.75) 
0.03 
 
HWE  
p = 0.85 
 1.62 
(0.71-3.70) 
0.26  
 
HWE  
p = 0.42 
 1.01  
(0.48-2.13) 
0.99 
GG 403 (65.2) 115 (57.2) 15 (51.7) 9 (40.9) 25 (53.2) 12 (46.1) 
GA 191 (30.9) 74 (36.8) 12 (41.4) 9 (40.9) 17 (36.2) 13 (50.0) 
 
AA 24 (3.9) 12 (6.0) 
 
2 (6.9) 4 (18.2) 
 
5 (10.6) 1 (3.9) 
 
TGFB1 -509 c>t 
rs1800469 
 HWE  
p = 0.91 
 1.08  
(0.85-1.38) 
0.52  
 
HWE  
p = 0.85 
 1.15  
(0.48-2.74) 
0.75  
 
HWE  
p = 0.58 
 1.09  
(0.52-2.27) 
0.82 
CC 308 (49.9) 100 (49.0) 15 (51.7) 11 (47.8) 27 (56.3) 14 (51.9) 
CT 255 (41.3) 81 (39.7) 12 (41.4) 10 (43.5) 17 (35.4) 11 (40.7) 
 
TT 54 (8.8) 23 (11.3) 
 
2 (6.9) 2 (8.7) 
 
4 (8.3) 2 (7.4) 
 
IL1A -889 c>t 
rs1800587 
 HWE  
p = 0.88 
 0.82  
(0.63-1.07) 
0.15  
 
HWE  
p = 0.14 
 1.63  
(0.64-4.18) 
0.31  HWE  
p = 0.58 
 1.03  
(0.47-2.26) 
0.94 
CC 297 (48.1) 97 (51.9) 21 (72.4) 11 (52.4) 29 (61.7) 15 (62.5) 
CT 264 (42.7) 80 (42.8) 6 (20.7) 9 (42.8) 15 (31.9) 7 (29.2) 
 
TT 57 (9.2) 10 (5.4) 
 
2 (6.9) 1 (4.8) 
 
3 (6.4) 2 (8.3) 
 
IL10 -819 c>t 
rs1800871 
 HWE  
p = 0.59 
 1.18  
(0.91-1.53) 
0.21 
 
HWE  
p = 0.42 
 1.03  
(0.45-2.35) 
0.95  HWE  
p = 0.67 
 1.34 
(0.62-2.86)  
0.46 
CC 382 (62.3) 94 (47.5) 17 (56.7) 12 (54.5) 31 (67.4) 17 (63.0) 
CT 201 (32.8) 85 (42.9) 10 (33.3) 8 (36.4) 13 (28.3) 7 (25.9) 
 
TT 30 (4.9) 19 (9.6) 
 
3 (10.0) 2 (9.1) 
 
2 (4.3) 3 (11.1) 
 
IL4R q576r 
rs1801275 
 HWE  
p = 0.99 
 1.14  
(0.88-1.48) 
0.32  
 
HWE  
p = 0.52 
 1.74 
(0.72-4.17)  
0.22  HWE  
p = 0.27 
 0.84  
(0.42-1.67) 
0.61 
AA 379 (61.3) 121 (60.8) 19 (63.3) 10 (43.5) 25 (52.1) 16 (59.3) 
AG 210 (34.0) 60 (30.1) 9 (30.0) 11 (47.8) 17 (35.4) 8 (29.6) 
 
GG 29 (4.7) 18 (9.1) 
 
2 (6.7) 2 (8.7) 
 
6 (12.5) 3 (11.1) 
 
  !
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Figure 3-1: Results of logistic regression modelling of associations between 6 
functional candidate SNPs and primary using a sample of 206 Caucasian adults 
with primary ITP gender-matched with 618 healthy Caucasian controls. A 
statistically significant association was observed between the disease and TNF-A -308 g>a. 
 
        
Figure 3-2: Results of logistic regression modelling of associations between 6 
functional candidate SNPs and both disease severity and H. pylori infection in 
Caucasian adults with primary ITP. No statistically significant associations were observed.   
  !
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Discussion  
While the failure to observe significant associations between the candidate 
SNPs and either disease severity or H. pylori infection may reflect a true lack of 
association, it is similarly possible that the conducted analyses possessed inadequate 
statistical power, the primary limitation of the study. The minimum threshold of 
cases established for the above association analyses was predicated on the remote 
possibility of uncovering a pronounced effect (e.g., OR = 3.0). Were significant SNP 
associations with these outcomes to exist, they would likely be less pronounced and 
require a greater sample size to detect. For example, assuming the study design 
detailed in Figure 3-3 and a rare allele frequency of 0.1, 267 cases, or patients with 
severe disease or H. pylori infections, would be required to uncover an OR of 1.6.  
 
 
Figure 3-3: A graph of cases necessary to detect moderate SNP-severity, H. 
pylori infection, and treatment response associations.  
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Two further potential limitations of this study should be noted relating to 
methodological differences in the evaluation of cases and controls. First, the use of 
different genotyping platforms may have led to spurious differences in SNP 
frequencies between cases and controls. Second, reliance on self-declared ethnicity 
for cases may have resulted in a greater admixture, or accidental inclusion of non-
Caucasian patients, than among controls, for whom principal component analyses 
had been performed. Although the possibility that these systematic differences may 
have biased the results of the study cannot be excluded, their impact would have 
likely been minimal. The candidate SNPs under investigation were all directly typed 
(i.e., data imputation was not performed). Furthermore, as the rare allele at TNFA       
-308 is more common among Caucasians than among individuals of Japanese, 
Chinese, or African ancestry, the accidental inclusion of non-Caucasian cases in our 
study would have likely biased our odds ratio toward, rather than away, from the 
null.  
Coupled with these limitations, the principle finding of a borderline 
statistically significant OR of 1.34 (95% CI, 1.03-1.75; p = 0.03) raises the question as 
to whether the uncovered association between TNFA -308 g>a and primary ITP 
among Caucasian adults may be a false positive result. The high frequency of false 
positives among initially reported findings in genetic association studies has been well 
documented, with subsequent investigations often unable to replicate these results.54 
As Wacholder et al.54 note, evaluation of the likelihood of false positives should 
include not only the reported p-value, which reveals the probability of a study 
yielding data as, or more, extreme than that observed given a true null hypothesis 
(i.e., that no association exists), but also on the statistical power of the study, and the 
prior probability of a true association. While the p-value and statistical power of the 
study are admittedly moderate, the prior probability for this candidate SNP 
association was arguably high, prompting me to speculate that it may represent a 
true positive result.  
The observed association between TNFA -308 g>a and primary ITP among 
Caucasian adults is consistent with the latter’s categorisation as a Th1-disease. TNF-
! plays a critical role in the development of pro-inflammatory Th1 responses,55 and 
the rare allele at -308 has been linked with elevated production of the cytokine. In a 
Dutch study of patients with inflammatory bowel disease and healthy controls, 
Bouma et al.37 reported that participants with TNF-E and TNF-C haplotypes secreted 
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the highest and lowest levels of TNF-!, respectively.37 Crucially, these haplotypes 
only differed at the -308 g>a position (TNF-E: -308 a; TNF-C: -308 g). As a functional 
polymorphism, then, TNFA -308 g>a may serve as a marker of pro-inflammatory 
events.  
 Three previous studies in primary ITP have evaluated TNFA -308 g>a. In a 
pilot study involving 37 cases and 218 controls, Foster et al.23 reported a significant 
association (association-p = 0.0032; HWE-p = 0.02)* between the SNP and chronic 
ITP in children.. Investigations by Satoh et al.15 and Suzuki et al.21 were conducted 
among Japanese cohorts. Suzuki et al., however, evaluated the association of the SNP 
with H. pylori infection in patients with primary ITP and not primary ITP itself. 
Furthermore, although Satoh et al. did not observe a significant association, the 
frequency of the rare allele in the Japanese population is significantly lower than 
among Caucasians (HapMap-JPT: 2.3% vs. HapMap-CEU: 21.7%†). Hence, for a 
Japanese population, between 1,502 and 3,796 patients with primary ITP would be 
required to detect an association of similar magnitude as presented in this report. 
In conclusion, the finding of a significant association between TNFA -308 g>a 
and primary ITP in Caucasian adults represents a promising step forward, highlighting 
the merits of further research into the genetic contribution to the Th1/Th2 
imbalance in the disease. Importantly, this study represents the largest investigation 
of SNPs in primary ITP to date. Thus, its primary limitation of suboptimal power 
provides a convincing rationale for the development of an international registry for 
adults with primary ITP. Such a registry would enable validation of reported SNP-
disease associations, as required of this study, while laying the necessary foundation 
for the long-term goal of genome-wide association studies (GWAS).  
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* Notably, the observed genotype frequencies among controls differed significantly from expected 
frequencies under an assumption of HWE in Foster et al.’s study. While such a deviation may have 
resulted from chance or bias (e.g., genotyping errors), it is also possible for it to have been real (e.g., 
selection). Nonetheless, results where HWE-deviations are observed must be interpreted cautiously. !
† Allele frequency data obtained from the National Center for Biotechnology Information SNP 
database.!
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Chapter 4: The utility of autologous 111In-labelled platelet 
sequestration studies in patients with primary ITP prior to 
splenectomy 
 
Summary 
Although splenectomy is widely recognised as an effective therapy for 
primary ITP, the risk of peri- and post-operative complications, limited data on long-
term relapse, and an observed lack of efficacy in roughly one-third of patients suggest 
merit in further research into possible pre-surgical predictors of response. The 
effectiveness of platelet sequestration site in predicting short, medium, and long-
term responses to splenectomy was evaluated through multivariable logistic 
regression modelling of outcome data on patients who had undergone autologous 
111In-labelled platelet sequestration studies at Barts and The London NHS Trust. In 
total, 256 patients with primary ITP underwent scanning, with 91 (35.5%) proceeding 
to splenectomy. Logistic regression models revealed significantly increased adjusted 
(gender, age at splenectomy, and mean platelet lifespan) odds of response in purely 
or predominantly splenic versus mixed or hepatic, splenectomised patients at 1-3 
(OR: 7.47 [95% CI, 1.89-29.43]) and 6-12 (OR: 4.85 [95% CI, 1.04-22.54]) months 
post-splenectomy and at last follow-up (median post-surgical time: 3.8 years [range: 
0.5-13.1 years]; OR: 5.39 [95% CI, 1.34-21.65]). An independent, inverse association 
of age at splenectomy and long-term response (OR: 0.95 [95% CI, 0.91-0.99]) was 
further observed. Taken together, these results highlight splenectomy as better 
treatment for younger patients with purely or predominantly splenic sequestration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
68!
 
Introduction  
Although primary ITP specialists have increasingly adopted a less 
interventional management paradigm, therapy is still indicated for patients with 
symptomatic thrombocytopenia, at high risk of bleeding, or undergoing procedures 
likely to induce blood loss.1 The spleen serves as a principal site of anti-platelet 
antibody production and platelet phagocytosis.2,3 Splenectomy has, thus, proved a 
particularly effective treatment for primary ITP, with a complete response (CR)* 
observed in approximately two-thirds of adults.4 However, the procedure carries a 
risk of peri- and post-operative complications, including intra-abdominal 
haemorrhages,5 TEs,6 and opportunistic post-splenectomy infections.7 Although low,8 
the combined risk of these complications in primary ITP provides sufficient impetus 
to investigate potential pre-operative predictive variables of response, particularly 
when coupled with a known risk of non-CR in a third of patients and limited data on 
long-term relapse. 
To date, a number of such predictors have been posited, including 1) 
response to corticosteroid and IVIg therapies, 2) platelet turnover and lifespan, 3) 
patient age, 4) duration of disease, 5) platelet-bound immunoglobulin, and 6) site of 
platelet destruction as determined by radionuclide labeling techniques. As noted in 
Chapter 1, Kojouri et al.4 reported inconclusive evidence in support of this last 
variable in a systematic review of the effectiveness of splenectomy among adult 
patients with primary ITP.4 Evaluating a series of 15 studies, the authors found the 
site of platelet destruction to be correlated with post-splenectomy outcome in 6,9-14 
uncorrelated in 8,15-22 and inconclusive in 1.23  
 
 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* A normal platelet count (> 150 x 109/L or as defined and at least > 100 x 109/L) and no ITP-specific 
treatment 30 days post-splenectomy.  
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Table 4-1(a): Past Investigations of Radioisotope-Labelled Platelet Sequestration Studies in Primary ITP (1976-1984) 
Author, Year (Country) 
Inclusion Criteria Beyond 1997 ASH 
Diagnosis Guidelines 
Study 
Size 
Sex 
Age at 
Surgery 
Platelet 
Label 
Origin 
Sequestration 
Classification 
Outcome 
Success Criteria 
Results 
Ries, 1976 (USA) 
 
•Included 28 patients with primary ITP and 6 
patients with systemic lupus erythematosus 
(SLE) or other systemic autoimmune disease-
associated thrombocytopenia 
Scans 
34 
 
Surgeries 
34 
Female 
24 
 
Male 
10 
Mean 
26.2 years 
 
 
51Cr 
Not stated 
Not stated 
Post-Surgery Assessment  
 (a) 1 month  
 (b) Last follow-up  
Mean: 22.8 months  
 
Complete response (CR) 
Count > 150 x 109/L 
 
Partial response (PR) 
Count = 50–150 x 109/L 
1 month post-surgery 
Splenic: 26 (76.5%) 
CR: 21 (80.8%); PR: 4 (15.4%) 
 
Mixed: 8 (23.5%) 
CR: 6 (75.0%); PR: 1 (12.5%) 
 
Last follow-up 
Splenic 
CR: 24 (92.3%); PR: 2 (7.7%) 
 
Mixed 
CR: 7 (87.5%); PR: 1 (12.5%) 
Ikkala et al., 1978 (Finland) 
Scans 
20 
 
Surgeries 
24 
 
Total  
Cohort 
 
Female 
34 
 
Male 
11 
N " 40 years 
15 
 
N > 40 years 
9 
 
51Cr 
Not stated 
Not stated 
Post-Surgery Assessment  
Median: 60 months 
Range: 24–96 months 
CR 
Count > 100 x 109/L 
No bleeding 
PR 
Count = 50-100 x 109/L 
No major bleeding 
Splenic: 9 (45.0%) 
CR: 8 (88.9%); PR: 0 
 
Normal: 8 (40.0%) 
CR: 5 (62.5%); PR: 2 (25.0%) 
 
Hepatic: 3 (15.0%) 
CR: 1 (33.3%); PR: 1 (33.3%) 
Burger et al., 1978 (Hungary) 
 
•Count < 50 x 109/L 
 
•Corticosteroids impractical or ineffective after 
3 months 
Scans 
86 
 
Surgeries 
40 
Female 
33 
 
Male 
7 
Not stated 
51Cr 
Not stated 
•Spleen:liver ratio (S:L) at 
10% survival 
 
Splenic 
S:L > 1.5 
Mixed 
S:L & L:S < 1.5 
Hepatic 
L:S > 1.5 
Post-Surgery Assessment  
Likely > 2 years 
CR 
Count > 100 x 109/L 
PR 
40–100 x 109/L 
NR 
< 40 x 109/L 
Relapse 
Undefined 
Splenic: 28 (70.0%) 
CR: 25 (89.3%); PR: 1 (3.6%) 
 
Mixed: 7 (17.5%) 
CR: 3 (4.3%); PR: 2 (2.9%) 
 
Hepatic: 5 (12.5%) 
CR: 2 (40.0%); PR: 0 
 
Relapse: 4 (10.0%) 
den Ottolander et al., 1984 (Holland) 
 
•Count < 60 x 109/L 
 
Scans 
87 
 
Surgeries 
49 
 
Not 
stated 
Not stated  
51Cr 
Not stated 
Not stated 
Post-Surgery Assessment  
Not stated 
CR 
Count > 120 x 109/L; 0-1 Relapses 
PR 
Count = 60-120 x 109/L 
Relapse 
Count ! 60 x 109/L after  
Count > 120 x 109/L 
Splenic: 42 (85.7%) 
CR: 28 (66.7%); PR: 5 (11.9%) 
 
Mixed or Hepatic: 7 (14.3%) 
CR or PR: 4 (57.1%) 
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Table 4-1(b): Past Investigations of Radioisotope-Labelled Platelet Sequestration Studies in Primary ITP (1987-1992) 
 
 
 
Author, Year (Country) 
Inclusion Criteria Beyond 1997 ASH 
Diagnosis Guidelines 
Study 
Size 
Sex 
 
Age at 
Surgery 
Platelet 
Label 
Origin 
Sequestration 
Classification 
Outcome 
Success Criteria 
Results 
Russo et al., 1987 (Italy) 
 
•Chronic thrombocytopenia  
(count < 100 x 109/L) 
 
Scans 
119 
 
Surgeries 
119 
Female 
78 
 
Male 
41 
Mean 
~29 years 
51Cr 
If count 
> 50 x 109/L 
Autologous 
 
If count 
!"50 x 109/L 
and if not 
transfused or 
pregnant 
Allogeneic 
•Spleen:precordium & 
liver:precordium ratios at 
50% survival   classified as 
follows, respectively 
 
Splenic 
> 2.9 & " 1.5 
Mixed 
> 2.9 & > 1.5 
Hepatic 
" 2.9 & > 1.5 
Post-Surgery Assessment  
1 month  
 
CR 
Count > 150 x 109/L 
 
PR 
Count = 80–149 x 109/L 
 
Relapse 
Count < 150 x 109/L at last 
follow-up (mean: 128 months) 
among CR patients at 1 month 
Splenic: 82 (68.9%) 
CR: 66 (80.5%); PR: 10 (12.2%) 
 
Mixed: 21 (17.6%) 
CR: 14 (66.7%); PR: 2 (9.5%) 
 
Hepatic: 3 (2.5%) 
CR: 0; PR: 2 (66.7%) 
 
Relapse: 11 of 89 (12.4%) 
 
NB: Results of 13 patients with diffuse 
pattern not shown 
Siegel et al., 1989 (USA) 
 
•Unresponsive to prednisolone or unacceptably 
high dose required 
Scans 
59 
 
Surgeries 
21 
Not 
stated 
Median 
40 years 
 
Range 
20–84 years 
111In- 
oxine 
Autologous 
•S:L ratio at 24 hours   
 
Splenic 
S:L > 1.2 
Mixed 
0.8 ! S:L  ! 1.2 
Mixed 
S:L < 0.8 
Post-Surgery Assessment  
1-1.5 months 
 
CR 
Count > 180 x 109/L 
No treatment 
Splenic: 15 (71.4%) 
CR: 9 (60.0%) 
 
Mixed: 3 (14.3%) 
CR: 2 (66.7%) 
 
Hepatic: 3 (14.3%) 
CR: 2 (66.7%) 
Lamy et al., 1992 (France) 
 
•Count < 50 ! 109/L 
 
Scans 
111 
 
Surgeries 
51 
Scan  
Cohort  
 
Female 
66 
 
Male 
45 
 
Not stated 
111In- 
oxine 
Autologous 
•Relative increase in 
spleen and liver activity 
from 0.5 hours to last day 
of activity 
 
Splenic 
S increase  > 1.2 
Mixed 
S & L increase  > 1.2 
Hepatic 
L increase  > 1.2 
Post-Surgery Assessment  
3 months 
 
CR 
Count > 150 x 109/L 
 
PR 
Count = 50-150 x 109/L 
Splenic: 38 (74.5%) 
CR: 33 (86.8%); PR: 1 (2.6%) 
 
Mixed: 9 (23.7%) 
CR: 2 (22.2%); PR: 0 
 
Hepatic: 4 (10.5%) 
CR & PR: 0 
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 Table 4-1(c): Past Investigations of Radioisotope-Labelled Platelet Sequestration Studies in Primary ITP (1993-1997) 
Author, Year (Country) 
Inclusion Criteria Beyond 1997 ASH 
Diagnosis Guidelines 
Study 
Size 
Sex 
 
Age at 
Surgery 
Platelet 
Label 
Origin 
Sequestration 
Classification 
Outcome 
Success Criteria 
Results 
Naouri et al., 1993 (France) 
 
•Chronic thrombocytopenia 
 
Scans 
35 
 
Surgeries 
72 
 
Female 
58 
 
Male 
14 
 
Mean 
36.4 years 
 
 
51Cr 
Allogeneic 
Not stated 
Post-Surgery Assessment  
(a) 3 months 
 
(b) Last follow-up 
Median 5.4 years  
Range: 0.6–11.9 years 
 
CR 
Count > 120 x 109/L 
 
PR 
Count = 50-120 x 109/L 
Splenic: 22 (62.9%) 
CR & PR: Not stated 
 
Hepatic: 2 (5.7%) 
CR & PR: Not stated 
 
•Splenic pattern a predictor of CR at 
3 months (p = 0.02) but not at last 
follow-up. 
 
NB: Results of patients with mixed and 
diffuse patternsnot shown 
Winde et al., 1996 (Germany) 
 
•Count < 100 x 109/L 
 
Scans 
68 
 
Surgeries 
72 
Female 
42 
 
Male 
30 
Mean 
48.0 years 
51Cr 
Not stated 
Not stated 
Post-Surgery Assessment  
As below for > 2 months or at 2 
weeks post-surgery 
CR 
Count > 150 x 109/L 
No bleeding 
PR 
Count = 50-100 x 109/L 
No bleeding 
•CR & PR results by sequestration 
site not stated 
 
“Patients with clearly defined splenic 
thrombocytolysis had a …more than 90 
percent [chance] of experiencing [CR], 
whereas patients with hepatic 
thrombocytolysis more frequently had an 
unsuccessful…follow-up” 
Najean et al., 1997 (France) 
 
•Extension of Najean et al., 1991 
 
•Chronic thrombocytopenia  
Count < 100 ! 109/L 
 
•Mean platelet lifespan < 48 hours 
 
•No pregnant women & young children 
Scans 
580 
 
Surgeries 
268 
Not 
stated 
Not stated 
111In- 
oxine 
Autologous 
•Relative increase in S:L 
from 0.5 hours to 20% 
survival 
 
Purely Splenic 
S:L increase > 2 
Predominantly Splenic 
1.4 < S:L increase "!# 
Mixed 
0.8 < S:L increase " 1.4 
Hepatic 
0.8 < S:L increase 
Post-Surgery Assessment  
Undefined 
 
CR 
Count > 300 ! 109/L 
 
PR 
Count > 100 ! 109/L 
 
Purely splenic: 138 (51.5%) 
CR: 132 (95.7%); PR: 4 (2.9%) 
 
Predominantly splenic: 74 (27.6%) 
CR: 66 (89.2%); PR: 7 (9.6%) 
 
Mixed: 29 (10.8%) 
CR: 11 (37.9%); PR: 7 (24.1%) 
 
Hepatic: 16 (6.0%) 
CR: 2 (12.5%); PR: 1 (6.3%) 
Louwes et al., 1999 (Holland) 
 
•Count < 100 ! 109/L 
 
•Mean platelet lifespan ! 9.2 days 
Scans 
141 
 
Surgeries 
53 
Scan  
Cohort 
 
Female 
91 
 
Male 
50 
Not stated 
111In-
tropolone 
Autologous 
Not stated 
Post-Surgery Assessment  
Undefined 
CR 
Count > 150 x 109/L 
No prednisolone 
PR 
Count = 50-150 x 109/L 
No prednisolone 
Splenic: 32 (60.4%) 
CR or PR: 28 (87.5%) 
 
Hepatic: 8 (15.1%) 
CR or PR: 2 (25.0%) 
 
Non-splenic: 13 (24.5%) 
CR or PR: 9 (69.2%) 
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 Table 4-1(d): Past Investigations of Radioisotope-Labelled Platelet Sequestration Studies in Primary ITP (2000-Present) 
 
Author, Year (Country) 
Inclusion Criteria Beyond 1997 ASH 
Diagnosis Guidelines 
Study 
Size 
Sex 
 
Age at 
Surgery 
Platelet 
Label 
Origin 
Sequestration 
Classification 
Outcome 
Success Criteria 
Results 
Radaelli et al., 2000 (Italy) 
 
•Unresponsive to prednisolone 
Scan 
59 
 
Surgeries 
65 
Female 
45 
 
Male 
20 
Mean 
37.3 years 
 
Pre-1988 
51Cr 
Not stated 
 
Post-1988 
111In- 
oxine 
Not stated 
Not stated 
Post-Surgery Assessment  
Mean: 129.8 months 
 
CR 
Count > 100 x 109/L 
 
PR 
Count = 50-100 x 109/L 
Splenic: 25 (42.4%) 
CR or PR: 21 (84%) 
 
Mixed or Hepatic : 6 (10.2%) 
CR or PR: 3 (50%) 
 
Other: 28 (47.4%) 
CR or PR: 21 (75%) 
Rossi et al., 2002 (Italy) 
 
•Unresponsive to prednisolone: 
Count  ! 50 ! 109/L after 1 month 
 
•Decision to undergo splenectomy partially 
based on sequestration pattern 
Scans 
71 
 
Surgeries 
25 
Not 
stated 
Mean 
43.4 years 
111In- 
oxine 
Autologous 
•Imaging at 15, 30, 60, 120 
and 240 minutes & 1, 2, 3, 
and 4 days post-injection 
 
•Maximum increase in 
splenic and hepatic uptake 
expressed as a percentage 
of baseline values: " 30% 
(0), 30–49% (1), 50-99% 
(2), 
# 100% (3) 
Post-Surgery Assessment  
(a) Not stated 
(b) Last follow-up 
Median 3 months  
Range: 1-8 months 
CR 
Count > 100 x 109/L 
PR 
Count > 50 x 109/L 
Relapse 
Count < 50 x 109/L 
After initial CR or PR 
Initial CR 
CR: 23 (92.0%), PR: 2 (8.0%) 
 
Relapse 
6 (24.0%) 
 
Non-relapsed vs. relapsed  
No difference in splenic (1.7 vs. 1.3 [p 
= 0.45]) and hepatic (0.5 vs. 0.6 [p = 
0.88]) uptake 
Bourgeois et al., 2002 (France) 
 
•Extension of Fenaux et al., 1989 
 
•Chronic thrombocytopenia 
 
•Lifespan ! 5 days 
 
Scans 
255 
 
Surgeries 
183 
Female 
119 
 
Male 
64 
Median 
32 years 
 
Range 
4–75 years 
111In- 
oxine 
Autologous 
•Relative increase in the 
S:L ratio from 0.5 hours 
to MPLS 
 
Splenic 
S:L increase > 1 
 
Hepatic 
S:L increase < 1 
Post-Surgery Assessment  
3 months 
Response (R) 
Count > 100 x 109/L 
Relapse 
Relapse: Success at least 1 year 
post-surgery among patients with 
success at 3 months 
 
 
Splenic: 157 (86.7%) 
R: 131 (83.4%), relapse: 7 (4.5%) 
 
Hepatic: 24 (13.3%) 
R: 10 (41.7%), Relapse: 2 (20.0%) 
 
Long-Term 
Difference noted in mean S:L ratio 
between responders (2.21) and non-
responders (1.37), p = 0.025 
 
NB: 2 patients who underwent 
splenectomy added in follow-up study 
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The methodologies of these studies were, however, notably heterogeneous 
with regard to the isotopic label used, sequestration classification scheme, patient 
inclusion criteria, and both the definition of and period for response (Table 4-1). 
Moreover, 615,18,19,21-23 (66.7%) uncorrelated or inconclusive studies assessed fewer 
than 50 patients undergoing both a platelet sequestration study and a splenectomy. 
The power of many of these investigations to detect an association between 
sequestration site and response to splenectomy was therefore limited. These 
shortcomings underscore the need for an additional, suitably powered study, which 
incorporates currently standardised isotopic labelling techniques and consensus 
criteria for response evaluation.   
Barts and The London NHS Trust is the principal ITP referral centre for 
adults in the UK, and autologous 111In-labelled platelet sequestration studies have 
been routinely practiced there as part of the planning process prior to splenectomy 
for over a decade. Using the cohort of patients with primary ITP who have 
undergone such studies, the objectives of our investigation were as follows: 1) to 
evaluate the prognostic utility of platelet sequestration site as a predictor of short, 
medium, and long-term response to splenectomy through multivariable logistic 
regression modelling and 2) to compare long-term outcomes from splenectomy with 
alternate therapeutic approaches in patients with primary ITP. 
 
Methods 
Study Design and Population 
A retrospect cohort design was adopted. Inclusion in the study cohort was 
restricted to patients with primary ITP as defined by 2003 BCSH guidelines24 who 
had undergone a 111In-labelled autologous platelet sequestration study at Barts and 
The London NHS Trust between March 1st, 1994 and December 31st, 2008. All 
patients were required to have platelet counts between 5 x 109/L and 100 x 109/L at 
the time of their scan, and no antibody therapies were permitted four weeks prior 
to this date.  
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Autologous 111In-Labelled Platelet Sequestration Study Protocol 
Autologous 111In platelet-labelling was performed in accordance with 
recommendations of The International Committee for Standardization in 
Hematology Panel on Diagnostic Applications of Radionuclides.25 Briefly, whole blood 
(50 mL) was withdrawn from the patient using acid citrate glucose (ACG, 6:1) and 
centrifuged at 90–100 g for 10 minutes. The supernatant (platelet rich plasma [PRP]) 
was adjusted to a pH of 6.5 by further addition of ACG and centrifuged at 650 g for 
10 minutes. The resulting supernatant (platelet poor plasma [PPP]) was used (0.3–0.5 
mL) to suspend the derived platelet pellet. Tropolone (50 µL, 0.054% [w/v] 
tropolone in HEPES-saline buffer [pH 7.6]) was then added to the suspension, 
followed immediately by 111In-chloride (4 MBq). The mixture was incubated at room 
temperature for 5 minutes, washed with PPP (5 mL), and centrifuged at 650g for 10 
minutes. The supernatant (containing unbound 111In-tropolone) was discarded, 
leaving 111In-tropolone-labelled platelets, which were suspended in PPP (5 mL) and 
injected into a peripheral vein.  
At 0.5, 3, 24, and 48 hours post-injection, blood samples (5 mL) were taken 
and centrifuged in a two-stage process to yield PPP and a platelet pellet. Surface 
counting was performed on both products, with a gamma camera set to register 
111In-photon peaks at 171 and 245 KeV. Counting, corrected for background and 
decay, was similarly performed over the heart, liver, and spleen at these intervals 
using the geometric mean of anterior and posterior views. Regions of interest were 
drawn over these organs using the 0.5-hour acquisition and transferred to 
subsequent acquisitions to ensure analysis of identical anatomical areas.  
A semi-logarithmic graph of platelet-associated radioactivity versus time was 
constructed to derive the platelet half-clearance time (t50%), which in turn was used 
to compute the mean platelet lifespan (MPLS) using the algorithm, 1.44! t50%.
17,26 
Najean et al.’s proposed classification system26 was adopted to catergorise platelet 
sequestration. The relative increase in the spleen:liver (S:L) ratio from 0.5 hours to 
the time of 80% platelet destruction was calculated under this scheme, with an 
increase of greater than 2.0 characterised as purely splenic sequestration, between 
1.4 and 2.0 as predominantly splenic sequestration, between 0.8 and 1.4 as mixed 
sequestration, and less than 0.8 as hepatic sequestration.  
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Follow-Up 
 At least one-year following the sequestration study, haematologists were 
questioned as to whether their patients had undergone a splenectomy. For patients 
who had, 1-3 and 6-12 months post-surgery platelet counts were requested in 
addition to treatment status and platelet count at last follow-up. Haematologists of 
patients who did not have a splenectomy were alternatively asked to supply a reason 
(open-field) why surgery was not performed in addition to providing the treatment 
status and platelet count of their patients at last follow-up (Figure 2-3). Official death 
certificates were obtained for patients who died over the course of follow-up.  
 
Outcomes 
 The outcome of interest among the splenectomised population was CR, 
defined using recent guidelines by the International Working Group on ITP27 as a 
platelet count greater than 100 x 109/L at 1-3 (short-term) and 6-12 (medium-term) 
months post-surgery and a platelet count less than 100 x 109/L or reliance on an ITP-
specific treatment at last follow-up (long-term). For the descriptive comparison of 
long-term outcomes among splenectomised and non-splenectomised patients, 
platelet count and ITP-specific treatment status at last follow-up were assessed 
independently.  
 
Exposures & Covariates 
 Platelet sequestration site, dichotomised as purely or predominantly splenic 
and mixed or hepatic, comprised the principal exposure in the study. Additional 
covariates included gender, age at surgery (continuous), and MPLS (continuous).  
 To create a suitable comparative cohort for splenectomised patients, a categorical 
variable of reason(s) for not undergoing surgery was constructed. Open-field 
responses from haematologists were grouped into one of the following ten 
categories: 1) an asymptomatic or only mildly symptomatic patient; 2) co-morbid 
condition(s); 3) a spontaneous, first-line (corticosteroids or IVIg) treatment-based, 
or unspecified remission; 4) a well-controlled patient on a first-line treatment; 5) 
physician, parent, or patient choice 6) a non-first-line treatment-based remission; 7) 
a well-controlled patient on a non-first-line treatment; 8) platelet sequestration study 
test result; 9) multiple reasons; 10) no reason provided. Patients listed as having 
undergone surgery for reason 5, 6, 7, 8, or 9 (without their reasons classifiable under 
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1, 2, 3, or 4 above) were selected to comprise the comparative, non-splenectomised 
cohort.   
 
Statistical Analyses  
The investigation was framed with an aim to determine whether autologous 
111In-labelled platelet sequestration studies could identify patients who would benefit 
from surgery. Unadjusted and adjusted (gender, age at splenectomy, and MPLS) odds 
ratios (ORs) and 95% confidence intervals (95% CIs) for CR at 1-3 and 6-12 months 
post-surgery and last follow-up were modelled using logistic regression (STATA 9.2; 
College Station, Texas).    
For all secondary analyses, differences between groups were evaluated at ! = 
0.05 using Student’s t (two-tailed), Kruskal-Wallis, and Pearson’s chi-square tests for 
normally distributed, non-parametric, and dichotomous outcomes, respectively. 
Determination of normality for continuous variables was based on visual inspection 
of both box-plots and histograms.  
 Date of primary ITP diagnosis was available for a subset of patients 
undergoing autologous 111In-labelled platelet sequestration studies. A pre-hoc 
decision was therefore made to perform subgroup analyses, incorporating disease 
duration at the time of splenectomy as an additional covariate in the multivariable 
logistic regression models outline above.     
 To supplement these analyses, histograms were constructed of platelet 
counts among the purely or predominantly splenic and mixed or hepatic, 
splenectomised cohorts at 1-3 months and 6-12 months post-surgery. Similar 
histograms were made of platelet counts at last follow-up for both these cohorts and 
the comparative, non-splenectomised cohort.  
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Ethics 
The study was conducted under the auspices of the UK Adult ITP Registry, 
an active, linked-anonymised repository of hospital-based clinical data and biological 
samples of adult patients with primary ITP established to uncover information 
pertaining to disease pathogenesis, treatment effectiveness, and co-morbid burden. 
Launched in late-2007, the UK Adult ITP Registry has been approved for multi-
centre operation by the London Research Ethics Committee (Reference: 
07/H0718/57) until mid-2017 and is sponsored by Barts and The London NHS Trust. 
Informed consent was obtained from every patient prior to enrolment. All patients 
who were children (< 16 years) at the time of their autologous 111In-labelled platelet 
sequestration study had reached adulthood by the time of study initiation.  
 
Results 
Autologous 111In Sequestration Studies 
A total of 272 autologous 111In sequestration studies were conducted at Barts 
and The London NHS Trust between March 1st, 1994 and December 31st, 2008. As 
illustrated by Figure 4-1, scans were performed on 256 patients with primary ITP, 9 
with secondary ITP (7 with SLE-induced thrombocytopenia and 2 with HIV-induced 
thrombocytopenia), 4 with congenital or familial thrombocytopenia, and 3 with Evans 
syndrome. The female-to-male ratio of patients with primary ITP was 1.7:1, and the 
median age at the time of scan was 38.0 years (range: 7.3-75.4 years).  
Platelet sequestration patterns among the primary ITP cohort were 
heterogeneous: 68 (26.6%) patients exhibited purely splenic sequestration, 76 
(29.7%) predominantly splenic sequestration, 60 (23.4%) mixed sequestration, and 52 
(20.3%) hepatic sequestration (Figure 4-2). The median MPLS in patients with 
primary ITP was 28.2 hours (range: 6.8-407.0 hours). A significant difference (p = 
0.491) was not noted between the MPLS of patients with purely or predominantly 
splenic platelet sequestration and patients with mixed or hepatic platelet 
sequestration (median: 25.9 hours [range: 6.8-407.0 hours] vs. 31.1 hours
[range: 7.2-271.0 hours]).
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Figure 4-1: An overview of the study population. In total, 265 patients with primary ITP underwent autologous 111In-labelled platelet sequestration studies at 
Barts and The London NHS Trust between March 1994 and December 2008, with 91 (35.5%) of patients subsequently proceeding to splenectomy. 
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Follow-Up 
   Over one-third of patients with primary ITP (N = 91 [35.5%]) elected to 
undergo a splenectomy following their autologous 111In sequestration study while 
roughly half (N = 131 [51.2%]) did not. Thirty-four patients (13.3%) were lost to 
follow-up (Figure 4-1). These patients did not differ significantly from patients not 
lost to follow-up with regard to age at the time of the scan (mean: 39.5 ± 18.7 years 
vs. 38.3 ± 17.5 years; p = 0.712), sex (female:male ratio: 2.8:1 vs. 1.6:1; p = 0.183), 
platelet sequestration pattern (purely and predominantly splenic: mixed &  hepatic 
ratio: 1.4:1 vs. 1.3:1; p = 0.745), or MPLS (median: 36.3 hours [range: 9.0-169.3 
hours] vs. 27.6 hours [range: 6.8-407.0 hours]; p = 0.314).   
 
    
Figure 4-2: Sequestration patterns of patients who underwent an autologous 
111In-labelled platelet study and patients who subsequently underwent 
splenectomy. A statistically significant difference (p < 0.001) was observed between the 
proportions of purely or predominantly splenic versus mixed or hepatic patterned patients 
proceeding to splenectomy. 
 
Haematologist supplied reasons for patients not undergoing splenectomy, 
documented in Table 4-2, most commonly included 1) the platelet sequestration test 
result (i.e., a mixed or hepatic sequestration finding suggesting a lower probability of 
response to splenectomy, N = 39 [29.8%]); 2) an asymptomatic or only mildly 
symptomatic patient (N = 26 [19.8%]); and 3) patient, parent, or clinician choice (N 
= 23 [16.0%]).  
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  Of 71 patients with purely or predominantly splenic sequestration who opted 
for a splenectomy, 57 (80.3%) had evaluable results at 1-3 months post-surgery, 54 
(76.1%) at 6-12 months post-surgery, and 69 (97.2%) at last follow-up. CRs were 
observed in 50 (87.7%), 44 (87.0%), and 60 (87.0%) of these patients, respectively. Of 
20 patients undergoing splenectomy with a mixed or hepatic pattern of platelet 
sequestration, 19 (95.0%) had evaluable results at 1-3 months post-surgery, 18 
(90.0%) at 6-12 months post-surgery, and 20 (100%) at last follow-up, with 7 (36.8%), 
5 (27.8%), and 7 (35.0%) experiencing CRs, respectively. Median post-surgical times 
at last follow-up were 3.8 years (range: 0.5-13.1 years) for the purely or 
predominantly splenic, splenectomised cohort, over which no deaths were reported, 
and 2.8 years (range: 0.5-10.8 years) for the mixed or hepatic, splencetomised 
cohort, over which the following 2 non-haemorrhagic fatalities were observed: 1) 
acute myocardial infarction and coronary atherosclerosis, 2) cerebral infarction and 
type II diabetes.  Histograms of patient platelet counts within these cohorts at the 
aforementioned assessment intervals are illustrated in Figures 4-3 and 4-4. 
Table 4-2: Reasons for Not Proceeding to Splenectomy
Reason (s) Number (%) 
Test Result  39 (29.8) 
Asymptomatic or Only Mildly Symptomatic  26 (19.8) 
Patient, Parent, or Clinician Choice 23 (16.0) 
Treatment-Based Remission 
              Corticosteroids 
              Rituximab 
              IVIg 
              Various Treatments 
              Platelet Transfusion & Corticosteroids 
              Unspecified Treatment  
11 (8.4) 
5 
2 
1 
1 
1 
1 
Multiple Reasons  
              Test Result & Patient Choice 
              Test Result & Mildly Symptomatic Patient  
              Test Result & Treatment-Based Remission (Corticosteroids) 
              Co-Morbid Condition & Only Mildly Symptomatic Patient  
8 (6.1) 
5 
1 
1 
1 
Co-Morbid Condition(s) 5 (3.8) 
Spontaneous Remission  5 (3.8) 
Unspecified Remission  4 (3.1) 
Well Maintained on Non-First Line Treatment 
              Azathioprine 
              Rituximab  
              Tranexamic Acid 
3 (2.3) 
1 
1 
1 
No Reason Provided  6 (4.6) 
Total                                                       131 
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Figure 4-3: Histograms of platelet counts (!109/L) among the purely or predominantly splenic (0) and mixed or hepatic (1), 
splenectomised cohorts at 1-3 months (a) and 6-12 (b) months post-splenectomy. The size of each bar is representative of the proportion of patients 
in the cohort with a platelet count in the specified range.    
a b 
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Figure 4-4: Histograms of platelet counts (!109/L) among the purely or predominantly splenic (0) and mixed or hepatic (1), 
splenectomised cohorts and the comparative, non-splenectomised cohort (2) last follow-up. The size of each bar is representative of the proportion 
of patients in the cohort with a platelet count in the specified range.     
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Multivariable Modelling  
   Unadjusted and adjusted (gender, MPLS, and age at splenectomy) odds of short, 
medium, and long-term CR to splenectomy were increased in patients with purely or 
predominantly splenic versus mixed or hepatic sequestration. Logistic regression 
modelling yielded statistically significant, unadjusted ORs at 1-3 months post 
splenectomy (OR = 4.96 [95% CI, 1.41-17.46]) and last follow-up (OR = 3.59 [95% 
CI, 1.13-11.40]), but not at 6–12 months post-splenectomy (OR = 2.58 [95% CI, 
0.70-9.49]). Adjusted ORs at these intervals were all significant: 1-3 months post-
splenectomy (OR = 7.47 [95% CI, 1.89-29.43], 6-12 months post-splenectomy (OR = 
4.85 [95% CI, 1.04-22.54], and last follow-up (OR = 5.39 [95% CI, 1.34-21.65]. The 
median post-surgery time at last outpatient visit was 3.8 years (range: 0.5-13.1 years). 
No other potential, pre-surgical, predictive variable achieved statistical significance at 
1-3 months and 6-12 months post-surgery (Table 4-3). However, age at the time of 
surgery did emerge as an independent predictor of CR at last follow-up (OR: 0.95 
[95% CI, 0.91-0.99]).  
 
Table 4-3: Multivariable Logistic Regression Results 
 
Post-Surgery 
Assessment Time 
N 
Pattern 
PS/PS vs. M/H* 
OR (95% CI)† 
Gender 
Female vs. Male 
OR (95% CI) 
MPLS 
OR (95% CI) 
Per Hour 
 
Age at 
Surgery 
OR (95% CI) 
Per Year 
Post-ITP 
Duration 
OR (95% CI) 
Per Month 
Primary Analyses 
1-3 Months 71 7.47 (1.89-29.43) 0.76 (0.18-3.13) 1.01 (0.98-1.03) 0.99 (0.94-1.03) 
6-12 Months 67 4.85 (1.04-22.54) 3.69 (0.85-15.91) 1.01 (0.98-1.05) 0.96 (0.91-1.00) 
Last Follow-Up 
Median: 3.8 years 
(Range: 0.5-13.1 years) 
84 5.39 (1.34-21.65) 2.70 (0.75-9.68) 1.01 (0.98-1.04) 0.95 (0.91-0.99) 
 
Subgroup Analyses 
1-3 Months 43 8.01 (1.63-39.50) 1.45 (0.26-8.07) 1.00 (0.96-1.05) 1.00 (0.95-1.06) 1.10 (0.90-1.35) 
6-12 Months 39 23.40 (1.87-292.33) 0.21 (0.02-1.78) 1.04 (0.97-1.10) 1.00 (0.93-1.08) 0.93 (0.74-1.17) 
Last Follow-Up 
Median: 4.1 years 
(Range: 0.5-13.1 years) 
52 9.20 (1.54-54.94) 0.20 (0.04-1.11) 1.03 (0.98-1.08) 0.96 (0.91-1.02) 1.32 (0.77-2.27) 
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Inclusion of the lapse of time between primary ITP onset and splenectomy as 
an additional covariate for patients with available diagnosis dates, while altering the 
OR point estimates, did not influence the statistical significance of platelet 
sequestration pattern as a pre-surgical predictor of response at 1-3 months post 
splenectomy (OR: 8.01 [95% CI, 1.63-39.50], 6-12 months post-splenectomy (OR: 
23.40 [95% CI, 1.87-292.33]), or last follow-up (OR: 9.20 [95% CI, 1.54-54.94]).   
 
Splenectomised vs. Comparative, Non-Splenectomised Cohorts 
   In total, 72 (55.0%) patients with primary ITP who did not undergo 
splenectomy met inclusion criteria for the comparative, non-splenectomised cohort. 
CRs were observed in 13 (19.1%) of these patients over a median post-scan follow-
up time of 2.7 years (range: 0.1-11.4 years; Table 4-4). Over this period, the 
following two non-haemorrhagic deaths were reported: 1) parieto occiptal 
ependymoma and 2) chronic myelomonocytic leukaemia and renal 
impairment/septicaemia. While the median platelet count of this cohort (58 ! 109/L 
[range: 2-358 ! 109/L]) was significantly lower than both the mixed or hepatic, 
splenectomised cohort (199 ! 109/L [range: 2-577 ! 109/L]) and the purely or 
predominantly splenic, splenectomised cohort (292 ! 109/L [range: 14-589 ! 109/L]; 
p < 0.001) at last follow-up (Figure 4-4), the proportion of patients on treatment 
within the comparative, non-splenectomised cohort was comparable to that of the 
mixed or hepatic, splenectomised cohort (28 [41.2%] patients vs. 6 [30.0%] patients, 
respectively; p = 0.47). Furthermore, of the 28 patients in the comparative, non-
splenectomised cohort on treatment at last follow-up, 8 (28.6%) were solely taking 
low-dose corticosteroids (< 10 mg/day). Notably, only 3 (4.3%) splenectomised 
patients with purely or predominantly splenic platelet sequestration were on 
treatment at last follow-up (Table 4-4).  
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Table 4-4: Long-Term Outcomes of Study Participants 
 
 
Discussion 
The results of this investigation revealed increased odds of short, medium, 
and long-term response to splenectomy in patients with purely or predominantly 
splenic sequestration as determined by autologous 111In-labelled platelet studies. CRs 
at these intervals were observed between 85% and 90% of splenectomised patients 
comprising this cohort, with reliance on treatment limited to 3 (4.3%) patients at last 
follow-up, a median post-surgery time of 3.8 years (range: 0.5-13.1 years). Patient age 
at the time of splenectomy additionally emerged as an independent predictor of long-
term response, implicating a 5% increased odds of CR per year difference between 
patients, a finding consistent with a majority of past investigations.4 Taken together, 
these results highlight splenectomy as an extremely effective treatment for younger 
patients with purely or predominantly splenic sequestration. 
The observation of a significant association between platelet sequestration 
pattern and CR was not affected by the incorporation of primary ITP duration as an 
additional covariate in subgroup analyses (Table 4-3). Curiously, this association also 
did not appear tied to differences in median MPLS, estimates of which were similar 
between patients with purely or predominantly splenic (31.1 hours [range: 7.2-271.0 
hours] and mixed or hepatic (25.9 hours [range: 6.8-407.0 hours]; p = 0.491) 
sequestration. These data suggest that the rate of platelet destruction may be 
independent of both the primary site of platelet destruction and the likelihood of 
response to splenectomy in patients with primary ITP, a different conclusion than 
reached by Siegel et al. 22  
 Long-term outcomes, as measured by platelet count and ITP-specific 
treatment status, among patients indicated but not opting for splenectomy (i.e., the 
comparative, non-splenectomised cohort) were poor in relation to splenectomised 
Cohort 
Total 
N 
Evaluable 
N 
Complete 
Response 
N (%) 
Post-Scan Time 
Median (Range) 
Years 
Platelet Count 
Median (Range) 
!  109/L 
On 
Treatment 
N (%) 
Purely or Predominantly 
Splenic, Splenectomised  
71 69 60 (87.0) 3.0 (0.7-14.4) 292 (14-589) 3 (4.3) 
Mixed or Hepatic, 
Splenectomised  
20 20 7 (35.0) 3.0 (0.8-12.0) 199 (2-577) 6 (30.0) 
Comparative, 
Non-Splenectomised 
72 
72-Count 
68-Treatment 
55 (80.9) 2.8 (0.1-11.4) 56 (1-358) 28 (41.2) 
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patients with purely or predominantly splenic platelet sequestration. However, the 
treatment status of patients within this cohort was comparable to that of 
splenectomised patients with mixed or hepatic sequestration. At last follow-up, 28 
(41.2%) and 6 (30.0%) patients from these cohorts were on treatment, respectively 
(Table 4-4). Moreover, when excluding patients taking solely low-dose 
corticosteroids, the difference between these proportions narrowed as follows: 20 
(30.0%) vs. 5 (25.0%) patients, respectively.  
More controversially, then, the study data may further support the adoption 
of a cautious approach to splenectomy for patients with mixed or hepatic 
sequestration. Coupled with increased recognition of the physiological importance of 
the spleen, potential long-term vascular complications following splenectomy for 
haematological disorders,28 and arguably similar long-term clinical outcomes (e.g., 
reliance on treatment) in patients indicated but not opting for splenectomy, the 
association platelet sequestration pattern with CR raises the question as to whether 
patients with mixed or hepatic platelet sequestration may fare comparably or better 
without splenectomy. The median platelet count of the comparative, control cohort 
(56 ! 109/L [range: 1-358 ! 109/L]) was admittedly lower than that of the mixed or 
hepatic, splenectomised cohort (199 ! 109/L [range: 2-577 ! 109/L]; p < 0.001). 
However, most patients, 83.8% (57 of 68 patients), in the former cohort had counts 
above what ITP specialists conventionally consider a primary threshold for increased 
risk of major bleeding events, 10 ! 109/L (Figure 4-4).29 Furthermore, no fatal 
haemorrhages were observed in this group over a median of 2.7 years (range: 0.1-
11.4 years).  
 Four methodological strengths make our study an important addition to 
existing literature on the utility of platelet sequestration studies in patients with 
primary ITP. First, the use of 111In-tropolone may have contributed to more accurate 
test results than previous investigations utilising either 51Cr or 111In-oxine. 111In-
tropolone has been reported by some research groups to exhibit better platelet 
labelling efficiency and imaging properties than 51Cr.30 It is additionally more soluble 
than 111In-oxine in aqueous media, sparing possible platelet impairment from the 
addition of ethyl alcohol used with the latter radionuclide label.31 
Second, the labelling of autologous platelets enabled accurate adjustment for 
MPLS in our logistic regression models, preventing potentially spurious findings that 
may have resulted from alloimunization.32 Importantly, it was this substitution of 
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allogeneic platelets with autologous platelets by Ballem et al. that illustrated the 
existence of suboptimal levels of platelet production among a segment of primary 
ITP population.33 
Implementation of separate, multivariable logistic regression models to gauge 
short, medium, and long-term post-splenectomy, thirdly, enabled adjustment for 
potential confounders such as age at the time of surgery.  
Fourth, the creation of a cohort of patients indicated but not opting for 
splenectomy represented a novel construct by which to compare long-term 
outcomes in splenectomised and non-splenectomised patients. Although past 
investigations have aptly documented a high success rate for splenectomy in patients 
with primary ITP, it remained unclear whether equivalent outcomes were possible 
under an alternate management paradigm.  
 Four limitations to the study should similarly be noted. First, while data were 
collected on 91 patients undergoing splenectomy following an autologous 111In-
labelled platelet sequestration study, the results of the scan were not blinded to 
patients or their haematologists. As a result, only 20 (20.4%) patients with mixed or 
hepatic sequestration elected to undergo surgery. The significant difference in the 
proportions of patients with mixed or hepatic versus purely or predominantly 
splenic sequestration proceeding to splenectomy (p < 0.001; Figure 4-2) raises the 
possibility of selection bias, namely that mixed or hepatic patterned patients who 
opted for splenectomy were worse off than those who did not. Though plausible, it 
is similarly possible for haematologists to have encouraged surgery among mixed or 
hepatic patterned patients deemed more likely to succeed. To address this issue, 
post-hoc analyses were conducted on a subset of patients for whom pre-surgery 
platelet counts and post-diagnosis duration were available. Neither variable differed 
significantly (p = 0.59 and p = 0.83, respectively). Furthermore, mixed or hepatic 
patterned patients who underwent splenectomy were on average eleven years (p = 
0.01) younger than those who did not, suggesting that results would have been 
biased toward, rather than away from, the null.  
 Second, though advocated by the International Working Group on ITP,27 use 
of 100 ! 109/L as a platelet count threshold for CR may have discounted clinically 
relevant responses to splenectomy. Ideally, effectiveness would have been assessed 
by therapeutic impact on not only platelet count but also the bleeding events and 
HRQoL. However, sufficient data were not available to gauge the effect of 
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splenectomy on the latter two variables, an inherent limitation of retrospective 
investigations. Despite this shortcoming, the relative distributions of platelet counts 
among the purely or predominantly and mixed or hepatic, splenectomised cohorts at 
each of the assessment intervals (Figures 4-3 and 4-4) suggest that a greater 
proportion of patients within the latter cohort continued to have platelet counts 
placing them at increased risk of major haemorrhage (i.e., < 10 ! 109/L) following 
surgery.   
Third, the algorithm used to capture MPLS yielded skewed results for 
patients with near-normal platelet lifespans, as it has been shown to perform poorly 
in situations of uniform destruction (i.e., normal MPLS).34 These errant results at the 
normal end of the MPLS spectrum may have been compounded by the limited time 
points at which blood samples were taken (0.5, 3, 24, and 48 hours post-injection), 
which may have hindered accurate regression of platelet associated radioactivity on 
time. However, as the vast majority of study patients, 94.5% (225 of 238 patients for 
whom MPLS was evaluable), exhibited a markedly reduced MPLS of less than 4 days, 
it is unlikely that the multivariable models were appreciably biased.  
 Fourth, haematologists’ supplied reasons for patients not undergoing 
splenectomy were subjective and susceptible to possible recall bias. Use of these 
reasons nevertheless likely resulted in an improved picture of probable long-term 
outcomes had patients in the splenectomised cohort not opted for surgery than 
evaluation of results from the non-splenectomised cohort as a whole.  
  In conclusion, while this investigation demonstrates utility in including 
autologous 111In-labelled platelet sequestration studies as an adjunct predictive tool 
prior to splenectomy in primary ITP, the aforementioned limitations illustrate that 
considerable work is still needed on this topic. Potentially useful next steps include a 
meta-analysis of observational studies and the development of an international 
prospective cohort study. The latter project would permit critical appraisal of 
proposed refinements to the scanning protocol and the incorporation data from 
autologous 111In-labelled platelet sequestration studies, which were beyond the scope 
of this investigation (e.g., platelet production levels). 
 
 
 
 
 
 !
! 89!
References 
 
1.Provan D, Stasi R, Newland AC, et al. International consensus report on the  
investigation and management of primary immune thrombocytopenia. Blood. 
2010;115:168-186. 
 
2.Cines DB, McKenzie SE, Siegel DL. Mechanisms of action of therapeutics in   
idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25 Suppl 
1:S52-56. 
 
3.Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site  
for activation of platelet-reactive T and B cells in patients with immune  
thrombocytopenic purpura. J Immunol. 2002;168:3675-3682. 
 
4.Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with 
idiopathic thrombocytopenic purpura: a systematic review to assess long-term 
platelet count responses, prediction of response, and surgical complications. Blood. 
2004;104:2623-2634. 
 
5.Wanachiwanawin W, Visudhiphan S, Pinankijagum A, Vatanavicharn S. Therapy of 
chronic idiopathic thrombocytopenic purpura in adults: experiences from Thailand. 
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:71-75. 
6.Robinette CD, Fraumeni JF, Jr. Splenectomy and subsequent mortality in veterans 
of the 1939-45 war. Lancet. 1977;2:127-129. 
 
7.Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-
splenectomy patients. J Infect. 2001;43:182-186. 
 
8.Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up 
after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J 
Hematol. 2003;72:94-98. 
 
9.Burger T, Schmelczer M, Kett K, Kutas J. Immune thrombocytolytic purpura (ITP): 
a diagnostic and therapeutic survey of 86 cases with regard to the results of 
splenectomy and conservative therapy. Acta Med Acad Sci Hung. 1978;35:213-224. 
 
10.Russo D, Gugliotta L, Mazzucconi MG, et al. Long-term results of splenectomy in 
adult chronic idiopathic thrombocytopenic purpura. Haematologica. 1987;72:445-
449. 
 
11.Najean Y, Rain JD, Billotey C. The site of destruction of autologous 111In-labelled 
platelets and the efficiency of splenectomy in children and adults with idiopathic 
thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J 
Haematol. 1997;97:547-550. 
 
12.Lamy T, Moisan A, Dauriac C, Ghandour C, Morice P, Le Prise PY. Splenectomy 
in idiopathic thrombocytopenic purpura: its correlation with the sequestration of 
autologous indium-111-labeled platelets. J Nucl Med. 1993;34:182-186. 
 !
! 90!
13.Winde G, Schmid KW, Lugering N, et al. Results and prognostic factors of 
splenectomy in idiopathic thrombocytopenic purpura. J Am Coll Surg. 1996;183:565-
574. 
 
14.Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-
term follow-up of chronic autoimmune thrombocytopenic purpura refractory to 
splenectomy: a prospective analysis. Br J Haematol. 2003;120:1079-1088. 
 
15.Ries CA. Platelet kinetics in autoimmune thrombocytopenia: relation between 
splenic platelet sequestration and response to splenectomy. Ann Intern Med. 
1977;86:194-195. 
 
16.den Ottolander GJ, Gratama JW, de Koning J, Brand A. Long-term follow-up 
study of 168 patients with immune thrombocytopenia. Implications for therapy. 
Scand J Haematol. 1984;32:101-110. 
 
17.Fenaux P, Caulier MT, Hirschauer MC, Beuscart R, Goudemand J, Bauters F. 
Reevaluation of the prognostic factors for splenectomy in chronic idiopathic 
thrombocytopenic purpura (ITP): a report on 181 cases. Eur J Haematol. 
1989;42:259-264. 
 
18.Naouri A, Feghali B, Chabal J, et al. Results of splenectomy for idiopathic 
thrombocytopenic purpura. Review of 72 cases. Acta Haematol. 1993;89:200-203. 
 
19.Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in 
patients with idiopathic thrombocytopenic purpura. Am J Med. 1999;106:430-434. 
 
20.Radaelli F, Faccini P, Goldaniga M, et al. Factors predicting response to 
splenectomy in adult patients with idiopathic thrombocytopenic purpura. 
Haematologica. 2000;85:1040-1044. 
 
21.Rossi G, Cattaneo C, Motta M, Pizzocaro C, Lanzi S, Pouche A. Platelet kinetic 
study in patients with idiopathic thrombocytopenic purpura (ITP) refractory or 
relapsing after corticosteroid treatment. Hematol J. 2002;3:148-152. 
 
22.Siegel RS, Rae JL, Barth S, et al. Platelet survival and turnover: important factors in 
predicting response to splenectomy in immune thrombocytopenic purpura. Am J 
Hematol. 1989;30:206-212. 
 
23.Ikkala E, Kivilaakso E, Kotilainen M, Hastbacka J. Treatment of idiopathic 
thrombocytopenic purpura in adults. Long-term results in a series of 41 patients. 
Ann Clin Res. 1978;10:83-86. 
 
24.Guidelines for the investigation and management of idiopathic thrombocytopenic 
purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-596. 
 
25.Recommended method for indium-111 platelet survival studies. International 
Committee for Standardization in Hematology. Panel on Diagnostic Applications of 
Radionuclides. J Nucl Med. 1988;29:564-566. 
 
 !
! 91!
26.Najean Y, Dufour V, Rain JD, Toubert ME. The site of platelet destruction in 
thrombocytopenic purpura as a predictive index of the efficacy of splenectomy. Br J 
Haematol. 1991;79:271-276. 
 
27.Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, 
definitions and outcome criteria in immune thrombocytopenic purpura of adults and 
children: report from an international working group. Blood. 2009;113:2386-2393. 
 
28.Crary SE, Buchanan GR. Vascular complications after splenectomy for 
hematologic disorders. Blood. 2009;114:2861-2868. 
 
29.Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): 
management of refractory itp in adults. Br J Haematol. 2002;118:933-944. 
 
30.Robertson JS, Dewanjee MK, Brown ML, Fuster V, Cesebro JH. Distribution and 
dosimetry of 111In-labeled platelets. Radiology. 1981;140:169-176. 
 
31.Dewanjee MK, Rao SA, Rosemark JA, Chowdhury S, Didisheim P. Indium-111 
tropolone, a new tracer for platelet labeling. Radiology. 1982;145:149-153. 
 
32.Stratton JR, Ballem PJ, Gernsheimer T, Cerqueira M, Slichter SJ. Platelet 
destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of 
indium-111-labeled autologous platelets. J Nucl Med. 1989;30:629-637. 
 
33.Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. 
Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic 
purpura. Evidence of both impaired platelet production and increased platelet 
clearance. J Clin Invest. 1987;80:33-40. 
 
34.Cook GJR MM, Britton KE, Chengazi V.  Clinical Nuclear Medicine (ed 4th). 
London: Hodder Arnold; 2006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
! 92!
Chapter 5: Effects of eradication of Helicobacter pylori infection in 
patients with primary ITP 
 
Summary 
Multiple single-centre studies have been conducted on the effect of 
eradication therapy on platelet counts in Helicobacter pylori (H. pylori)-infected 
patients with primary ITP. To synthesise and interpret the results of these 
investigations, a meta-analysis was performed. PubMed, EMBASE and Cochrane 
databases were interrogated for English-language articles detailing studies of 15 or 
more patients. Twenty-five such studies were identified, encompassing 696 evaluable 
patients. To enable comparisons of response to eradication therapy, recently 
adopted criteria by the International Working Group on ITP were employed to re-
catergorise individual study results. Owing to observed heterogeneity, DerSimonian 
and Laird random-effects models were used to pool data across studies, revealing a 
mean complete response (> 100 ! 109/L) of 42.7% (95% CI, 31.8%-53.9%) and a 
response (> 30 ! 109/L and at least double the baseline count) of 50.3% (95% CI, 
41.6%-59.0%). Linear regression demonstrated a significant, direct correlation. (r = 
0.351, p = 0.018) between the reported response and the prevalence of infection in 
the source population. Given the limited invasiveness of diagnostic tests and both the 
limited toxicity and low costs of eradication therapy, these findings support the 
routine testing for and eradication of H. pylori infection in patients with primary ITP 
in regions with a high prevalence of infection. 
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Introduction 
H. pylori is a Gram-negative microaerophilic bacterium capable of colonising 
the human stomach.1 Evidence for its causal role in the onset of peptic ulcer disease 
was first uncovered by Marshall and Weiner2 almost 30 years ago, spurring a 
dramatic increase in research into the bacterium and its possible involvement in the 
pathogenesis of other diseases. The prevalence of H. pylori infection is strongly 
correlated with the underlying socioeconomic conditions of a population, with higher 
rates of infection commonly observed in developing countries (Figure 5-1).1  
Conventional treatment for the eradication of the bacterium consists of triple 
therapy, a combination of amoxicillin, clarithromycin, and a proton pump inhibitor 
administered for one to two weeks.1 
       
 
Figure 5-1: A map of the global prevalence (in percentages) of H. pylori infection.  
With the exception of Japan, higher rates of infection are typically present in developing countries. 
Image courtesy of the Helicobacter Foundation.  
 
As discussed in Chapter 1, a relationship between H. pylori infection and 
primary ITP was first described by Gassbarini et al.3 1998, who reported a significant 
increase in platelet counts among 8 (72.7%) patients in whom the bacterium had 
been eradicated. Since then, numerous single-centre investigations have been 
conducted, yielding seemingly discrepant results. To synthesise and interpret these 
data, a meta-analysis of studies describing the effects of H. pylori eradication on 
platelet counts in adult patients with primary ITP was performed. 
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Methods 
Literature Search  
Searches for English language articles were conducted independently by two 
investigators in April 2008 using the electronic databases PubMed, EMBASE, the 
Cochrane Central Register of Controlled Trials, the Cochrane Database of 
Systematic Reviews, and the Cochrane Database of Abstracts of Reviews of Effects. 
PubMed was interrogated by combining the medical subject heading (MeSH) term 
“Helicobacter pylori” with “thrombocytopenia” or “purpura, thrombocytopenic, idiopathic”. 
A similar search strategy was employed for EMBASE whereas the Cochrane 
databases were reviewed for titles containing terms “Helicobacter pylori” or 
“thrombocytopenia”. The bibliographies of articles retrieved in this manner were 
further scanned for relevant publications. The abstracts of all articles secured from 
this combined search were subsequently evaluated on the criteria detailed below.  
 
Criteria for Article Selection 
An initial screening was performed for RCTs, cohort studies, and case-
control studies evaluating the effects of H. pylori eradication on platelet counts in 
adult patients with primary ITP. Studies published in abstract form or involving less 
than 15 patients alone were deemed ineligible for inclusion, while those of 15 or 
more patients were reviewed to determine whether diagnoses had been made 
according to ASH guidelines.4 Studies lacking reference to these guidelines were 
considered eligible only if secondary causes of thrombocytopenia had been clearly 
excluded (e.g., HCV, HIV, and SLE).  
Documentation of H. pylori infection was required to have been carried out 
by tests indicating active infection (e.g., a 13C-Urea Breath Test [UBT], a stool antigen 
test, or a histology of gastric biopsies). Serological tests were not considered 
adequate in this regard due to their comparatively low sensitivity and specificity.5  
Finally, studies had to be evaluable for the effects of H. pylori eradication on 
platelet count over time. Disagreements over the final selection of articles were 
resolved by consensus in all cases. When a study had generated multiple publications, 
the latest or most informative version was used. Duplicate publications were used to 
provide information on baseline characteristics or methodology where necessary.  
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Data Extraction 
Data extraction of each article was similarly carried out independently by two 
investigators. Individual-level patient data from studies were sought in the first 
instance. If patient-level data were not reported, group-level data were used. For the 
purposes of this review, the following data were collected: 1) study design and use of 
controls, 2) patient demographics, 3) previous and concomitant treatment for 
primary ITP, 4) baseline platelet count, 5) duration of primary ITP before eradication 
treatment, 6) diagnostic methods for H. pylori detection, 7) type and duration of the 
eradication regimen administered, 8) proportion of H. pylori infections eradicated, 9) 
criteria for platelet count response, 10) proportion of patients with platelet count 
responses, 11) time to platelet count responses, 12) follow-up and duration of 
platelet count responses, 13) effects of H. pylori eradication therapy on uninfected 
patients, and 14) predictors of platelet response. Discrepancies in extracted data 
were resolved by the two reviewers through joint reassessment of the original 
publication. For publications with missing or incomplete information, attempts were 
made to obtain additional data from study authors. 
 
Assessment of Validity  
The quality of cohort studies was assessed with the Newcastle-Ottawa Scale,6 
which assigns a score to three aspect of a study: selection bias, comparability of 
cohorts on the basis of design or analysis, and outcome assessment. An overall 
measure of quality was generated by adding these scores (highest score: 9). 
The quality of RCTs were assessed with a scale created by Jadad et al.7 In this 
instrument, 0 to 2 points are assigned for randomisation, 0 to 2 points are assigned 
for double blinding, and 0 to 1 points are assigned for a description of withdrawals 
and dropouts, resulting in a possible cumulative score of 0 to 5 (highest score: 5).  
 
Assessment of Publication Bias 
Susceptibility of the systematic review to publication bias, the tendency of 
studies with positive findings to be preferentially published, was formally assessed 
with Eggar’s test, an inverse-variance weighted linear regression of the effect against 
its standard error, and was coupled with an informal visual inspection of funnel plot 
asymmetry.8 Heterogeneity among studies was assessed with Cochran’s Q test9 and 
the I2 test of inconsistency.10 
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Quantitative Data Synthesis 
To enable comparisons of response to eradication therapy across studies, 
recently adopted criteria by the International Working Group on ITP11 were 
employed to re-catergorise individual study results. Accordingly, a complete 
response (CR) was defined as a platelet count greater than 100 x 109/L and an 
overall response as a platelet count greater than 30 x 109/L and at least doubling of 
the baseline count. Where possible, mean platelet counts at baseline and at the time 
of response assessment were calculated, and sensitivity analyses performed in 
patients with baseline platelet counts greater than or less than 30 x 109/L. 
As heterogeneity in response was anticipated, DerSimonian and Laird 
random-effects models were used to pool data for summary estimates.12 Meta-
analyses represent quantitative methods to combine data across similarly structured 
studies (i.e., studies with comparable populations, designs, and outcome measures), 
resulting in greater analytic power. Statistical methods implemented in such analyses 
conventionally place less weight on results from smaller studies owing to their 
greater susceptibility to chance deviation. While fixed-effects meta-analysis models 
are based on an assumption of the existence of a single true value for a population 
parameter, random-effects models are premised on the existence of multiple 
normally distributed values of this parameter and, therefore, incorporate an 
additional measure of between-study variation. This component results in a relatively 
greater weight for smaller studies. 
To stabilize variance, eradication and treatment-response proportions were 
subjected to a Freeman-Tukey arcsin square root transformation and back-
transformed following quantitative data synthesis.13 Proportions of 0 and 1 were 
adjusted as follows to enable their inclusion in study weighting: 0 = 1/(4 ! sample 
size); 1 = (number of successes - 0.25)/(sample size). Results are presented as the 
weighted means with 95% CI. 
Linear regression models were used for correlation analyses. Unweighted, 
chance-corrected " values were calculated to assess agreement on study selection 
between the reviewers.14 Assessment of publication bias and tests of heterogeneity 
were performed with Stata 8.2 (StataCorp, College Station, Texas); all other 
statistical tests were carried out with NCSS 2007 (NCSS, Kaysville, Utah). 
 
!
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Results 
Selection of Studies 
Figure 5-2 illustrates the results of our literature search. In total, 116 
abstracts were reviewed. Thirty-five articles were selected for full-text evaluation. 
Of 25 non-English language publications excluded, 14 were noted to be narrative 
reviews, 8 were case reports, and one was a survey of current treatment strategies 
in Japan; only 2 articles detailed cohort studies (one with 11 primary ITP patients, 
the other with 20). 
The proportion of agreement for initial study inclusion was 93% (" = 0.84). 
Five duplicate publications and 4 studies reporting less than 15 patients were 
excluded as was one cohort study, which assessed H. pylori infections by serological 
tests alone. In total, 25 studies (1,555 patients with primary ITP) were included in 
our efficacy analyses.  
 
Study Design  
The designs of included studies are detailed in Table 5-1. Briefly, 22 
prospective3,16-36 and 2 restrospective37,38 cohort studies were secured along with a 
single RCT.15 Control populations were used in only 2 cohort studies.27,28 In the 
study by Stasi et al.,28 eradication therapy was only administered to H. pylori-positive 
patients with symptoms of dyspepsia or with platelet counts below 50 x 109/L.  
Newcastle–Ottawa scores for cohort studies included in the meta-analysis 
were all greater than 5. The Jadad score for the sole RCT was 2; although the 
authors reported that patients were randomly assigned by concealed allocation, no 
information was provided on the precise method of randomisation. 
!
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Figure 5-2: A step-wise overview of the literature search. Twenty-five studies were 
included in the systematic review. 
 
Patient Demographics 
Table 5-1 details the baseline characteristics of patients (N = 1,555) from 
studies included (N = 25) in the meta-analysis. The pooled prevalence of H. pylori 
infection among the study population was 65.0% (95% CI, 62.8%-67.3%) and did not 
differ significantly between males (63.4%) and females (66.5%). Information on 
baseline age was available for 1,132 patients from 13 studies.3,17-22,28,29,31,33,36,37 H. pylori-
positive patients were on average 10 years older than H. pylori-negative patients (57.5 
years [95% CI, 56.4-58.5 years] vs. 45.3 years [95% CI, 43.7-46.8 years], respectively; 
p < 0.001). Infection status was not found to be significantly associated with gender, 
primary ITP duration, platelet count, or number of prior treatments.  
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Of 584 H. pylori-positive patients in 11 studies with a detailed treatment 
history,17-22,28,30,35-37 227 (38.9%) had not received any therapy prior to eradication 
while 341 (58.4%) had been administered corticosteroids. Conventional ITP 
treatments such as corticosteroids, azathioprine, and danazol were given 
concomitantly to eradication therapy in 121 (20.7%) patients. 
 !
! 100!
 
Table 5-1: Baseline Characteristics of Patients in Included Studies 
!
    
* Males/Females 
    † Median (range) 
    ‡ Randomised-controlled trial 
!
Authors (Year) Country  Design Total  
N 
Gender 
M/F* 
Infected 
N (%) 
Infected  
Age 
Years  
Non-Infected  
Age 
Years 
Infected  
Count 
!109/L  
Non-Infected  
Count 
!109/L 
ITP 
Duration 
Months 
Concurrent 
Treatment 
Gasbarrini et al. (1998) Italy Prospective Cohort 18 5/13 11 (61) 43 ± 14 49 ± 12 95 ± 39 103 ± 24 NR NR 
Jarque et al. (2001) Spain Prospective Cohort 56 18/38 40 (71) 54 (17-80)† 57 ± 22 58 ± 23 32 (2-50) 0/56 
Kohda et al. (2002) Japan Prospective Cohort 40 12/28 25 (62) 54 ± 14 48 ± 13 67 ± 54 60 ± 41 41 ± 38 19/40 
Hino et al. (2003) Japan Prospective Cohort 30 8/22 21 (70) 55 ± 15 51 ± 17 38 ± 20 22 ± 12 NR 7/30 
Hashino et al. (2003) Japan Prospective Cohort 22 9/13 14 (64) 53 ± 13 42 ± 19 61 ± 26 63 ± 20 110 ± 81 8/22 
Ando et al. (2003) Japan Prospective Cohort 61 12/49 50 (82) 58 ± 11 40 ± 16 56 ± 24 42 ± 24 78 ± 65 NR 
Michel et al. (2004) USA Prospective Cohort 74 21/53 16 (22) 53± 16 39 ± 18 32 ± 15 26 ± 17c 122.4 9/25 
Takahashi et al. (2004) Japan Prospective Cohort 20 5/15 15 (75) 54 ± 13 46 ± 18 40 ± 27 39 ± 22 51 ± 15 NR 
Sato et al. (2004) Japan Prospective Cohort 53 16/37 39 (74) 62 (37-87) 52 (39-77 54 ± 17 59 ± 22 59 (6-624) 27/53 
Ando et al. (2004) Japan Prospective Cohort 20 5/15 17 (85) 62 (38-83) 48 (4-86) 41 (12-82) NR NR 
Nomura et al. (2004) Japan Prospective Cohort 42 15/27 28 (66) NR NR 29 ± 6 31 ± 5 NR NR 
Veneri et al. (2005) Italy Prospective Cohort 52 23/29 34 (65) 57 (24-72) NR 57 ± 23 NR NR NR 
Inaba et al. (2005) Japan Prospective Cohort 35 11/24 25 (71) 57 (25-82) 52 ± 26 40 0/35 
Stasi et al. (2005) Italy/UK Prospective Cohort 137 57/80 64 (47) 58 ± 13 42 ± 16 42 ± 25 46 ± 23 25 ± 19 16/137 
Fujimura et al. (2005) Japan Retrospective Cohort 435 120/315 300 (69) 59 ± 14 47 ± 16 NE NE 98 ± 82 NR 
Suzuki et al. (2005) Japan RCT‡ 36 NR 25 (69) NR NR 55 ± 27 NR NR NR 
Suvajdzic et al. (2006) Serbia Prospective Cohort 54 12/42 39 (72) 54 ± 13 42 ± 16 68 ± 32 78 ± 32 72 (12-360) 0/54 
Ahn et al. (2006) USA Prospective Cohort 15 5/10 15 (100) 57± 19 NE 72 ± 45 NE 104 ± 79 11/15 
Sayan et al. (2006) Turkey Prospective Cohort 34 22/12 20 (59) 51 ± 16 54 ± 18 37 ± 16 39 ± 16 19 ± 15 NR 
Asahi et al. (2006) Japan Prospective Cohort 37 14/23 26 (70) NR NR NR NR NR NR 
Kodama et al. (2007) Japan Prospective Cohort 116 32/74 67 (58) 58 ± 14 48 ± 17 39 ± 29 30 ± 24 NA NA 
Campuzano-Maya (2007) Colombia Retrospective Cohort 32 7/25 29 (91) NR NR 57 ± 38 NR NR NR 
Estrada-Gomez (2007) Mexico Prospective Cohort 23 NR 14 (61) NR NR NR NR NR NR 
Satake (2007) Japan Prospective Cohort 38 9/29 12 (68) NR NR NR NR NR NR 
Emilia et al. (2007) Italy Prospective Cohort 75 36/39 38 (51) 58 ± 19 50 ± 21 41 ± 24 28 ± 18 24 ± 30 24/75 
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Publication Bias and Eradication of H. pylori infection 
Treatment for H. pylori eradication consisted of triple-therapy in all studies 
save that by Estrada-Gomez et al.,34 in which a four-drug regimen was used. Random-
effects modeling revealed successful eradication in 89.7% (95% CI, 85.1%-93.5%) of 
treated patients. With the exception of the study by Nomura et al.,25 all studies 
reported clearance of the bacterium in greater than 70% patients. 
The effects of eradication therapy on platelet count were evaluable in 825 
(82.7%) of 998 H. pylori-infected patients with primary ITP. As expected, a high 
degree of variance was observed (heterogeneity !2 = 115.600, p < 0.001; I2 = 86.3%), 
with responses ranging from 7% in the US study by Ahn et al.30 to 100% in the 
Japanese study Nomura et al. (Table 5-2).25 Egger’s test revealed no evidence of 
significant publication bias (p = 0.167), and although a plot of study precision versus 
response failed to form a funnel shape, a symmetric spread around the pooled 
response was nevertheless noted, with greater divergence evident among studies 
possessing greater standard error (Figure 5-3). A decision was therefore made to 
pool response data across studies.  
!
         
Figure 5-3: A funnel plot compares the effect size of each study (Freeman-Tukey 
arcsin square root transformed proportion of the response) against a measure of 
precision (its standard error). Studies with a smaller sample size (i.e., precision) should have a 
larger random error and, thus, spread when graphed. In the absence of publication bias, then, effect 
estimates from smaller studies should have a larger, but symmetric, spread around the pooled effect. 
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Table 5-2: Results of H. pylori Eradication 
 
Author (Year) Successful 
Eradication 
N (%) 
Count 
Before 
Eradication 
Mean ±  SD§ 
x 109/L 
Count 
After 
Eradication 
Mean ±  SD 
x 109/L 
Response 
N (%) 
Complete 
Response 
N (%) 
Follow-up 
Time 
Median 
Months 
Relapse 
N  
Gasbarrini et al. (1998) 8 (73) 95 ± 39 140 ± 34 NA NA 4 NA 
Jarque et al. (2001) 23 (72) 58 ± 24 65 ± 32 3 (13) NA 21  2 
Kohda et al. (2002) 19 (100) 67 ± 54 120 ± 50 12 (63) 12 (63) 15  0 
Hino et al. (2003) 18 (86) 37 ± 21 67 ± 54 8 (44) 6 (33) 38 NA 
Hashino et al. (2003) 13 (93) 58 ± 30 99 ± 56 9 (69) 8 (62) 15 1 
Ando et al. (2003) 27 (93) 56 ± 24 93 ± 49 16 (59) 13 (48) 11  1 
Michel et al. (2004) 14 (93) 32 ± 15 66 ± 98 4 (29) 2 (14) 12  1 
Takahashi et al. (2004) 13 (87) 40 ± 27 101 ± 86 7 (54) 6 (46) 4 NA 
Sato et al. (2004) 27 (84) 54 ± 17 110 ± 21 15 (56) NA 12 0 
Ando et al. (2004) 15 (88) 49 ± 26 168 ± 43 10 (67) 10 (67) 24 0 
Nomura et al. (2004) 12 (43) 29 ± 6 78 ± 11 12 (100) NA NA NA 
Veneri et al. (2005) 32 (94) 57 ± 23 122 ± 33 18 (56) NA 24  1 
Inaba et al. (2005) 25 (100) 52 ± 26 NA 11 (44) NA NA 0 
Stasi et al. (2005) 52 (100) 42 ± 25 129 ± 61 16 (31) 13 (25) 25  6 
Fujimura et al. (2005) 161 (78) NA
**
 NA 88 (55) 34 (21) 12  NA 
Suzuki et al. (2005) 22 (88) 55 ± 27 114 ± 90 6 (27) 6 (27) 6 NA 
Suvajdzic et al. (2006) 23 (77) 68 ± 33 84 ± 45 6 (26) NA 18  0 
Ahn et al. (2006) 15 (100) 72 ± 45 69 ± 65 1 (7) NA NA 1 
Sayan et al. (2006) 18 (90) 39 ± 16 100 ± 63 11 (61) 8 (44) 11  0 
Asahi et al. (2006) 26 (100) 35 ± 13 114 ± 61 16 (62) 16 (62) >12 0 
Kodama et al. (2007) 44 (85) 40 ± 29 NR 27 (61) 8 (18) NA NA 
Campuzano-Maya et al. (2007) 26 (90) 57 ± 38 198 ± 98 21 (81) 21 (81) 12 NA 
Estrada-Gomez et al. (2007) 14 (100) NA NA 2 (14) 2 (14) 5  1 
Satake et al. (2007) 23 (92) NA NA 13 (57) 12 (52) 25 0 
Emilia et al. (2007) 34 (89) 41 ± 24 134 ± 96 25 (74) 22 (65) 43 1 
!
 
§ Standard deviation 
** Not available 
!
 
!
!
     
!
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Response to Eradication Therapy 
Although platelet counts were most commonly assessed one month following 
the completion of eradication therapy, data suggested that responses might have 
transpired earlier. Hino et al.,18 for example, observed recovery as early as 3 days 
following eradication therapy while Asahi et al.32 noted increased platelet counts in 
roughly half of responders after one week. In the study by Emilia et al.36 initial platelet 
count improvement most commonly occurred 2 weeks after therapy.  
Using the criteria adopted for this review, CR and response were 
demonstrated in 42.7% (95% CI, 31.8%-53.9%) and 50.3% (95% CI, 41.6%-59.0%) of 
696 patients, respectively. Restriction of these analyses to patients with a baseline 
platelet count less than 30 x 109/L (15 studies, 222 eradicated patients) yielded a CR 
of 20.1% (95% CI, 13.5%-26.7%) and a response of 35.2% (95% CI, 28.0%-42.4%). 
Notably, regression analysis indicated a significant positive correlation (r = 0.351, p = 
0.018) between the prevalence of H. pylori infection and platelet response to 
eradication therapy (Figure 5-4). 
             
Figure 5-4: Response to H. pylori eradication. The solid boxes and horizontal lines are 
representative of the observed response and 95% confidence intervals for each study, respectively; 
the dimensions of the boxes are proportional to the relative weight given to each study. The dashed 
vertical line reveals the weighted mean response for the studies (56.5%). 
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A significant response among 15 (32.6%) patients in whom the eradication of 
infection was not successful was reported in the retrospective study by Fujimora et 
al.35 Such a response was, however, not observed in 41 uninfected patients from 6 
studies18,21,22,24,27,32 who had also received eradication therapy.  
 
 
Figure 5-5: Correlation between prevalence of infection and response. A significant 
positive correlation (simple Pearson coefficient r = 0.3510, p = .0182) was observed. 
 
Response Duration 
The duration of response was not reported in 4 studies.25,27,33,38 In the 
remaining 20 studies, the median duration of follow-up for responders ranged from 4 
to 43.5 months. Responses were ongoing at the time of the report for greater than 
90% of responders. In the study with the longest follow-up, that by Emilia et al. 36 
(median: 43.5 months [range 18-90 months]), only one (4.3%) responder relapsed 7 
or more months after eradication.  
 
!
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Predictors of a response to H. pylori eradication therapy 
Clinical variables were evaluated for possible associations with response in 13 
studies, encompassing 511 patients with eradicated H. pylori infections. As with 
response itself, postulated predictors of response proved heterogeneous. The most 
commonly reported predictor was duration of primary ITP, with studies by Kodama 
et al.,33 Stasi et al.,28 and Fujmura et al.37 all documenting significantly shorter disease 
duration among responders. A genetic predisposition to response among carriers of 
the HLA–DQB1*03 allele was reported by Veneri et al.26 while studies by Ando et 
al.20 and Sato et al.23 uncovered response associations with prior and concomitant 
corticosteroid therapy, respectively. These findings, however, have yet to be 
reproduced.  
 
Discussion 
Results from the meta-analysis revealed a CR and response in 42.7% (95% CI, 
31.8%-53.9%) and 50.3% (95% CI, 41.6%-59.0%), respectively, in patients in whom H. 
pylori had been successfully eradicated. Responses were noted to persist in greater 
than 90% of initial responders over median follow-up times, which ranged from 4 to 
43.5 months. While responses appeared lower in patients with more severe 
thrombocytopenia, participant-level data for studies by Nomura et al.25 and Satake et 
al.35 were not available. As these studies documented high responses among cohorts 
with low mean baseline platelet counts, the theory that eradication therapy is 
relatively ineffective in elevating platelet counts among markedly thrombocytopenic 
patients could not be reliably assessed. 
As Crowther et al.39 note, the heterogeneity of observed responses would 
typically preclude quantitative pooling of results across studies. However, the similar 
methodologies employed by the studies, the lack of significant publication bias, and 
the comparable number of studies with similar weight at both extremes of the 
response spectrum suggested that pooling was justified, particularly if coupled with 
subgroup analyses to explore possible sources of heterogeneity.  
As shown in Figure 5-5, such analyses demonstrated a direct correlation 
between response and the prevalence of H. pylori infection. One plausible 
explanation for this finding may relate to the cytotoxin-associated gene A (CagA)-
positive strain of H. pylori. CagA, a virulence factor protein, has been identified as a 
possible pathogenic candidate for primary ITP by Franceschi et al.40 and Takahasi et 
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al.,22 who demonstrated its capacity to molecularly mimic platelet antigens; their 
investigations further documented associations between H. pylori eradication and 
both the disappearance of anti-CagA antibodies and an increase in platelet counts.22,40 
CagA-positive strains of H. pylori vary depending upon geographic location. For 
example, in Japan, where prevalence and response to eradication therapy are 
generally high, most H. pylori strains express CagA, whereas the proportion of CagA-
positive strains in Western countries is h lower.41,42 While this theory appears 
promising, considerable work is still needed to evaluate it formally.   
The failure to include non-English language articles and conference abstracts 
served as source of potential bias in this study. Both types of publications are more 
likely than prominent journals to include investigations yielding null findings.43 As 
many of these studies are methodologically rigorous,44 their exclusion may have 
resulted in skewed findings. Only one PubMed-indexed, non-English language cohort 
study of 15 of more patients with primary ITP was excluded from this investigation. 
It is, however, unknown how many conference abstracts may have met the 
remaining stringent inclusion criteria. The potential for publication bias in this regard 
must be considered.  
Similarly, confounding may have also been present, as a substantial proportion 
of patients were previously or concurrently treated with immunosuppressive agents 
at the time of eradication therapy. These treatments may have contributed in part to 
observed increases in platelet counts. However, in a recent follow-up meta-analysis, 
Arnold et al.45 reported 14.5-fold higher odds (95% CI, 4.2-83.0) of H. pylori-positive 
patients achieving a response from eradication therapy than H. pylori negative 
patients, suggesting that the high response observed in this study was tied to 
removal of the H. pylori bacterium from the body.  
In conclusion, given the low costs, the non-invasiveness of diagnostic 
methods, and favourable toxicity profile of eradication therapy compared to 
conventional ITP treatments, the results of this meta-analysis support routine 
detection and eradication of H. pylori in adults with primary ITP in populations with a 
high prevalence of infection. A large international RCT will be required to determine 
whether the results of this meta-analysis can be replicated in an environment free 
from substantial bias and confounding and to assess the results of eradication 
therapy relative to an existing standard of care (e.g., corticosteroids). Such an RCT 
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would ideally be coupled with molecular investigations, which would further explore 
possible pathogenic mechanisms by which H. pylori infection may trigger primary ITP.     
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Chapter 6: Health-related lifestyle among patients with primary 
ITP 
 
Summary 
In an effort to complement ongoing health-related quality of life (HRQoL) 
research, a 43-question, closed-field questionnaire was used to identify health-
related lifestyle concerns among patient members of the UK Adult ITP Support 
Association. In total, 790 patients, 696 (88.1%) adults and 94 (11.9%) children, 
returned completed questionnaires. Elective surgery had been delayed due to a low 
platelet count in 31.3% of adult patients, and a further 30.2% experienced difficulty 
obtaining travel insurance. Notably, 12.5% of all patients reported “always” or 
“often” missing work or school due to fatigue. These results highlight several 
promising and necessary avenues for patient advocacy and future HRQoL research. 
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Introduction!
As discussed in Chapter 1, patients with primary ITP have historically been 
subject to considerable lifestyle restrictions. Investigation into the impact of these 
restrictions, of highly visible bleeding manifestations, and of patient concerns over 
the side effects of treatment, though only recently begun,1,2 has helped highlight the 
considerable burden posed by the disease.3,4 To complement ongoing HRQoL 
research, the UK ITP Support Association conducted a questionnaire-based survey 
with the aim of identifying health-related lifestyle concerns among its membership. 
 
Methods 
In collaboration with ITP specialists, a 43-question, closed-field questionnaire 
was developed, addressing bruising and bleeding frequency; disease management; 
social engagement; work and school performance; and recreational activities. 
Questionnaires were mailed to members of the ITP Support Association (N = 
1,767). Results from returned questionnaires were stratified by age (adults [> 16 
years] and children) and platelet count at last follow-up, which served as a surrogate 
marker for disease severity (mild: > 50 ! 109/L, moderate: 20-49 ! 109/L, and severe: 
< 20 ! 109/L). Differences between groups were evaluated using generalised 
Cochrane-Mantel-Haenszel tests and were restricted to fields completed by at least 
three-fourths of responders. 
 
Results 
In total, 790 (44.7%) completed surveys were received from 696 (88.1%) 
adults and 94 (11.9%) children with primary ITP. The female-to-male ratio was 2.2:1, 
with respondents reporting a 5.0-year median (range: 0.1-54.0 years) duration of 
disease. Mild, moderate, and severe disease was noted in 57.2%, 17.5%, and 15.4% of 
patients. Bruising occurred “always” or “often” in 37.4% of adults and 56.8% of 
children, while bleeding of similar frequency was noted in 10.6% of all patients 
(Figure 6-1). Adults were twice as likely as children (89.4% vs. 45.3%; p < 0.001) to 
have been prescribed an ITP-specific treatment.  
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                                                 (a)                                                                  (b) 
Figure 6-1: Frequency of bruising (a) and wet bleeding (b) in adults and children 
with primary ITP. A low frequency of wet bleeding was reported by respondents, supporting 
data from population-based studies. 
 
Children were more likely than adults to experience frustration over activity 
restrictions (23.3% vs. 9.5% respectively; p < 0.001). However, the impact of primary 
ITP on healthcare, insurance coverage, and social engagement was more pronounced 
among adults; 31.3% of adults reported having surgery delayed due to a low platelet 
count, and 30.2% experienced difficulty obtaining travel insurance. Although the 
incidence of bleeding manifestations were comparable between men and women, 
significant gender disparities were noted with regard to suspicion of physical violence 
(women: 7.1% vs. men: 1.6%; p = 0.001) and efforts at bruise concealment (women: 
13.5% vs. men: 3.2%; p < 0.001) (Table 6-1). Notably, 12.5% of all patients with 
primary ITP reported “always” or “often” missing work or school due to fatigue. 
These absences were not significantly associated with disease severity (p = 0.301).  
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Table 6-1: Health-Related Lifestyle Survey Summary Results 
 
POSITIVE RESPONSE % 
Adults 
N = 696 
Children 
N = 94 QUESTION 
TOTAL 
 
N = 790 Male 
N = 199 
Female 
N = 497 
Male 
N = 51 
Female 
N = 43 
Have you ever taken prescribed 
drugs for your primary ITP? 
84.9 
 
741* 
89.3 
 
187 
89.1 
 
479 
45.0 
 
40 
45.7 
 
35 
Have you ever tried alternative 
therapies or vitamins and minerals 
supplements for your primary ITP? 
29.4 
 
625 
24.2 
 
157 
31.4 
 
392 
24.4 
 
41 
37.1 
 
35 
Have you had difficulty obtaining or 
been refused travel insurance? 
28.8 
 
608 
29.2 
 
154 
30.5 
 
383 
10.0 
 
40 
9.7 
 
31 
Have you ever had surgery 
postponed or delayed because of a 
low platelet count? 
29.5 
 
620 
28.4 
 
158 
30.4 
 
391 
18.8 
 
39 
12.8 
 
32 
Do you try to hide your bruises?† 
10.7 
 
756 
3.2 
 
190 
13.5 
 
475 
10.0 
 
50 
14.6 
 
41 
Are people ever suspicious that the 
bruises are a result of physical 
violence?† 
5.7 
 
750 
1.6 
 
193 
7.1 
 
468 
5.9 
 
49 
10.0 
 
40 
I get bothered because I cannot do 
the activities I like.† 
11.8 
 
726 
10.1 
 
184 
10.9 
 
456 
23.9 
 
46 
22.5 
 
40 
Have you ever been unable to go to 
work or school because of tiredness 
and fatigue?† 
12.5 
 
710 
10.8 
 
186 
14.3 
 
435 
6.1 
 
49 
10.0 
 
40 
 
 
 
 
* Total number of responses recorded for the given question. !
* Questions with ordinal responses (i.e., always, often, sometimes, never, and rarely) collapsed into 
dichotomous results (i.e., yes and no) for the purposes of this table. 
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Discussion 
This study represents one of the largest HRQoL investigations in primary ITP 
to date and strengthens recurrent reports of fatigue in patients. A pathological basis 
for its onset has not been determined and warrants further investigation.2 The 
results of our study further demonstrate the need for HRQoL metrics to 
incorporate the effects of treatments on fatigue, bruising, and activity restriction. 
The ITP-PAQ and KIT do so, but our findings suggest that increased weighting of 
bruising and activity restriction may be merited in women and children, respectively. 
The reported difficulty of adults in securing travel insurance prompts 
concern. Population-based studies have revealed a low incidence of major bleeding 
events in adults with primary ITP.5 Dissemination of this information to insurers may 
be facilitated by patient support groups, which may help to make access to coverage 
more straightforward and affordable. 
Finally, reports of delayed surgery in one-third of adults with primary ITP 
highlights a need for improved coordination of care between surgeons and 
haematologists. Surgery may often be safely performed in thrombocytopenic 
patients;6 in this respect, an international consensus group of ITP specialists has 
recently published a table of recommended platelet counts for a variety of 
procedures.‡  
While this large-scale survey provides useful insight into health-related 
lifestyle concerns among patients with primary ITP, its limitations warrant 
consideration. First, the questionnaire utilised was designed as a descriptive tool and 
is not a validated instrument. Second, the proportion of respondents (44.7%) was 
low, raising questions about the representativeness of the sample. It should be 
noted, however, that membership to the ITP Support Association was not restricted 
to patients with primary ITP; spouses and parents of patients comprised a minority 
population within the group. Although the exact number of non-patient members at 
the time of the survey was not known, it is reasonable to assume that the 
proportion of patient responders was significantly higher than 45%. Third, our use of 
last platelet count as a proxy for disease severity did not account for disease 
progression or treatment effects over time and may have therefore biased our 
observation of a non-significant association between disease severity and fatigue.  
 
‡ http://bloodjournal.hematologylibrary.org/cgi/data/blood-2009-06-225565/DC1/8 !
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Despite these limitations, the results of our health-related lifestyle survey of 
patients with primary ITP in the UK successfully highlight several avenues for 
research, including demographically-dependent variable weighting in HRQoL metrics 
and the pathogenesis of primary ITP associated fatigue, while uncovering the need 
for greater dialogue between both patient support groups and insurers and 
haematologists and surgeons. 
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Chapter 7: Thromboembolic events among adults with primary ITP 
A study using the General Practice Research Database 
 
Summary 
The risk of thromboembolic events (TEs) in adults with primary ITP has been 
minimally investigated despite findings of increased susceptibility in other 
thrombocytopenic autoimmune conditions. The risk of TEs was therefore evaluated 
in adult patients with and without primary ITP in the United Kingdom General 
Practice Research Database (GPRD). In total, 1,070 adults ("!18 years) with coded 
records for primary ITP first referenced between January 1st 1992 and November 
30th 2007 and having at least one year pre-diagnosis and 3 months post-diagnosis 
medical history were matched (1:4) with 4,280 ITP-free patients by age, sex, primary 
care practice, and pre-diagnosis observation time. The baseline prevalence and 
incidence rate of TEs were quantified, with comparative risk evaluated with 
multivariable (ITP treatment and co-morbid conditions) Cox proportional hazards 
models. Over a median time of 47.6 months (range: 3.0-192.5 months), adjusted 
hazard ratios of 1.58 (95% CI, 1.01-2.48), 1.37 (95% CI, 0.94-2.00), and 1.41 (95% CI, 
1.04-1.91) were found for venous, arterial, and combined (arterial and venous) TEs 
in the primary ITP cohort relative to the ITP-free cohort, respectively. Further event 
categorisation revealed elevated incidence rates of each occurring venous TE 
subgroup among adults with primary ITP. These results illustrated an increased, 
consistent risk of venous TEs in adults with primary ITP. 
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Introduction 
While efforts to understand disease progression in adults with primary ITP 
have understandably centred on site-specific haemorrhagic risks, further investigation 
into thromboembolic susceptibility may be warranted. Elevated rates of arterial and 
venous thrombembolic events (TEs) have been well documented in a series of 
autoimmune diseases, including idiopathic thrombotic thrombocytopenic purpura 
(TTP)1 and systemic lupus erythematosus (SLE).2 A retrospective study conducted by 
Aledort et al.3 suggests that a heightened risk may be present in primary ITP. In their 
multi-centre cohort of 186 adults, a total of 18 TEs were recorded in 10 patients, of 
which 11 TEs (61.1%) occurred following the diagnosis of primary ITP. More 
recently, using administrative claims from a large health plan affiliated with the 
company i3 Drug Safety in the United States, Bennett et al.4 reported a 6.9% 
cumulative incidence of TEs among adult patients with chronic, primary ITP over a 
median follow-up time of 15 months.4 Knowledge of an association between primary 
ITP and TEs among adults, were one to exist, may influence the long-term 
management strategies. The objective of this study was to evaluate the risk of TEs 
among adult patients with and without primary ITP in the General Practice Research 
Database (GPRD).  
  
Methods 
Data Source 
   As discussed in Chapter 1, data from the GPRD are drawn from the computer 
systems of general practices throughout the UK and currently include information 
regarding diagnoses, prescriptions, referrals, outcomes, and laboratory results, 
together with basic demographic information, for approximately 6.4 million patients 
from over 480 centres. The database is population-based and representative of the 
age, sex, and geographic regions of the UK.5 Inclusion is based on registration with a 
contributing general practice, rather than consultations, and there is no requirement 
for patients to be actively receiving treatment. Disease-associated data are stored in 
the GPRD using Oxford Medical Information System (OXMIS) or Read codes, which 
are cross-referenced to International Classification of Diseases (ICD-9) codes6  
(OXMIS code usage was primarily restricted to the period prior to the introduction 
of Read codes in 1997). The quality of entered data is continuously monitored by the 
MHRA, with practices failing to adhere to established standards excluded from 
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participation. GPRD coding has been subject to a number of validation studies, which 
have found it an accurate identification tool for a wide spectrum of conditions and 
diseases.7-9 
  
Study Design and Population  
  A retrospective cohort design was adopted for the study. Data were collected 
for adult patients (age ! 18 years) with OXMIS or Read codes for primary ITP first 
referenced between January 1st, 1992 and November 30th, 2007 in the GPRD. 
Utilised codes (Read: 288599, D313000, D313012, 42P2.11 and OXMIS: 2871C) 
were determined by the study team, which included a physician with extensive 
experience managing adult patients with primary ITP in the NHS. Inclusion within the 
primary ITP cohort was restricted to code-identified patients with at least one year 
pre-diagnosis and three months post-diagnosis medical history. These criteria were 
applied to ensure sufficient information was available to determine a patient’s 
baseline medical status and provide a minimum period of post-ITP follow-up. To 
define thrombocytopenia, a commonly utilised platelet count threshold of less than 
150 ! 109/L was selected a priori during protocol development in 2007, prior to 
publication of new consensus terminology recommendations published by the 
International Working Group on ITP10 in 2009.  
   For comparative purposes, a non-case cohort was assembled and consisted of 
primary ITP-disease free adult patients from the GPRD matched at a ratio of 1:4 by 
age (5-year bands), gender, primary care practice, and pre-index observation time (1, 
2, 3 & 4 years). Date of entry into the primary ITP cohort (index date) was defined 
as the date of diagnosis, and index dates for the primary ITP-disease free cohort 
were taken from their matched counterparts. 
  
Outcomes 
   The outcomes of interest were TEs, grouped as venous, arterial, and combined 
(venous or arterial) TEs. Events were identified using OXMIS/Read codes and sub-
grouped by deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein 
thrombosis (PVT), other venous TEs, myocardial infarction (MI), unstable angina 
(UA), ischaemic stroke (IS), transient ischaemic attack (TIA), other arterial TEs, and 
unclassifiable TEs. 
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Exposures & Covariates  
  Primary ITP status comprised the principal exposure in the study. Additional 
covariates included ITP-treatment (oral corticosteroid usage, IVIg treatment, and 
splenectomy status), age (grouped as 18-39, 40-49, 50-59, 60-69, 70-79, 80-89 & ! 
90 years), gender, and baseline co-morbid status (hypertension, diabetes, chronic 
renal failure, and prior TEs).   
  
Follow-Up Time  
  Follow-up time for each patient extended from the date of cohort entry until 
censoring, disenrollment from the database (by the patient or contributing primary 
care practice), death, or end of the study period (31 December 2007). Censoring 
took place at the time of first event occurrence (e.g., patients with a prior history of 
arterial but not venous TEs were excluded from arterial and combined TE rate 
analyses). Thus, only truly incident TEs were assessed.  
  
Statistical Analyses  
  Incidence and Cox survival analyses were based on the follow-up time detailed 
above. For analyses of prevalence and cumulative incidence, TEs were counted over 
discrete, post-index intervals of 1-90 days, 91-180 days, 181-360 days, 361 days to 
2.5 years, and greater than 2.5 years. Incidence rates (IRs) for venous, arterial, and 
combined TEs were reported within these intervals, with cumulative incidence 
estimates compiled over post-index periods of 180 days, 360 days, and 2.5 years.  
  Following inspection of logarithmic graphs of cumulative survival to verify 
assumptions of proportional hazards between the cohorts, unadjusted and adjusted 
(covariates: ITP-treatment and co-morbid conditions) hazard ratios (HRs) of venous, 
arterial, and combined TEs were calculated using Cox regression models on SAS 
9.1.3 (Cary, North Carolina). 
  To explore the relationship between thrombocytopenic severity with incident 
TEs, post-hoc subgroup analyses were performed to calculate TE incidence rate 
ratios (IRRs) of primary ITP patients with baseline platelet counts (1) < 50 ! 109/L, 
(2) 50-75 ! 109/L, and (3) 75-150 ! 109/L relative to the primary ITP disease-free 
cohort. 
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Ethics 
  The study protocol was approved by the Independent Scientific Advisory 
Committee of the GPRD for the UK Medicines and Healthcare Products Regulatory 
Agency. 
 
Results 
Study Population 
  Baseline characteristics of the primary ITP and primary ITP-disease free 
cohorts are illustrated in Table 7-1. Briefly, 1,070 and 4,280 adult patients with and 
without primary ITP were identified, respectively, and followed for a median time of 
47.6 months (range: 3.0-192.5 months). The female-to-male ratio within the primary 
ITP cohort was 1.4:1, with platelet count data available for 694 (64.9%) patients. 
  Differences in the prevalence of several co-morbidities at baseline were noted 
between adult patients with and without primary ITP, including diabetes (100 [9.3%] 
v. 231 [5.4%], p < 0.001), chronic renal failure (30 [2.8%] v. 56 [1.3%], p < 0.001), 
previous venous TEs (64 [6.0%] v. 198 [4.6%], p = 0.066), and previous arterial TEs 
(105 [9.8%] v. 280 [6.5%], p < 0.001). 
  Oral corticosteroids had been used by 200 (18.7%) patients with primary ITP 
within a one-year period prior to study entry; a further 25 (2.3%) patients had 
already undergone splenectomy. By two years post-index, the proportion of oral 
corticosteroid-treated and splenectomised adult patients with primary ITP had 
climbed to 294 (37.7%) and 53 (6.8%) respectively. The GPRD did not, however, 
capture the administration of IVIg, an acute treatment administered in hospital care 
settings. 
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Table 7-1: Baseline Characteristics of the Study Population 
 
Description 
Primary ITP 
Cohort 
Primary 
ITP-Disease Free 
Cohort 
P Value 
Unmatched 
Variables 
All patients 1,070 4,280  
Gender & Age-Years (%) 
Female 620 (57.9) 2,480 (57.9)  
18-39 179 (16.7) 716 (16.7)  
40-49 73 (6.8) 292 (6.8)  
50-59 97 (9.1) 388 (9.1)  
60-69 93 (8.7) 372 (8.7)  
70-79 101 (9.2) 404 (9.2)  
80-89 70 (6.5) 280 (6.5)  
! 90 7 (0.7) 28 (0.7)  
Male 450 (42.1) 1,800 (42.1)  
18-39 81 (7.6) 324 (7.6)  
40-49 58 (5.4) 232 (5.4)  
50-59 68 (6.4) 272 (6.4)  
60-69 72 (6.7) 288 (6.7)  
70-79 120 (11.2) 480 (11.2)  
80-89 45 (4.2) 180 (4.2)  
! 90 6 (0.6) 24 (0.6)  
Co-Morbid Conditions (%) 
Hypertension 297 (27.8) 1,110 (25.9) 0.226 
Diabetes 100 (9.3) 231 (5.4) < 0.001 
Chronic Renal Failure 30 (2.8) 56 (1.3) < 0.001 
Platelet Count x 109/L (%) 
< 50 173 (16.2) 1 (0) 
50-75 136 (12.7) 0 (0) 
75-150 246 (23.0) 34 (0.8) 
No Data Available 376 (35.1) 3,152 (73.6) 
 
 
< 0.001 
 
ITP-Specific Treatment (%) 
Past Year OCS 200 (18.7) 180 (4.2) < 0.001 
Past Year IVIg Use 0 (0) 1 (~0.0) 0.617 
Splenectomy 25 (2.3) 3 (0.1) < 0.001 
Thromboembolic Event History (%) 
Venous TEs 64 (6.0) 198 (4.6) 0.066 
Arterial TEs 105 (9.8) 280 (6.5) < 0.001 
Combined TEs 165 (15.4) 453 (10.6) < 0.001 
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Table 7-2: Incidence Rates of Venous & Arterial TEs by Code 
 
 
Primary ITP Cohort Primary ITP-Disease Free 
Cohort 
Codes 
Patients 
At Risk 
Events Incidence Rate 
(95% CI) 
Patients 
At Risk 
Events Incidence Rate 
(95% CI) 
Venous TEs 
Idiopathic Codes 
Read 
Idiopathic Thrombocytopenic 
Purpura 
D313000 & D313012  
 
ITP-Idiopathic 
Thrombocytopenic Purpura 
42P2.11 
 
OXMIS 
Idiopathic Thrombocytopaenia 
2871C 
932 29 
67.47 
(45.18, 96.90) 
Autoimmune Codes 
Read 
Autoimmune 
Thrombocytopenia 
D313.12 
74 2 
56.06 
(6.79, 202.50) 
4,082 82 
42.45 
(33.76,52.70) 
Arterial TEs 
Idiopathic Codes 
Read 
Idiopathic Thrombocytopenic 
Purpura 
D313000 & D313012  
 
ITP-Idiopathic 
Thrombocytopenic Purpura 
42P2.11 
 
OXMIS 
Idiopathic Thrombocytopaenia 
2871C 
897 40 
94.28 
(67.36 128.93) 
Autoimmune Codes 
Autoimmune 
Thrombocytopenia 
288599 
68 4 
124.75 
(33.99, 319.40) 
 
4,000 
 
128 
67.40 
(56.23,80.14) 
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Cumulative Incidence & Incidence Rates 
  The cumulative incidence of first venous, arterial and combined TEs during the 
study was 2.9%, 4.1%, and 6.1% in the primary ITP cohort and 1.9%, 3.0%, and 4.6% 
in the primary ITP-disease free cohort, respectively.  
   IRs* of venous (IR: 66.59 [95% CI, 45.25-94.52]) vs. 42.45 [95% CI, 33.76-
52.70]) and arterial TEs (IR: 96.42 [95% CI, 70.06-129.45]) vs. 67.40 [95% CI, 56.23-
80.14]) were elevated among patients with primary ITP, an increased risk seen 
across the autoimmune (Read: 42P2.11) and idiopathic ([Read: D313.12, D313000 & 
D313012] & OXMIS [2871C]) coding strata (Table 7-2). Sub-grouping shown in 
Figure 7-1 depicts increased rates of MI (IR: 52.21 vs. 22.73), UA (IR: 24.32 vs. 
13.36), other arterial TEs (IR: 7.98 vs. 1.47), DVT (IR: 22.42 vs. 11.43), PE (IR: 16.11 
vs. 4.93), and other venous TEs (IR: 37.44 vs. 30.93). Overlap was noted between 
the 95% CIs of the latter five sub-group estimates for the two cohorts. No cases of 
PVT were identified within the study population during the defined follow-up period.  
  Results from the stratification of venous and arterial TEs by baseline 
characteristics, highlighted in Tables 7-3 and 7-4, respectively, demonstrated 
noticeable disparities in the IRRs of both types of events in women and men, in 
patients with and without a past history TEs, and in patients taking oral 
corticosteroids.  
  Further subgroup analyses of combined TEs by baseline platelet count suggest 
the possibility of a direct relationship between disease severity and thrombosis as 
seen in Figure 7-2. Restriction of the primary ITP cohort to adult patients with 
presenting counts less than 100 ! 109/L, a threshold recently advocated by the 
International Working Group on ITP10 to exclude asymptomatic, mildly 
thrombocytopenic patients from disease categorisation, resulted in an elevated IRR 
of 1.55 (95% CI, 0.97-2.43) for combined TE. Moreover, IRR point estimates for 
combined TEs were increasingly elevated for moderately (50-75 ! 109/L: 1.50 [95% 
CI, 0.67-3.39]) and severely (< 50 ! 109/L: 1.74 [95% CI, 0.95-3.19]) 
thrombocytopenic adult patients.  
  
 
 
* Expressed per 10,000 person-years 
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Table 7-3: Stratified incidence rates of venous TEs 
Primary ITP Cohort Primary ITP-Disease Free Cohort  
Description 
Patients Events Incidence Rate 
(95% CI) 
Patients Events Incidence Rate 
(95% CI) 
Incidence Rate 
Ratio (95% CI) 
All patients 1,006 31 
66.59 
(45.25,94.52) 
4,082 82 
42.45 
(33.76,52.70) 
1.57 
(1.04,2.37) 
Gender & Age (Years) 
Female 579 20 
71.40 
(43.61,110.27) 
2,362 53 
45.67 
(34.21,59.73) 
1.56 
(0.93,2.62) 
Female; 40-49 69 2 
47.01 
(5.69-169.80) 
285 3 
18.97 
(3.91,55.44) 
2.48 
(0.41-14.83) 
Female; 50-59 83 3 
74.92 
(15.45,218.96) 
375 5 
25.58 
(8.31,59.69) 
2.93 
(0.70,12.26) 
Female; 60-69 84 3 
71.14 
(14.67,207.91) 
359 11 
58.08 
(29.00,103.93) 
1.22 
(0.34,4.39) 
Female; 70-79 92 5 
126.93 
(41.21,296.22) 
369 15 
87.53  
(48.99,144.36) 
1.45 
(0.53,3.99) 
Female; 80-89 68 2 
92.54 
(11.21,334.30) 
242 11 
134.67 
(67.22,240.95) 
0.69 
(0.15,3.10) 
Male 427 11 
59.33 
(29.62,106.16) 
1,720 29 
37.62 
(25.19,54.02) 
1.58 
(0.79,3.16) 
Male; 40-49 56 1 
35.76 
(0.91,199.24) 
227 2 
19.22 
(2.33,69.42) 
1.86 
(0.17,20.52) 
Male; 50-59 63 3 
92.53 
(19.08,270.42) 
266 6 
43.61 
(16.01,94.93) 
2.12 
(0.53,8.48) 
Male; 60-69 66 0  276 8 
59.66 
(25.76,117.55) 
 
Male; 70-79 113 3 
70.07 
(14.45,204.77) 
437 11 
57.21  
(28.56,102.37) 
1.22 
(0.34,4.39) 
Male; 80-89 43 3 
274.45 
(56.60,802.07) 
170 1 
20.91  
(0.53,116.53) 
13.12 
(1.36,126.16) 
Baseline Platelet Count (x109/L) 
< 50 164 1 
15.08 
(0.38,84.00) 
1 0   
50-75 128 2 
48.35 
(5.86,174.67) 
0 0   
75-150 233 5 
61.80 
(20.07,144.22) 
29 1 
95.92 
(2.43,534.41) 
0.64 
(0.08,5.52) 
No Data Available 354 20 
87.56 
(53.49,135.24) 
3,030 63 
39.95 
(30.70,51.11) 
2.19 
(1.33,3.62) 
ITP-Specific Treatment 
Corticosteroid Yes 474 14 
60.37 
(33.00,101.29) 
641 16 
51.16 
(29.24,83.08) 
1.18 
(0.58,2.42) 
Corticosteroid No 532 17 
72.77 
(42.39,116.52) 
3441 66 
40.77 
(31.53,51.87) 
1.78 
(1.05,3.04) 
IVIg Yes 2 0  8 0   
IVIg No 1004 31 
66.93 
(45.48,95.00) 
4074 82 
42.56 
(33.85,52.83) 
1.57 
(1.04,2.38) 
Splenectomy Yes 79 3 
67.96 
(14.01,198.60) 
3 0   
Splenectomy No 927 28 
66.45 
(44.16,96.04) 
4079 82 
42.48 
(33.79,52.73) 
1.56 
(1.02,2.40) 
Thromboembolic Event History 
Prior TEs Yes 101 4 
117.03 
(31.89,299.65) 
255 5 
49.38  
(16.03,115.23) 
2.37 
(0.64,8.83) 
Prior TEs No 905 27 
62.60 
(41.25,91.08) 
3,827 77 
42.07 
(33.20,52.58) 
1.49 
(0.96,2.31) 
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Table 7-4: Stratified incidence rates of arterial TEs 
Primary ITP Cohort Primary ITP-Disease Free Cohort  
Description 
Patients Events Incidence Rate 
(95% CI) 
Patients Events Incidence Rate 
(95% CI) 
Incidence Rate 
Ratio (95% CI) 
All patients 965 44 
96.42 
(70.06,129.45) 
4,000 128 
67.40 
(56.23,80.14) 
1.43 
(1.02,2.02) 
Gender & Age (Years) 
Female 583 20 
69.33 
(42.35,107.08) 
2375 71 
60.34 
(45.52,74.05) 
1.15 
(0.70,1.89) 
Female; 40-49 73 0  291 4 
24.74 
(6.74,63.35) 
 
Female; 50-59 92 2 
44.78 
(5.42,161.75) 
379 6 
30.12 
(11.05,65.55) 
1.49 
(0.30,7.37) 
Female; 60-69 91 7 
149.80 
(60.23,308.64) 
362 16 
83.92 
(47.97,136.29) 
1.78 
(0.73,4.34) 
Female; 70-79 89 6 
160.41 
(58.87,349.14) 
365 24 
138.23 
(88.56,205.67) 
1.16 
(0.47,2.84) 
Female; 80-89 55 3 
164.83 
(33.99,481.71) 
236 19 
240.70 
(144.92,375.88) 
0.68 
(0.20,2.31) 
Male 382 24 
142.98 
(91.61,212.74) 
1625 57 
78.89 
(59.75,102.22) 
1.81 
(1.12,2.92) 
Male; 40-49 56 0 
 
 
227 5 
48.91 
(15.88,114.14) 
 
Male; 50-59 62 3 
97.56 
(20.12,285.12) 
262 7 
51.49 
(20.70,106.09) 
1.89 
(0.49,7.33) 
Male; 60-69 61 9 
353.18 
(161.49,670.44) 
251 6 
50.89 
(18.67,110.76) 
6.94 
(2.47,19.50) 
Male; 70-79 92 9 
260.52 
(119.13,494.55) 
400 27 
158.28 
(104.31,230.29) 
1.65 
(0.77,3.50) 
Male; 80-89 29 2 
247.53 
(29.98,2,894.15) 
144 11 
268.17 
(133.87,479.83) 
0.92 
(0.20,4.16) 
Baseline Platelet Count (x109/L) 
< 50 156 10 
161.54 
(77.46,297.07) 
1 0 
 
 
 
50-75 119 6 
156.60 
(57.47,340.85) 
0 0 
 
 
 
75-150 219 5 
66.23 
(21.50,154.55) 
27 0   
No Data Available 348 19 
81.32 
(48.96,126.99) 
2,995 89 
57.15 
(45.90,70.33) 
1.42 
(0.87,2.33) 
ITP-Specific Treatment 
Corticosteroid Yes 448 22 
96.51 
(60.48,146.11) 
626 23 
74.28 
(47.09,111.46) 
1.30 
(0.72,2.33) 
Corticosteroid No 517 22 
96.34 
(60.38,145.86) 
3,374 105 
66.06 
(54.03,79.97) 
1.46 
(0.92,2.31) 
IVIg Yes 2 0 
 
 
8 0  
 
 
IVIg No 963 44 
96.72 
(70.28,129.84) 
3,992 128 
67.57 
(56.37,80.34) 
1.43 
(1.02,2.02) 
Splenectomy Yes 81 5 
113.41 
(36.82,264.66) 
3 0   
Splenectomy No 884 39 
94.61 
(67.28,129.33) 
3,997 128 
67.45 
(56.27,80.19) 
1.40 
(0.98,2.01) 
Thromboembolic Event History 
Prior TEs Yes 60 6 
261.81 
(96.08,569.84) 
173 12 
168.31 
(86.97,294.00) 
1.56  
(0.58,4.14) 
Prior TEs No 905 38 
87.68 
(62.05,120.35) 
3,827 116 
63.46 
(52.44,76.12) 
1.38 
(0.96,1.99) 
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Figure 7-1: Incidence rates of venous & arterial TEs by subgroups. The incidence rates of deep vein thrombosis, pulmonary embolism, and other venous 
TEs were elevated in adults with primary ITP versus adults without primary ITP. No portal vein thromboses were observed over the course of follow-up.  
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Figure 7-2: Incidence rate ratios of combined TEs among subgroups of the 
primary ITP cohort relative to the non-primary ITP cohort. A step-wise increase in 
incidence rate ratios was noted between patients with mild, moderate, and severe baseline 
thrombocytopenia, respectively.   
 
Hazard Ratios 
  Unadjusted HRs of 1.58 (95% CI, 1.05-2.39), 1.42 (95% CI, 1.01-2.00), and 1.42 
(95% CI, 1.07-1.88) were obtained for venous, arterial, and combined TEs, 
respectively. Adjustment for ITP-treatment (oral corticosteroid usage, IVIg 
treatment, and splenectomy) and co-morbid status (hypertension, diabetes, chronic 
renal failure, and history of prior TEs) altered these ratios only slightly, resulting in 
HRs of 1.58 (95% CI, 1.01-2.48), 1.37 (95% CI, 0.94-2.00), and 1.41 (95% CI, 1.04-
1.91), respectively.  
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Discussion 
  Derived from population-based data,5 the results of this study provide evidence 
of an increased risk of venous TEs among adults with primary ITP. An IRR of 1.57 
(95% CI, 1.04-2.37) was observed between the primary ITP and non-primary ITP 
cohorts, with multivariable Cox regression modelling yielding an adjusted, significant 
HR of 1.58 (95% CI, 1.01-2.48). The IRs of each occurring venous TE subgroup, 
moreover, were higher in adults with primary ITP, demonstrating a consistency of 
effect (Figure 7-1). While evidence of an elevated risk of arterial TEs was similarly 
present, it was admittedly weaker, with modelling revealing an adjusted, non-
significant HR of 1.37 (95% CI, 0.94-2.00). Owing to increasing challenges to the 
prevailing theory of distinct aetiologies for venous and arterial TEs,12,13 further 
analyses were conducted on the risk of combined TEs, with data supporting a 
significantly increased hazard (adjusted HR = 1.41 [95% CI, 1.04-1.91]) in patients 
with primary ITP.  
  An initial concern of this investigation centred on the accuracy of the OXMIS 
and Read codes used to identify adults with primary ITP in the GPRD. In a recently 
published study, Schoonen et al.,8 reported a very high positive predictive value (PPV, 
91% [95% CI, 84-96%]) of a collection of 9 such codes. The following 4 (44.4%) 
codes from their investigation were, however, non-specific and, as a result, excluded 
from this study: 1) Evans syndrome (Read: D313.11), 2) platelet count (OXMIS: L 
146N), 3) platelet count (Read: 42P..00), and 4) platelet count, nos (Read: 42PZ.00)). 
It is therefore likely the PPV of codes adopted for this investigation was 
commensurate, if not higher, than 91%. 
  The existence of two coding vocabularies (OXMIS and Read) and multiple 
codes for the same medical concept within these vocabularies raised an additional 
question as to whether patients labelled with one of the 5 codes selected to identify 
adult patients with primary ITP were systematically different from those classed 
under another. To investigate, IRs of venous and arterial TEs were calculated for the 
two primary classes of primary ITP codes, the autoimmune (Read: 42P2.11) and 
idiopathic ([Read: D313.12, D313000 & D313012] and OXMIS [2871C]) codes.* 
Similar estimates across both strata suggest that no appreciable differences were 
present (Table 7-2). 
   Two limitations of this study should be noted. First, the available number of 
adults with primary ITP in the GPRD may have hampered the power of the 
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investigation to detect a significant association between primary ITP and arterial TEs. 
Although 1,070 adult patients were included, making this study one of the largest 
investigations into primary ITP to date, pre-investigation power calculations revealed 
the need for 8,120 patients with primary ITP to detect a twofold increase in the 
estimated annual incidence of arterial TEs in the Western world.21† 
  Second, the paucity of available platelet counts and IVIg usage reflected a 
general limitation of the GPRD in capturing specific, hospital-based data. However, as 
numerous investigative teams have shown for a variety of conditions, including 
primary ITP,8,9,11,12 this limitation nevertheless does not diminish the accuracy of the 
data that were captured.  
   Importantly, the uncovered associations do not in themselves implicate primary 
ITP as a causative agent for venous and combined TEs. Hospitalisation, for instance, 
may have been more common among the primary ITP cohort and is itself a widely 
recognised, independent risk factor for venous TEs.13,14 Similarly, while significantly 
increased hazards of venous and combined TEs persisted following adjustment for 
co-morbid conditions and ITP-treatment, it is possible that treatment modalities 
other than those included (or adequately captured) may have played a role in the 
creation of a pro-thrombotic environment.   
  While knowledge of an elevated risk of venous TEs among adults with primary 
ITP may support increased use of thromboprophylactic treatment in patients at 
lower risk of haemorrhage, further work is first needed to confirm the uncovered 
association and to examine whether evidence exists implicating a causative role for 
ITP pathogenesis in thrombus formation, topics explored at greater length in 
Chapters 8 and 9, respectively. As with future investigations into SNP associations 
with primary ITP (Chapter 3), follow-up studies would benefit from the development 
of an international registry, which would enable suitably powered evaluation of a 
wider range of variables (i.e., hospital-based data).  
 
 
 
 
 
† At 80% 1-! and 5% ". 
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Chapter 8: Thromboembolic events among adults with primary ITP  
A study using the United Kingdom Adult ITP Registry 
 
Summary 
While an increased risk of venous thromboembolic events (TEs) was found 
among adults with primary ITP in the GPRD, the external validity of this finding was 
unclear. In particular, it was uncertain whether code-identified patients were 
representative of adults under active management for primary ITP. Data from the 
United Kingdom Adult ITP Registry and population-based studies in the medical 
literature were therefore used to conduct a retrospective cohort study on the age- 
and sex-adjusted risk of TEs in Registry participants relative to the general adult 
population. Increased, though non-significant, risks were observed in the primary ITP 
cohort for each arterial and venous TE subgroup evaluated. The pooling of these 
estimates via random-effects meta-analyses yielded significant standardised rate ratios 
(SSRs) for venous (2.43 [95% CI, 1.01-5.83]), arterial (2.45 [95% CI, 1.48-4.06]), and 
combined TEs (2.44 [95% CI, 1.58-3.79]), respectively, illustrating an over two-fold, 
consistent risk of TEs in actively managed adults with primary ITP. Considerable 
work is required to ascertain whether these associations may reflect a causal 
relationship between primary ITP pathogenesis and TE onset. 
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Introduction 
As discussed at the conclusion of Chapter 7, the finding of significantly 
increased risks of combined and venous TEs among adults with primary ITP in the 
GPRD warrants further investigation. Although results from the study by Schoonen 
et al.1 support the accurate classification of patients in the primary ITP cohort, it 
remains unclear whether they were representative of patients under active 
management. Validation of GPRD findings in such a representative population is 
required prior to discussion of the potential impact these associations may have on 
disease management. The objective of this study was to evaluate the risk of TEs 
among patients in the UK Adult ITP Registry with respect to the general adult 
population in the UK. 
 
Methods 
Study Design 
Data from the UK Adult ITP Registry and population-based studies in the 
medical literature were used to conduct a retrospective cohort study on the relative 
risk of TEs between adult patients with primary ITP and the general adult population.   
 
Primary ITP Cohort 
The disease cohort comprised adults (age > 16 years) with primary ITP 
attending an outpatient haematology clinic at Barts and The London NHS Trust 
between January 2000 and May 2005, at one of 10 collaborating UK centres between 
August 2002 and May 2005, or at one of 9 collaborating UK centres between 
October 2008 and March 2010 (Figure 2-5). Diagnoses were made in accordance 
with BCSH guidelines (i.e., thrombocytopenia [i.e., < 150 ! 109/L] in the absence of 
demonstrable causes such as HIV, HCV, or SLE).2 Patients diagnosed as children but 
in whom primary ITP persisted into adulthood were eligible for inclusion.  
 
Primary Outcomes and Covariates 
The primary outcomes of interest were arterial, venous, and combined TEs, 
consisting of MI, UA, IS, and TIA; DVT and PE; and arterial and venous TEs, 
respectively. Covariates evaluated for the study included baseline (i.e., at the time of 
diagnosis) participant characteristics (sex, age, referral status, laboratory results), 
ITP-specific treatments, and co-morbid conditions (Figure 2-1[a-d]). Data collection 
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was retrospectively performed via extraction of hospital medical records and, in the 
case of patients who died over the course of follow-up, examination of death 
certificates. Outcomes were considered prevalent if they had been recorded prior to 
the diagnosis of primary ITP or within 7 days thereof. 
 
Follow-up and Censoring 
Registry participants were retrospectively followed until censoring, death, or 
study closure in March 2010. Censoring took place at the time of discharge from 
clinic or first outcome occurrence. Thus, only first TEs were assessed. 
 
Statistical Methods and Control Cohorts 
IRs and 95% CIs of TEs were estimated assuming a Poisson distribution of 
events and were stratified by baseline age [dichotomous: ! 44 and < 44 years]* and 
sex. Comparisons of event rates between patients within different strata of the 
primary ITP cohort were performed using Cox regression modelling. Assumptions of 
proportional hazards were assessed by fitting interaction terms between the 
stratifying variables and time, enabling evaluation of the change of HRs over time.     
As the UK Adult ITP Registry consisted solely of patients with primary ITP, 
comparisons of TE IRs with disease-free adults were not possible using Registry data 
alone. Age and sex-stratified IR estimates of TEs were therefore drawn from 
population-based studies whose cohorts were sufficiently representative of the 
general adult population in the UK and used to calculate expected IRs within the 
primary ITP cohort (Tables 8-1 and 8-2). The ratios of observed-to-expected events 
served as estimates of the standardised rate ratios (SRRs) between the primary ITP 
cohort and the general adult population. Exact methods were used to calculate 
standard errors of the logarithms of the SRRs.  
SRRs for MI, UA, IS, and TIA; for DVT and PE; and for MI, UA, IS, TIA, DVT, 
and PE were pooled using a DerSimonian and Laird random-effects meta-analyses to 
provide estimates for arterial, venous, and combined TE SSRs, respectively. All 
analyses were performed using Stata release 10 (StataCorp LP, College Station, 
Texas). 
 
 
* A pre-hoc decision was made to dichotomise the cohort by the median age of its members. 
 !
138!
!
Ethics 
The study was conducted under the auspices of the UK Adult ITP Registry, 
which has been approved for multi-center operation by the London Research Ethics 
Committee (Reference: 07/H0718/57) until mid-2017. Written informed consent 
was obtained from all patients prior to enrolment.   
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Table 8-1: Sex and Age-Stratified Incidence Rates of Arterial TEs from Population-Based Studies 
 
Rates 
Males Females 
Event Author 
 
Region 
Country 
Study Period 
Age Group 
Years Incidence  
Per 100,000 Person- Years 
Incidence  
Per 100,000 Person-Years 
39 > 22 2 
40-44 48 9 
45-49 95 16 
50-54 159 27 
55-59 265 74 
60-64 425 151 
65-69 656 282 
70-74 915 456 
75-79 1,353 741 
80-84 1,812 1,091 
Myocardial Infarction (MI) Goldacre3 
Oxford 
United Kingdom 
1994-1998 
85 ! 2,212 1,528 
35 > 1 0 
35-44 13 10 
45-54 60 18 
55-64 47 42 
65-74 97 123 
75-84 189 178 
Unstable Angina (UA) 
85 ! 397 70 
35 > 0 0 
35-44 35 21 
45-54 55 24 
55-64 187 119 
65-74 649 407 
75-84 913 982 
Ischaemic Stroke (IS) 
85 ! 1,984 1,723 
35 > 3 7 
35-44 13 5 
45-54 16 30 
55-64 74 105 
65-74 145 218 
75-84 327 561 
Transient Ischaemic Attack (TIA) 
Rothwell et al.4 
Oxford 
United Kingdom 
  
2002-2005 
85 ! 794 914 
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Table 8-2: Sex and Age-Stratified Incidence Rates of Venous TEs from Population-Based Studies 
 
 
Rates 
Males Females 
Event Author 
 
Region 
Country 
Study 
Period Age Group 
Years Incidence  
Per 100,000 Years 
Incidence  
Per 100,000 Years 
0-14 0 0 
15-19 6 0 
20-24 12 5 
25-29 4 19 
30-34 16 0 
35-39 10 5 
40-44 42 11 
45-49 35 20 
50-54 51 58 
55-59 79 41 
60-64 50 90 
65-69 177 86 
70-74 363 154 
75-79 139 241 
80-84 656 546 
Pulmonary Embolism (PE)  
85 ! 663 433 
0-14 0 0 
15-19 6 11 
20-24 0 30 
25-29 13 31 
30-34 36 34 
35-39 34 19 
40-44 48 34 
45-49 49 41 
50-54 25 25 
55-59 69 91 
60-64 113 79 
65-69 163 136 
70-74 282 168 
75-79 307 193 
80-84 328 303 
Deep Vein Thrombosis (DVT) 
 
Silverstein et al.5  
Olmsted County 
Minnesota 
USA 
  
 
85 ! 120 396 
 !
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Results 
Baseline Characteristics and Prevalence of TEs  
In total, 327 adults with primary ITP were retrospectively followed for a median time 
of 5.6 years (inter-quartile range: 2.4-9.2 years). Baseline characteristics of the primary ITP 
cohort are detailed in Table 2-1. Briefly, the mean age of patients was 42.9 ± 19.2 years, and 
a female-to-male ratio of 1.7:0 was observed. Of patients for whom data were available, 
41.5% had been referred to their centre by a haematologist, and 81.5% were Caucasian 
(self-reported). The median baseline platelet count was 31 x 109/L (inter-quartile range: 9-80 
x 109/L).  
Table 8-3 reveals the baseline prevalence of TEs and co-morbid diseases within the 
primary ITP cohort. Nineteen patients (5.8%; 95% CI, 3.5-8.9%) had experienced a prior TE, 
with 16 (4.9%; 2.8%-7.8%) having suffered an arterial TE and 4 (1.2%; 0.3%-3.1%) a venous 
TE.† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† One patient experienced both arterial and venous TEs prior to diagnosis.  
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Table 8-3: Baseline Prevalence of TEs and Co-Morbidities 
 
Event Number of 
Participants 
Percentage (95% CI) 
TEs 
Combined TEs 19 5.8 (3.5-8.9) 
Arterial TEs 16 4.9 (2.8-7.8) 
Myocardial infarction (MI) 6 1.8 (0.7-4.0) 
Unstable angina (UA) 6 1.8 (0.7-4.0) 
Ischaemic stroke (IS) 5 1.5 (0.5-3.5) 
Transient ischaemic attack (TIA) 4 1.2 (0.3-3.1) 
Venous TEs 4 1.2 (0.3-3.1) 
Deep vein thrombosis (DVT) 3 0.9 (0.2-2.7) 
Pulmonary embolism (PE) 2 0.6 (0.1-2.2) 
Co-Morbidities 
Hypertension 23 7.0 (4.5-10.4) 
Autoimmune diseases 16 4.9 (2.8-7.8) 
    Autoimmune Haemolytic Anaemia 4 1.2 (0.3-3.1) 
    Reynaud’s phenomenon 2 0.6 (0.1-2.2) 
    Rheumatoid arthritis 2 0.6 (0.1-2.2) 
    Autoimmune cytopenia 2 0.6 (0.1-2.2) 
    Eczema 2 0.6 (0.1-2.2) 
    Inflammatory bowel disease 1 0.3 (0-1.7) 
    Multiple Sclerosis 1 0.3 (0-1.7) 
    Psoriasis 1 0.3 (0-1.7) 
Hypothyroidism 10 3.1 (1.5-5.6) 
Renal disease 9 2.8 (1.3-5.2) 
Miscarriage* 8 3.9 (1.7-7.5) 
Osteoarthritis 8 2.4 (1.1-4.8) 
Type 2 diabetes 8 2.4 (1.1-4.8) 
Solid tumour 8 2.4 (1.1-4.8) 
Hyperthyroidism 6 1.8 (0.7-4.0) 
Candidiasis 4 1.2 (0.3-3.1) 
Long-bone fracture 3 0.9 (0.2-2.7) 
Cataracts 2 0.6 (0.1-2.2) 
Liver disease 2 0.6 (0.1-2.2) 
Haematological malignancy 2 0.6 (0.1-2.2) 
Peptic ulcer disease 1 0.3 (0-1.7) 
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Incident TEs 
Figure 8-1 presents a Kaplan-Meier curve of TE-free survival probabilities for the 308 
adults with primary ITP who were free from vascular disease at baseline. Over a mean 
follow-up time of 7.2 ± 7.0 years, 16 incident TEs were recorded. The IR of combined TEs 
was 60.25 (95% CI, 34.99-103.77) per 10,000 patient-years (Table 8-4). Corresponding rates 
for arterial and venous TEs were 45.39 (95% CI, 24.42-84.36) and 17.81 (95% CI, 6.68-
47.45), respectively. The most commonly experienced TE subgroups were MI: 22.06 (95% 
CI, 9.18-52.99) and IS: 22.09 (95% CI, 9.19-53.06). As expected, the IRs of arterial TEs were 
higher in males and the elderly (Table 8-5). 
 
 
 
Figure 8-1: Kaplan-Meier TE-free survival estimate for 308 patients with primary ITP. 13 
first incident TEs occurred during a mean follow-up time of 7.2 ± 7.0 years. Note: 19 (5.8%) patients from the 
UK Adult ITP Registry were excluded from the above analysis owing to existing vascular disease at baseline. 
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Table 8-4: Incident TEs among Registry Participants 
 
Outcome 
 
Person-Time 
Patient-Years 
First 
Events" 
Incidence Rate (95% CI) 
Per 10,000 Patient-Years 
Combined TEs 2157.5 13 60.25 (34.99-103.77) 
Arterial TEs 2203.1 10 45.39 (24.42-84.36) 
Myocardial Infarction (MI) 2266.8 5 22.06 (9.18-52.99) 
Unstable Angina (UA) 2270.4 3 13.21 (4.26-40.97) 
Ischaemic stroke (IS) 2263.9 5 22.09 (9.19-53.06) 
Transient Ischaemic Attack (TIA) 2270.7 2 8.81 (2.20-35.22) 
Venous TEs 2246.0 4 17.81 (6.68-47.45) 
Deep Vein Thrombosis (DVT) 2252.8 3 13.32 (4.30-41.29) 
Pulmonary Embolism (PE) 2278.5 2 8.78 (2.20-35.10) 
 
 
 
 
Table 8-5: Incidence Rates and Hazard Ratios of TEs 
 
Outcome Stratum 
Incidence Rate (95% CI) 
Per 10,000 Patient-Years 
Unadjusted  
Hazard Ratio (95% CI) 
Age- or Sex-Adjusted  
Hazard Ratio (95% CI) 
< 44 years 31.24 (11.72-83.23)   
Venous TEs 
! 44 years 102.63 (53.40-197.24) 3.25 (0.99-10.68) 3.18 (0.97-10.44) 
< 44 years 15.34 (3.84-61.32)   
Arterial TEs 
! 44 years 88.99 (44.50-177.95) 5.79 (1.20-27.86) 5.54 (1.16-26.42) 
Female 46.90 (22.36-98.37)   
Venous TEs 
Male 90.24 (40.54-200.87) 1.87 (0.63-5.57) 1.87 (0.62-5.61) 
Female 26.00 (9.76-69.28)   
Arterial TEs 
Male 90.24 (40.54-200.87) 3.32 (0.93-11.78) 3.11 (0.86-11.25) 
 
 
 
 
 
 
 
‡ As patients were censored on the occurrence of a first event within each of the outcome categories shown, 
the total number of first arterial and first venous TEs does not correspond to the total number of first 
combined TEs (e.g., a patients who experienced an MI followed by a DVT would have already been censored 
from the combined TE category at the time of his subsequent DVT. Similarly, the total numbers of first arterial 
and venous subgroup events do not correspond to the total numbers of first arterial and first venous TEs, 
respectively.   
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Standardised Rate Ratios 
As detailed in Figure 8-2, the observed numbers of events for each of the specific TE 
outcomes were higher than those expected. Random effects meta-analyses yielded 
significant, pooled SRRs for combined (2.44 [95% CI, 1.58-3.79]), arterial (2.45 [95% CI, 
1.48-4.06]), and venous TEs (2.43 [95% CI, 1.01-5.83]. 
 
 
 
 
Figure 8-2: Standardised rate ratios (SRRs) of TEs in adult patients with primary ITP 
relative to the general adult population. MI, UA, IS, and TIA; DVT and PE; and MI, UA, IS, TIA, DVT, 
and PE SRR estimates were pooled using DerSimonian and Laird random-effects meta-analyses to calculate 
arterial, venous and combined TE SSRs, respectively. Significant heterogeneity across the outcomes was not 
observed (I2 = 0.0%, p = 0.803). 
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Discussion 
Results from this Registry-based study revealed over two-fold increased risks of 
arterial (SRR: 2.45 [95% CI, 1.48-4.06]), venous (SRR: 2.43 [95% CI, 1.01-5.83]), and 
combined (SRR: 2.44 [95% CI, 1.58-3.79) TEs among actively managed adults with primary 
ITP respective to the general adult population. SRR point estimates for each TE subgroup 
were, moreover, greater than one (Figure 8-2), demonstrating a consistency of effect. These 
findings strengthen observations made using the GPRD (Chapter 7)6 and, importantly, 
suggest that increased risks of TE may not be restricted to patients with asymptomatic or 
only mildly symptomatic disease but likely extend to patients under continued follow-up for 
primary ITP.  
Two primary limitations of the study should be noted. First, the absence of a disease-
free cohort within the UK Adult ITP Registry prompted data usage from population-based 
studies for comparisons of TE IRs. As a result, study-level differences aside from primary 
ITP status may have contributed in part to observed differences in event rates (i.e., 
ecological fallacy). Attempts were made to reduce the effect of such biases by selecting 
comparator cohorts representative of the source population of the primary ITP cohort.§ 
The consistency of SRR estimates across TE subgroups suggested that impact of such biases 
were likely not appreciable.  
Second, although data were collected on potential confounders such as administered 
treatments and co-morbid conditions, the size of this cohort was not sufficient to yield 
robust IR estimates within these strata. This inadequacy of statistical power reflects a 
general limitation of current studies into primary ITP and will be discussed at greater length 
in Chapter 9.  
 
 
 
 
 
 
 
 
§ For incidence rates of PE and DVT in the general adult population, the most comprehensive population-based 
study available was selected (Silverstein et al.). Although this study was set in the USA, it was felt that 
differences between its source population and that of the UK Adult ITP Registry were not appreciable.  
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Considerable work is required to evaluate whether the uncovered associations are 
representative of a causal relationship between primary ITP pathogenesis and TE onset. 
Although plausible mechanisms have been postulated, including a greater proportion of 
young, activated platelets in circulation and the increased thrombogenecity of platelet 
microparticles released following immune-mediated destruction,7,8 it is similarly possible that 
the observed associations were due to confounding. As discussed in Chapter 7, for example, 
increased hospitalisation may have contributed to the observed association between 
primary ITP and venous TEs. Similarly, a high prevalence of antiphospholipid antibodies (e.g., 
anticardiolipin and lupus anticoagulant antibodies) has been reported in adults with primary 
ITP.9 These antibodies are hypothesised to trigger increased platelet activation and 
decreased production of prostacylcin, nitric oxide, and protein C,10 which may additionally 
resulted in elevated IRs of TE subgroups.10   
In conclusion, the present Registry-based retrospective cohort study of adults with 
primary ITP patients uncovered increased risks of arterial, venous, and combined TEs 
compared to the general adult population after adjustment for age and sex. These findings 
warrant further investigation in a larger cohort capable of direct within-study comparisons 
and adjustment for wider range of covariates.  
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Chapter 9: Discussion 
 
Summary 
The results of this thesis implicate primary ITP as a pro-thrombotic condition in 
adults and provide evidence of a genetic contribution to the Th1 polarisation characterising 
the disease. Analyses conducted herein further yielded data demonstrating the utility of 
autologous 111In-labelled platelet sequestration studies as an adjunct predictive tool prior to 
splenectomy and endorsing the routine testing for and eradication of H. pylori infection in 
patients residing in countries with a high prevalence of infection. Efforts are currently 
underway to develop a comprehensive, prospective international registry, which will ensure 
the availability of adequate sample sizes and, thus, statistical power for promising future 
research, including genome-wide association studies (GWAS) and investigations into the 
effects of the eradication of strain-specific H. pylori infection on platelet counts, the precise 
relative risk of non-response to splenectomy in patients with mixed or hepatic platelet 
sequestration, and the association of TEs with primary ITP in antiphospholipid antibody-
negative adults with respect to the general adult population. Perhaps most importantly, 
these data may one day enable epidemiologists to construct, test, and validate prognostic 
models of disease trajectory in primary ITP so that intensive, potentially toxic treatments 
may be spared patients not at heightened risk of major haemorrhage.   
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Introduction 
To further current understanding of disease pathogenesis, treatment effectiveness, 
and co-morbid burden among adults with primary ITP, this thesis aimed to characterise 
associations of primary ITP with both candidate SNPs and TEs, to assess the utility of 
autologous 111In-labelled platelet sequestration studies prior to splenectomy, and to gauge 
the effectiveness of eradication therapy in elevating platelet count in H. pylori-infected 
patients. This chapter details the principal findings of these investigations and discusses their 
potential implications, strengths, and weaknesses, concluding with a summary of ongoing 
work and recommendations for future studies.   
 
Data Sources 
Data used for the aforementioned investigations were drawn from peer-reviewed 
published studies, the WTCCC 1958 British Birth Cohort, the GPRD, and the UK Adult ITP 
Registry. The development, initiation, and expansion of the latter database constituted an 
integral part of my doctoral studies. Over this time, comprehensive clinical data pertaining 
to co-morbid conditions (N = 25), treatments (N = 22), bleeding events, platelet counts, 
and other laboratory results (Figure 2-1) were successfully collected on 327 adults with 
primary ITP across 17 centres (Figure 2-5), spanning a median post-diagnosis period of 5.6 
years (inter-quartile range: 2.4-9.2 years). DNA was further procured from 93 (44.9%) 
Caucasian participants comprising this cohort.* 
 
Principal Findings 
Candidate SNP Associations among Caucasians  
Logistic regression modelling of associations between primary ITP and 6 candidate 
SNPs in cytokine or cytokine receptor genes in 268 Caucasian patients sex-matched (1:3) 
with healthy controls from the WTCCC 1958 British Birth Cohort showed a significant per 
rare allele OR of 1.34 (95% CI, 1.03-1.75) for TNFA -308 g>a (rs1800629). However, no 
significant associations were observed between these SNPs and either disease severity or H. 
pylori infection status.    
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The Utility of Autologous 111In-labelled Platelet Sequestration Studies Prior to Splenectomy  
Results from autologous 111In-labelled platelet sequestration studies in 265 patients 
with primary ITP demonstrated a comparable median MPLS among patients with purely or 
predominantly splenic (25.9 hours [range: 6.8-407.0 hours]) and mixed or hepatic 
sequestration (31.1 hours [range: 7.2-271.0 hours]; p = 0.491). As expected in this non-
blinded study, a highly significant difference was noted between the proportions of patients 
with purely or predominantly splenic (53.5%, N = 71) and mixed or hepatic sequestration 
proceeding to splenectomy (17.9, N = 20; p < 0.001).  
Multivariable (gender, age at splenectomy, and MPLS) logistic regression analyses 
revealed increased odds of short (7.47 [95% CI, 1.89-29.43]), medium (4.85 [95% CI, 1.04-
22.54]), and long-term (5.39 [95% CI, 1.34-21.65]) responses (platelet count > 100 ! 109/L) 
to splenectomy in patients with purely or predominantly splenic sequestration and further 
highlighted an independent, inverse association between age at splenectomy and the 
likelihood of long-term success (0.95 [95% CI, 0.91-0.99]). Inclusion of post-ITP duration at 
the time of splenectomy as an additional covariate in subgroup analyses did not alter the 
significance of these results.  
While illustrating excellent outcomes from splenectomy in patients with purely or 
predominantly splenic sequestration (median platelet count: 292 ! 109/L [range: 14-589 ! 
109/L], number on treatment = 3 [4.3%]), long-term follow-up showed a similar proportion 
of patients reliant on treatment among the mixed or hepatic, splenectomised and the 
comparative, non-splenectomised cohorts (number on treatment: 6 [30.0%] vs. 28 [41.2%], 
respectively; p = 0.47).   
 
Effects of the Eradication of H. pylori Infection on Platelet Count 
 A random-effects meta-analysis of 25 studies revealed a weighted, mean response 
(platelet count > 30 ! 109/L and at least a doubling of the baseline count) to eradication 
therapy in 50.3% (95% CI, 41.6%-59.0%) of 696 evaluable, H. pylori-infected patients with 
primary ITP. Considerable heterogeneity was, however, observed between individual study 
findings. Exploration of these differences showed a direct correlation (r = 0.351, p = 0.018) 
between reported response and prevalence of infection among the source population. 
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Health-related lifestyle 
Although children were more likely than adults to experience frustration over 
activity restrictions (23.3% vs. 9.5%, respectively; p < 0.001), the impact of primary ITP with 
regard to healthcare, insurance coverage, and social engagement was more pronounced in 
adults; 31.3% of adult patients reported having surgery delayed due to a low platelet count, 
and 30.2% experienced difficulty obtaining travel insurance. Notably, 12.5% of all patients 
surveyed reported “always” or “often” missing work or school due to fatigue.  
 
TEs among Adults in the GPRD, the UK Adult ITP Registry, and Population-Based Studies 
 In a GPRD-based study, multivariable (ITP treatment and co-morbid conditions) Cox 
proportional hazards models revealed significantly increased risks of venous (HR = 1.58 
[95% CI, 1.01-2.48]) and combined (HR = 1.41 [95% CI, 1.04-1.91]) TEs in 1,070 adults with 
primary ITP matched (1:4) with ITP-free patients on the basis of age, sex, primary care 
practice, and pre-diagnosis observation time. With the exception of PVT, which did not 
occur in the study population over follow-up (median time: 47.6 months [range: 3.0-192.5 
months]), IRs of each venous TE subgroup (i.e., PE, DVT, and other venous TEs) were 
elevated in the primary ITP cohort (Figure 7-1). Though an increased risk of arterial TEs was 
similarly observed (HR = 1.37 [95% CI, 0.94-2.00]), it did not achieve statistical significance. 
The above associations did not appear tied to the category of code used to identify patients 
with primary ITP, as higher IRs for venous and arterial TEs were seen with respect to the 
ITP-free cohort across both the idiopathic and autoimmune coding strata (Table 7-2). 
A similar investigation, drawing data from the UK Adult ITP Registry and population-
based studies with similar source populations, found increased, though non-significant, age 
and sex-adjusted risks of MI, UA, IS, TIA, DVT, and PE among patients with primary ITP 
relative to the general adult population (Figure 8-2). The pooling of these estimates via 
random-effects meta-analyses yielded significant SRRs for venous (2.43 [95% CI, 1.01-5.83]), 
arterial (2.45 [95% CI, 1.48-4.06]), and combined TEs (2.44 [95% CI, 1.58-3.79]). 
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Potential Implications 
Disease Pathogenesis 
The observed association between primary ITP and TNFA -308 g>a implicates a 
moderately increased disease susceptibility among carriers of the rare allele in the Caucasian 
adult population. Although this finding may represent a false positive result, there arguably 
existed a high prior probability of the association being true. Multiple studies have reported 
Th1 polarisation in primary ITP,1-3 and TNFA -308 a has been tied to increased serum levels 
of TNF-!,4 a cytokine that is critical for the development of Th1 responses.5 However, the 
metaphorical littering of the literature with reports subsequently un-replicated genetic 
associations6,7 underscores the need for cautious interpretation of this finding pending the 
results of adequately powered follow-up studies.  
A validated association within a small series of candidate SNPs would suggest a high 
probability of uncovering further associations through GWAS, which have identified 
common susceptibility loci for such autoimmune diseases as ankylosing spondylitis, 
autoimmune thyroid disease, and multiple sclerosis.8 It is nonetheless unlikely that genetic 
susceptibility is sufficient cause of primary ITP. As Ermann and Fathman9 note, autoimmune 
disease concordance in monozygotic twins is less than 50%, highlighting the potential further 
requirement of an environmental trigger. The observed response to eradication therapy in 
50.3% (95% CI, 31.8%-53.9%) of H. pylori-positive patients with primary ITP suggests that 
one such trigger may be H. pylori infection. This theory is bolstered by the fact that greater 
responses were reported in countries with a higher prevalence of infection. CagA-positive 
strains of H. pylori are similarly more common in these countries10 and are capable of 
mimicking platelet antigens.11,12 Semple et al.13 and Bimczok et al.,14 moreover, have recently 
reported enhanced Fc-dependent platelet phagocytosis in the presence of 
lipopolysaccharides from Gram-negative bacteria (e.g., H. pylori) and Th1 induction by gastric 
dendritic cells in response to H. pylori, respectively. Collectively, these data highlight the 
potential role H. pylori infection in the onset of and exacerbation of primary ITP. 
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Treatment Effectiveness 
The limited invasiveness of diagnostic tests, high observed response, and low toxicity 
profile and costs of treatment,15 support the testing for and eradication of H. pylori infection 
in countries with a high prevalence of infection.  
The finding of a significantly increased likelihood of response to splenectomy in 
patients with purely or predominantly splenic sequestration, meanwhile, highlights the utility 
of autologous 111In-labelled platelet sequestration studies as an adjunct predictive tool prior 
to surgery. Although an insufficient number of patients with mixed or hepatic sequestration 
proceeded to splenectomy to enable precise estimation of the magnitude of this response, 
the observation of similar proportions of patients still reliant of therapy at last follow-up 
within the mixed or hepatic, splenectomised and comparative, non-splenectomised cohorts 
suggests that the adoption of alternate treatment strategies may have yielded comparable 
results for patients in the former cohort. However, considerable work is still needed to test 
this hypothesis.  
 
Co-Morbid Disease Burden 
 Results from the health-related lifestyle survey highlight several possible avenues for 
patient advocacy and HRQoL research. Specifically, improved dialogue between patient 
support groups and insurers and between haematologist and surgeons would improve 
patient access to travel insurance and avoid unnecessary delays to elective surgeries, 
respectively.     
The implications of associations of primary ITP with both venous and arterial TEs 
hinge on whether causal relationships were uncovered. To assess such a question, 
epidemiologists frequently employ the Bradford Hill criteria (Figure 9-1). A brief explanation 
of these criteria and evaluation of data follows.  
 
I. Strength: Owing to the existence of multiple sources of potential bias in any 
investigation, a stronger observed association is more likely to reflect true 
associations and, thus, causation. Results from both the GPRD and UK Adult ITP 
Registry studies were generally strong, with those of the latter investigation revealing 
two-fold greater risks of venous and arterial TEs in patients with primary ITP relative 
to the general adult population.  
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II. Consistency: An association that has been noted by different research groups and in 
different settings is similarly more likely to be true. A significant association of 
primary ITP with venous TEs was seen in both studies. Moreover, the IRs of each 
venous TE subgroup were elevated in adults with primary ITP. A significant 
association of primary ITP with arterial TEs was, however, not found in the GPRD. 
Furthermore, the results of these studies have not yet been replicated by other 
groups. 
 
III. Specificity: Causality may be more easily assigned to an isolated association. 
Paradoxically, the results of these studies implicate associations of primary ITP with 
both incident haemorrhages and TEs. Primary ITP has importantly also been tied to 
increased hospitalisation and antiphospholipid antibodies, themselves independent 
risk factors for TEs. In a study of 82 consecutive adults with primary ITP, for 
example, Diz-Küçükkaya et al.16 reported a statistically significant difference in five-
year, thrombosis-free survival between antiphospholipid-positive and negative 
patients in a study of 82 consecutive adults with primary ITP. 
 
IV. Temporality: A cause must precede its effect. The requirement of temporality was 
met by both investigations, as analyses were restricted to first incident, post-
diagnosis TEs.  
 
V. Biological Gradient: More of a cause should lead to more of an effect. Though 
sparse, data from the GPRD study revealed elevated IRs of combined TEs in 
patients with more severe baseline thrombocytopenia (Figure 7-2), illustrating a 
potential dose-response effect.   
 
VI. & VII. Plausibility and Coherence: A biological explanation that conforms to the 
existing knowledge base within a field provides credence to a proposed causal 
relationship. As discussed in Chapter 8, plausible mechanisms have been postulated 
for the onset of TEs in primary ITP, including a greater proportion of young, 
activated platelets in circulation and the increased thrombogenecity of platelet 
microparticles released following immune-mediated destruction.7,8 
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VIII. Experiment: If action can be taken to prevent a cause, its effect should abate. 
Long-term follow-up for patients in remission from primary ITP has not been 
conducted.  
 
IX. Analogy: A causal argument would be strengthened were related effects observed 
to result in similar outcomes. Other thrombocytopenic autoimmune conditions, 
including idiopathic TTP17 and SLE,18 have been associated with TEs.  
 
 Although the associations of primary ITP with venous and arterial TEs both fulfil the 
majority of the Bradford Hill criteria, the above discussion highlights a more convincing case 
for causality with the former association, which exhibited greater consistency. However, 
there is still insufficient data to account for the role confounding may have played. In 
particular, it remains to be seen whether the associations persist in antiphospholipid 
antibody-negative patients. Were they to do so, discussions may be warranted on the utility 
of increased utilisation of thromboprophylactic treatment in patients at lower risk of 
haemorrhage.
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Figure 9-1: Bradford Hill criteria. In a lecture to the Royal Society of Medicine, Sir Austin Bradford Hill proposed using the 9 criteria in the analytic prism above to 
assess whether observed associations reflect causality. Adapted from Bradford Hill A. The Environment and Disease: Association or Causation? Proceedings of the Royal Society of 
Medicine. 1956;58:295-300. 
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Strengths and Limitations 
 The strengths of the UK Adult ITP Registry and of the investigations comprising this 
thesis warrant mentioning. Although still in its infancy, the Registry is already one of the 
largest repositories of clinical and biological data on adult patients with primary ITP in the 
world, and the external validity of its findings is likely high. The median post-diagnosis 
follow-up time captured by the Registry, 5.6 years (inter-quartile range: 2.4-9.2 years), was 
considerable, and, as enrolment was led by consultant haematologists, the likelihood of 
falsely classified participants within it was low. The studies presented herein have, 
meanwhile, successfully advanced current understanding of disease pathogenesis, treatment 
effectiveness, and co-morbid burden of adult ITP, having included the largest investigation of 
SNPs in primary ITP to date, arguably the most comprehensive review of the effects of 
eradication therapy on platelet count in H. pylori-infected patients, and the first investigations 
to compare the long-term outcomes from splenectomy and risks of TEs with comparative 
cohorts.† 
 Insufficient statistical power served as the primary limitation of this thesis, having 
hampered not only SNP and TE subgroup analyses, but also preventing precise estimation of 
the increased odds of response to splenectomy among patients with purely or 
predominantly splenic sequestration. This limitation was not surprising, for although among 
the most common haematological autoimmune diseases in adults, primary ITP is rare in 
absolute terms. As discussed in Chapter 1, the estimated 5-year period prevalence of the 
disease is 20.6-24.1 per 100,000 adults.19,20 These figures underscore the importance of 
greater international collaboration among ITP specialists. Without such efforts, it is unlikely 
that suitable sample sizes will be available to investigate hypotheses generated from this 
work. 
 Two potential limitations additionally merit consideration. First, funding for the 
Registry was primarily provided by GSK, a pharmaceutical company with a newly licensed 
drug (eltrombopag) for primary ITP. It is therefore essential that the results of this thesis be 
viewed in light of the vested financial interests of this company. In particular, it can be 
argued that the conclusions reached from investigations into the utility of autologous 111In-
labelled platelet sequestration studies and risks of TEs in patients with primary ITP were of 
benefit to GSK, which may use these reports to position eltrombopag as an alternative to 
splenectomy in patients with mixed or hepatic sequestration and to defend against 
allegations that eltrombopag causes TEs, were they to occur. However, the analyses were 
designed independently by me, and the conclusions reached from the data generated were 
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mine alone. Despite these facts, studies have shown that the conclusions drawn by 
researchers may be influenced by the nature of the finding source.21 In a systematic review 
of 370 RCTs, for example, Als-Nielsen et al.22 found a five-fold greater odds of positive 
findings in cases where funding had been provided by a for-profit organisation. Therefore, 
the potential for such bias cannot be fully excluded.  
Pharmaceutical funding of research is, however, a reality of the current academic 
medical system. In a 2007 study, Campbell et al.23 reported that 60% of department chairs at 
American medical schools or teaching hospitals had personal relationships with industry. 
Evaluation of self-reported conflict of interest disclosures from the recently published 
international consensus guidelines for the management of primary ITP, moreover, revealed 
that 50% of clinician authors received research funding from or served as consultants for 
pharmaceutical companies with patented treatments for the disease.24         
 Second, selection bias may have been present in patient recruitment from external 
centres. As consecutive patients were not specifically targeted, it is possible that patients 
who were enrolled were systematically different from those were not. As discussed in 
Chapter 2, however, the mean age and platelet count did not differ significantly between 
participants from centres enrolling more than 3 patients and centres enrolling 3 or fewer 
patients (Table 2-3), suggesting that such bias was minimal.  
 
Ongoing Work and Recommendations for Future Studies 
Development of an International Adult ITP Registry 
In November 2009, I proposed a decentralised model for an international adult ITP 
registry, in which lead regional centres would be recruited to develop and operate 
independent, affiliated regional registries. With the exception of a minimum number of 
required data fields, which would be shared with the international registry, lead regional 
investigators would have autonomy to tailor data and sample collection according to their 
interests and would further be able to apply for independent funding. In return for securing 
ethical approval to initiate their registry, directing regional recruitment, and performing 
routine validation of submitted data, the investigators would be offered a position on the 
advisory board of the international registry (Figure 9-2), which would wield decision-making 
power over alterations to the required data collection, anonymised data sharing with third 
parties (i.e., pharmaceutical companies), and selection of studies for which the full repository 
of data may be used. This model will be piloted with the initiation of a Pan-American Adult 
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ITP Registry, which will be led by Dr. Provan, who will be joining the University of Toronto 
Faculty of Medicine as the Alexandra Professor of Benign Hematology in September 2010.  
 
 
Figure 9-2: The structure of the advisory board for the proposed international adult ITP 
registry. Membership would be comprised of the central study team; the heads of the UK, America, and 
Dutch patients support groups; lead regional investigators, and three internationally recognised clinical experts 
on adult ITP (i.e., ex-officio members).  
 
Future Studies 
Findings from this thesis support using data from the UK and Pan-American Adult 
ITP Registries to conduct GWAS and to investigate differences in both the response to 
eradication therapy in patients with CagA-positive and negative strains of H. pylori and the 
risk of TEs in antiphospholipid-negative patients with primary ITP and the general adult 
population. Studies should similarly be performed to estimate more precisely the increased 
risk of non-response to splenectomy in patients with mixed or hepatic sequestration and to 
evaluate whether more optimal predictive results are possible using alternate classification 
systems. As illustrated in Figure 9-3, the Najean et al.25 scheme does not well categorise 
patients who exhibit extremely rapid and complete splenic pooling (i.e., less than 30 minutes 
post-111In-labelled platelet injection).  
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Figure 9-3: An autologous 111In-labelled platelet sequestration study test result. Although 
sequestration appears centred in the spleen, this patient was categorised as having a hepatic pattern of platelet 
sequestration using the Najean et al. scheme.  
 
Lastly, it is imperative that data from these Registries be used to improve current 
understanding of disease progression, a topic not directly investigated in this thesis. I am 
currently constructing an analysis plan to develop, test, and validate26 a multivariable model of 
disease severity in adult patients with primary ITP (Figure 9-4). Considerable statistical 
power will be required to complete this project.  
 
  Figure 9-4: Examples of platelet count progression in adults with primary ITP. Disease 
trajectory will be modelled using baseline variables. 
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Conclusions 
 The results of this thesis support the concept of primary ITP as a pro-
inflammatory (i.e., TH-1 mediated), pro-thrombotic disease among adults. Analyses 
conducted herein reveal the utility of autologous 111In-labelled platelet sequestration 
studies in identifying patients more likely to respond to splenectomy and strengthen 
calls for routine H. pylori testing and eradication in countries with a high prevalence 
of infection. Efforts to develop a comprehensive, prospective international registry 
will likely bear considerable fruit, ensuring the availability of adequate sample sizes 
and, thus, statistical power for promising future research, including GWAS of SNPs 
in primary ITP and investigations into the effects of the eradication of strain-specific 
H. pylori infection on platelet count, the precise relative risk of non-response to 
splenectomy in patients with mixed or hepatic platelet sequestration, and the 
association of TEs with primary ITP in antiphospholipid antibody-negative adults with 
respect to the general adult population. 
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6. Disease progression, treatment effectiveness, and co-morbidities among adult 
patients with primary idiopathic thrombocytopenic purpura (ITP) in a United 
Kingdom Cohort. ITP National Convention, Oxford, UK (April 2007). 
 
7. Analysis of the ITP Support Association lifestyle survey. ITP National 
Convention, London, UK (November 2008). 
 
 
Patient Centred Activities 
8. Contributing writer, The Platelet, the official newsletter of the ITP Support 
Association. 
 
9. Administrator, the United Kingdom Adult ITP Registry Patient Forum, 
http://ukitpregistry.com/phpBB2/index.php. 
 
10. Co-host, United Kingdom Adult ITP Registry Podcasts, 
http://www.ukitpregistry.com/UKITPEducation/UKITPPodcasts.html.  
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!
!
168!
Appendix 3: The UK ITP Support Association Health-Related 
Lifestyle Survey 
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has helped fuel the drive to meet post regulatory needs, namely the timely collection of 
further epidemiological information on this poorly researched condition to assist safety-
monitoring and marketing efforts.  
As a potential complement to the ITP sample drawn from the General Practice 
Research Database (GPRD), the 734-participant, adult ITP cohort (UKITP Cohort) initiated 
by Dr. Drew Provan at the Royal London Hospital (RLH) and enrolees in the Revised Adult 
ITP Registry may help provide such data. Investigation into this combined study population 
via systematic extraction of patient-records presents a unique opportunity for uncovering 
information concerning the progression, treatment effectiveness, and co-morbid burden of 
adult ITP. Though resource-intensive, it is believed that such an undertaking will ultimately 
prove both feasible and fruitful, yielding findings applicable to the general and refractory 
populations of adult patients with primary ITP. 
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1. SUMMARY OF PROTOCOL 
The efficacy of eltrombopag/promacta (SB-497115-GR) in elevating peripheral platelet 
counts among adult patients with primary immune thrombocytopenia (ITP) in clinical trials has 
helped fuel the drive to meet post regulatory needs, namely the timely collection of further 
epidemiological information on this poorly researched condition to assist safety-monitoring and 
marketing efforts.  
As a potential complement to the ITP sample drawn from the General Practice Research 
Database (GPRD), the 734-participant, adult ITP cohort (UKITP Cohort) initiated by Dr. Drew 
Provan at the Royal London Hospital (RLH) and enrolees in the Revised Adult ITP Registry may 
help provide such data. Investigation into this combined study population via systematic extraction 
of patient-records presents a unique opportunity for uncovering information concerning the 
progression, treatment effectiveness, and co-morbid burden of adult ITP. Though resource-
intensive, it is believed that such an undertaking will ultimately prove both feasible and fruitful, 
yielding findings applicable to the general and refractory populations of adult patients with primary 
ITP. 
 
2. INTRODUCTION 
ITP is an autoimmune condition characterised by decreased levels of peripheral platelets   
(< 150 ! 109/L) resulting from premature destruction of autoantibody-coated platelets by the 
reticuloendothelial system and suboptimal megakaryocytic platelet production.1-3 ITP is a condition 
of imprecise aetiology and, as such, remains diagnosable only through thorough exclusionary 
clinical evaluation.4 Primarily acute (< 6 months) in duration among children, ITP is believed to 
manifest itself predominantly chronically among adults, giving visible rise to bruising and petechiae 
of the skin and increased susceptibility to major bleeding events, including intracranial 
haemorrhage.1 
Estimates of the incidence rate of ITP among adults range from 1.6-6.6 cases per 100,000 
person-years.1 However, epidemiological investigation into this condition has been sparse, 
throwing into sharp relief the uncertainty of these figures and the incompleteness of data with 
which to uncover disease progression, first-line treatment effectiveness, and both natural and 
treatment-induced co-morbid conditions.5;6 
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Since 2000, Dr. Drew Provan, an internationally recognised ITP expert and consultant 
haematologist at the RLH in Whitechapel, has worked to establish an adult ITP registry in the 
United Kingdom (UK). Before halting the project temporarily in 2005, he had successfully  
managed to identify 734 afflicted patients (UKITP Cohort), storing DNA samples (2x ~5mL) for 
over 40% of these individuals for future gene-association testing. Full reporting of all adult patients 
with primary ITP is, however, only known to have transpired at the RLH haematology clinic, which 
documented 332 consecutive patients from 2000 to 2005 (RLH UKITP Sub-Cohort).   
As illustrated by Table 1, the female:male distribution of these patients overlaps well with 
the ratio believed to characterise the general population of adult patients with primary ITP. 
Estimates of median age of diagnosis among both genders vary considerably in the epidemiological 
literature, preventing the use of this trait for precise veridical assessment. Nevertheless, 
knowledge that ITP remains a hospital-based diagnosis in the UK and that the RLH serves as a 
high-volume primary haematological referral centre suggests that primarily referred participants 
within this sub-cohort are well representative of the general population of adult patients with 
primary ITP. Remaining RLH Sub-Cohort participants constitute patients secondarily referred 
from clinics throughout the UK. These individuals were referred almost exclusively as a result of 
first-line treatment failure and are, thus, considered potentially representative of the refractory, 
primary, adult ITP population. A comprehensive gauge of the external validity of these participants 
will only be possible following an analysis of referral patterns among consultant haematologists. 
Owing to the possible existence of a high referral threshold among specialists, these secondarily 
referred participants may ultimately prove more representative of the severe end of the 
refractory spectrum.  
 
Table A4-1: Demographic Comparison of the RLH UKITP Cohort with 
Population & Hospital-Based Estimates 
 
Demographic Variable 
RLH UKITP Sub-
Cohort Subset (N=109) 
Age at Diagnosis 
Hospital-Based 
Adult ITP 
Cohort7 
Age at Diagnosis 
Population-Based 
Adult ITP Cohort8 
Age at Diagnosis 
Age 39.2 (mean); 35.4 (median) N/A 56 (median)  
Female:Male Ratio 1.7:1 1.7:1.0 1.7:1.0 
Female Age 37.6 (mean); 34.9 (median) 37 (mean) 56 (median) 
Male Age 41.7 (mean); 37.9 (median) 41 (mean) 62 (median) 
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More ambiguity exists concerning the external validity of the second sub-cohort, the 
remaining 402 adult patients with primary ITP submitted for enrolment by consultant 
haematologists throughout the UK from 2002 to 2005 (Non-RLH UKITP Sub-Cohort). 
Approximately one-fifth of consultant haematologists in the UK (76) enrolled at least one  
consenting adult patient with primary ITP for study inclusion. On average, 3.6 patients were 
submitted per consultant, suggesting the possible inclusion of only a subset of the overall patient 
population visiting these clinics. At present, it is unclear to what degree participants comprising 
the enrolled sample are representative of this larger population. However, their potential to 
unlock valuable information concerning disease progression, treatment effectiveness, and co-
morbid disease burden in ITP is nonetheless strong.  
Representatives from GlaxoSmithKline (GSK) have expressed interest in the data that may 
be uncovered from the UKITP Cohort and, further, from all participants enrolled during the first 
two years of the Revised Adult ITP Registry launched in October 2008. The company and one of 
its global competitors, Amgen, have both developed novel thrombopoietin (TPO) agonists, 
eltrombopag/promacta and AMG 531/romiplostin respectively, which have shown favourable 
phase I, II, and III results in safely elevating platelet counts among adult patients afflicted with 
chronic primary ITP.9;10 However, owing to limited epidemiological research into this condition, 
there exists a paucity of descriptive and analytical information from which to base safety and data 
monitoring efforts, treatment indications, and marketing strategies. There has, therefore, been a 
convergence of clinical, regulatory, and epidemiological support for investigating accessible ITP 
populations.  
Investigation of patients’ hospital medical records suggested that information could be 
validly obtained through the development and implementation of a systematic extraction, a 
resource-intensive and, therefore, costly undertaking. Having carefully weighed the merits and 
potential drawbacks of initiating the extraction process, we have reached the conclusion that such 
expenditure would ultimately prove both feasible and worthwhile.
!
3. OBJECTIVES 
a) To compile an anonymised database of demographic, ITP-specific, and co-morbid 
disease information on UK patients representative of adult patients with primary ITP  
 
b) To describe and categorise disease progression of adult patients with primary ITP via 
platelet count and bleeding events 
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c) To document treatment practices for adult patients with primary ITP  
 
d) To estimate the burden of co-morbid conditions among adult patients with primary ITP 
 
i. To estimate the prevalence and incidence of cataracts, osteoarthritis, type 
II diabetes, hypertension, peptic ulcers, H. pylori infection, renal 
failure/impairment, chronic liver disease, myocardial infarction (MI), 
ischaemic stroke (IS), transient ischaemic attack (TIA), unstable angina 
(UA), deep vein thrombosis (DVT), pulmonary embolism (PE), 
splenomegaly, anaemia, thyroid disease, depression/anxiety, miscarriage, 
Cushing’s syndrome, Candida infection, pneumonia, other autoimmune 
disease, haematological malignancy, solid tumour malignancy, phototoxicity, 
and mortality (incidence only) among the primary adult ITP populations at 
the time of and following both diagnosis and treatment  
 
e) To develop and test a prognostic model for major bleeding among adult patients with 
primary ITP  
 
f) To test the relationship of thromboembolic events with (i) antiphospholipids at 
presentation, (ii), co-morbid conditions, (iii) common ITP treatments, and (iv) platelet 
count-categories at presentation among adult patients with primary ITP 
 
g) To test the relationship between (a) autologous 111In-labelled platelet sequestration 
pattern and (b) complete response at (i) 1-3 months, (ii) 6-12 months and (iii) last 
follow-up post splenectomy in adult patients with primary ITP 
 
h) To launch an international registry of adult patients with primary ITP   
 
4. RATIONALE OR CONTRIBUTION TO GSK 
Eltrombopag/Promacta (SB-497115-GR), a GSK-patented TPO agonist, has shown 
favourable Phase II and III results in significantly boosting peripheral platelet counts among adult 
ITP patients, prompting New Drug Application (NDA) filing with regulatory agencies in both the 
United States and Europe. 
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However, as previously detailed, there exists at present limited epidemiological 
information concerning disease progression, treatment effectiveness, and both natural and drug-
induced co-morbidities of ITP among adults:  
 
Various clinical dilemmas persist in newly diagnosed ITP…These include an estimation of 
the bleeding risk and the need for treatment in the individual patient and the inability to 
predict the disease course for the individual patient at the time of diagnosis.11   
 
Such information will be crucial for monitoring and interpreting long-term safety signals, for 
establishing evidence-based treatment guidelines, and for designing efficient marketing strategies. 
Analyses conducted on the information collected from this cohort will help provide these details. 
In this respect, the reports submitted as part of this initiative may be used to supplement the 
Safety Database submitted to the Food and Drug Administration (FDA) and other regulatory 
agencies.  
!
5. TARGET AUDIENCE 
Members of the ITP team at GSK have been fully supportive of this study, having expressed 
particular interest in obtaining detailed information concerning the disease progression in ITP via 
longitudinal peripheral platelet count and bleeding events as well as prevalence and incidence 
estimates of natural and drug-induced co-morbid conditions. As aforementioned, it is possible that 
the reports submitted as part of this study will be reviewed by regulatory agencies. These reports 
may further be placed on the Clinical Trial Registry at the discretion of the Worldwide 
Epidemiology (WWEpi) oncology division at GSK.  
 
6. METHODOLOGY 
6.1   Study Population 
The study population will be comprised by the existing 734-participant, adult ITP cohort 
(UKITP Cohort) initiated by Dr. Drew Provan at the Royal London Hospital (RLH) as well as all 
enrolees in the Revised Adult ITP Registry launched in October 2008.  
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The UKITP Cohort may itself be broken down into two distinct sub-cohorts; the first of 
these groups constitutes all adult patients with primary ITP having visited the RLH haematology 
clinic from 200 to 2005 (RLH UKITP Sub-Cohort). As previously documented, the female:male 
ratio of these 332 patients (1.7:1) is in accordance with population-based estimates of the sex 
distribution among the primary adult ITP population.8;12 Although conclusions concerning the 
external validity of this sample are difficult to extrapolate, assumptions that primarily and 
secondarily referred patients comprising it well represent the general and refractory populations 
of adult patients with primary ITP, respectively, appears sound; ITP is hospital-diagnosed in the 
United Kingdom, and the RLH UKITP Sub-Cohort represents a full sampling of a high-volume 
primary and secondary referral centre.  
Admittedly, more ambiguity exists concerning the external validity of the second sub-
cohort, the remaining 402 adult patients with primary ITP submitted for enrolment by consultant 
haematologists throughout the UK from 2002 to 2005 (Non-RLH UKITP Sub-Cohort). 
Approximately one-fifth of consultant haematologists in the UK (76) enrolled at least one 
consenting, adult patient with primary ITP for study inclusion. On average, 3.6 patients were 
submitted per consultant, suggesting the possible inclusion of only a subset of the overall patient 
population visiting these clinics. At present, it is unclear to what degree participants comprising 
the enrolled sample are representative of this larger population. However, owing to the relative 
rarity of ITP in the general adult population, the paucity of available epidemiological data on this 
condition, and the roughly commensurate investment of resources required for a cursory versus 
comprehensive investigation, it was deemed prudent to proceed with a full extraction of the 
hospital medical records of these patients.   
Investigation into the UKITP Cohort will be complemented by the Revised Adult ITP 
Registry, which is open to all residents in the UK. As illustrated by Figure 1, the Revised Adult ITP 
Registry = automatically subsumed all patients in the UKITP Cohort upon its initiation in October 
2008. In addition to undergoing a retrospective evaluation upon enrolment, all Revised Registry 
participants will be prospectively followed at annual intervals. The final component of the study 
population, then, will consist of all patients enrolled during the first two years of the Revised 
Registry.  
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Figure A4-1: Study Population 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
The validity of identified primary ITP cases represents a key strength of this study. Enrolled 
participants have all been explicitly diagnosed and submitted for study inclusion by specialists, 
arguably the gold-standard for case ascertainment for exclusionary conditions. Due to occasionally 
encountered difficulties during diagnosis (e.g., the possession of an incomplete family history), 
consultant haematologists will be queried during routine annual follow-up whether they have 
changed their initial diagnosis based upon information gleaned from subsequent clinical 
investigation. Only participants with unchanged diagnoses will be included for analyses.         
 
6.2   Design: Outcomes, Exposures, Covariates & Analysis  
In total, two series of three reports will be submitted to the WWEpi oncology division at 
GSK as part of the study. The first set of reports will centre on the retrospective investigation of 
the RLH UKITP Sub-Cohort while the second will encompass the entirety of retrospective and 
prospective data collected on combined study population. An analysis plan, which will be used as a 
foundation for these reports, is provided in Appendix A4-A1. 
 
 
 
Key 
RLH UKITP Sub-Cohort (N = 332) 
Non-RLH UKITP Sub-Cohort (N = 402) 
UKITP Cohort (N = 734) 
Revised Adult ITP Registry (N ~ 1,000) 
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Exposure, outcome, and covariate status will be extracted from patient hospital medical 
records at haematology clinics where registration transpired. The validity of information contained 
in patient hospital medical records has been well documented in the epidemiological literature. 
Concern will rather rest with the extraction process itself, which will be centre-specific. While 
hospital medical records at the RLH will be interrogated on two separate occasions prior to 
extraction, it is likely that such a rigorous methodology will not be possible elsewhere. Extraction 
procedures at both the RLH and a random subset of collaborating centres will be subject to a 
validation study as detailed in Section 6.5 of this proposal.  
 
6.3   Adverse drug experience/event measures 
N/A 
 
6.4   Data collection and management 
The timeline for the study is illustrated in Figure A4-2. All study-related information will be 
collected and managed by the lead epidemiologist and principal investigator. Non-anonymous 
participant-linked data will be stored on two secure, password-enables drives alone. All 
information accessed on external hardware or provided to GSK, third-parties, or the public will be 
fully-anonymised.  
 
Figure A4-2: Data Extraction & Deliverables Timeline 
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2010 
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Reports Submitted  
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6.5   Validation procedures 
A validation study will be initiated mid-way through the second phase of the investigation. 
Random samples will be drawn separately from RLH and Non-RLH participants for whom data has 
been extracted. The hospital medical records of participants comprising these validation samples 
will be forwarded to a clinical consultant who will independently extract information to be 
contrasted with the original extractions performed by study personnel.     
 
6.6   Sample size and power/precision calculations 
The paucity of epidemiological information on primary ITP in adults introduces an 
additional element of uncertainty to the already inexact science of sample size estimation. 
Inspection of the participant numbers required to detect plausable ranges of effect sizes for the 
sampling of independent variables shown in Table A4-3 suggests that the cumulative study 
population will be insufficiently powered to detect co-morbid ITP associations with 80% power at 
a 0.05 level of signifance. The information gathered on disease burden will, however, still yield 
valuable descriptive information regarding both the incidence and prevalence of these conditions 
while potentially generating associative hypotheses for subsequent epidemiological testing. With 
regard to the areas of disease progression and treatment effectiveness, it is believed that these 
calculations are illustrative of the likely adeqauteness of the cumulative study population to 
uncover existing associations.  
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Table A4-3: Selection of Sample Size Calculations13 
Variable Adult 
Population 
Age  
Population 
Incidence Rate/ 
Proportion  
Incidence 
Rate/ 
Proportion 
Among 
Exposed 
Detectable 
Shift 
(%) 
Number of ITP 
Patients Required per 
Exposed/Unexposed 
Cohort  
! = 0.05, 1-" = 0.80 
0.05 25% 1892 Cataracts 
 
 
! 43 
 
0.0414  
0.07 75% 257 
0.00095 25% 99,547 Long-Bone  
Fractures-Men 
 
Osteoarthritis 
Proxy 
 
Rate per person-year 
 
! 20 
 
0.0007615 
0.00133 75% 13,519 
0.00059 25% 154,697 Long-Bone  
Fractures-Female 
 
Osteoarthritis 
Proxy 
 
Rate per person-year 
 
! 20 
 
0.0004615 
0.00100 75% 11,171 
0.00342 25% 27,522 Myocardial 
Infarction-Male 
Rate per person-year 
 
< 65 
 
0.0027316 
0.00479 75% 3,740 
0.00083 25% 108,349 Myocardial 
Infarction-Female 
Rate per person-year 
 
< 65 
 
0.0006616 
0.00112 75% 17,629 
0.008 50% 788 Bleeding Events 
Rate per person-year 
Not 
Specified 
 
0.01617 
0.004 75% 292 
12.8% 25% 1,048 Mortality-Male 
Proportion  
 
! 18 
 
10.2%18 
17.9% 75% 125 
7.9% 25% 1,950 Mortality-Female 
Proportion  
 
! 18 
 
6.3%18 
11% 75% 253 
30% 88% 51 Platelet Counts-
Dichotomous  
(> 50 ! 109/L) 
Not 
Specified 
 
16%19 
50% 313% 11 
Platelet Counts-
continuous  
(platelets/mm3) 
Not 
Specified 
 
25,00019 
 
50,000           
  (sd: 
15,000) 
100% 8 
 
6.7 Discussion 
This study will effectively complement ongoing GPRD work on adult patients with primary 
ITP conducted by WWEpi. The validity of GPRD codes has been well documented in the 
epidemiological literature, and it is believed that the database will provide accurate, population-
based estimates on the incidence, prevalence, and co-morbid burden of primary ITP in adults in 
the UK.20 
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Concern exists, however, as to the precise composition of the ITP population within the 
GPRD, particularly the prorportion of individuals warranting treatment consideration. While a 
diagnosis of primary ITP in adults may be indicated in the instance of platelet counts below 150 ! 
109/L, treatment guidelines put forward by the BCSH recommend intervention only in limited 
circumstances, namely cases of presentation with platelet counts below 30 ! 109/L or symptomatic 
presentation with platelet counts below 50 ! 109/L.21 Documentation of platelet counts in adult 
patients with primary ITP in the GPRD is unfortunately sparse, with approximately one-third of 
this cohort having no reported platelet counts.20  
Though admittedly stemming from a potentially innumerable genreral population 
denominator, segments of the study cohort will likely be well representative of the general and 
refractory populations of adults with primary ITP. Proposed analyses on this cohort will, 
therefore, yield valuable information on both natural and drug-induced co-morbidites, which may 
more accurately reflect the disease burden among the population to which eltrombopag/promacta 
may be marketed. Access to longitudinal platelet counts for all study participants moreover, 
presents the unique opportunity to uncover the progression of general and refractory, primary 
ITP among adults and the effectiveness of current ITP treatments within these populations. A 
summary of the potential strengths and limitations of utilising the study population are enumerated 
in Table A4-4.  
 
Table A4-4: Potential Strengths and Limitations of the Study Population  
 
 
 
 
 
 
 
 
 
 
 
7. STUDY MANAGEMENT 
 
7.1   Ethical approval and subject consent 
will contain variable follow-up time 
(~1-30 years) on participants 
 
will serve as one of the largest  
cohorts of adult patients with primary ITP ever 
assembled 
 
primarily referred RLH UKITP Sub-Cohort will likely be 
well representative of the general population of  adults 
with primary ITP 
 
secondarily referred RLH UKITP Sub-Cohort 
potentially will likely be well representative of the 
refractory population of adults with primary ITP  
 
will contain longitudinal platelet counts on all patients, 
enabling unique analysis of 
 
• disease progression 
• treatment effectiveness 
• natural & treatment-induced 
comorbidities 
!
!will contain variable follow-up time        
 (~1-30 years) on participants 
 
 the external validity of the study population will, as a 
whole, be potentially innumerable  
 
the sample size of the RLH UKITP Sub-Cohort is 
moderately small 
 
requires a significant and costly extraction effort 
!
!!!!!!"#$%&'#()!*+,+#-#+.&)!
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7.1   Ethical approval and subject consent 
The London Research Ethics Committee (REC) granted ethical approval in September 
2009 for the collection of information corresponding to the field categories shown in Tables A4-5-
7. Approval extended to non-anonymous data compilation, discussed at greater length in Section 
7.2, DNA and RNA extraction and storage, genome-wide gene expression and SNP testing. All 
study participants will have provided informed written consent prior to enrolment, as documented 
by Appendices A4-A2 & A3.   
 
7.2   Subject confidentiality 
Approval for the compilation of non-anonymous data for the purposes of 
prospective tracking of study participants has been granted by the London REC. All 
printed or electronic information provided to third-parties or the public are required to 
be fully anonymised. Furthermore, no identifiable participant data will be accessed on 
GSK-owned hardware. The confidentiality of study participants will be fully respected in 
this regard.  
  
7.3   Reporting of adverse drug events 
N/A 
 
7.4   Study closure/uninterpretability of results 
N/A 
 
7.5   Study milestones 
Relevant study milestones are illustrated in Figure A4-2. The study commenced on October 
17th, 2007 and will conclude in the fourth quarter of 2010. Over this period, two series of three 
reports will be submitted to the WWEpi oncology division at GSK.  
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Table A4-5: Participant Data for Extraction-I 
 
Demographic Information: [Re-/Registration Form Only]  
• Registration Date 
• Patient Name, Date of Birth, Gender & Mailing Address 
• Centre Name, Phone Number & Mailing Address 
• Consultant Haematologist Name 
 
Miscellaneous:  
• Date of Diagnosis [Re-/Registration Forms Only] 
• Date of Last Clinic Visit  
• Platelet Count(s) (Count & Date) 
• Weight at Diagnosis [Re-/Registration Forms Only] 
• Change of ITP Diagnosis (Yes/No) [Annual Form Only] 
 
Treatment: (Yes/No; Date(s), Dosage(s) & Duration(s) where applicable)  
• Prednisolone 
• IVIg 
• Splenectomy (Laparoscopy/Laparotomy) 
• Anti-D 
• Methylprednisolone 
• Dexamethasone 
• Danazol 
• Dapsone 
• Azathioprine 
• Cyclophosphamide 
• Vinca Alkaloids 
• Mycophenolate 
• Plasmapheresis 
• Protein A Immunoadsortion 
• Interferon 
• Cyclosporine 
• Rituximab 
• Platelet Transfusion 
• Red Blood Cell Transfusion 
• H. pylori  Treatment 
• Vitamin C Supplements 
• Romiplostim 
• Eltrombopag 
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Table A4-6: Participant Data for Extraction-II 
Co-Morbid Conditions: (Yes/No, Date) 
• Cataracts 
• Osteoarthritis 
• Type II Diabetes 
• Hypertension 
• Peptic Ulcers 
• H. pylori Infection 
• Renal Failure or Impairment 
• Chronic Liver Disease 
• Myocardial Infarction 
• Ischaemic Stroke 
• Transient Ischaemic Attack 
• Deep Vein Thrombosis 
• Pulmonary Embolism 
• Splenomegaly 
• Thyroid Disease 
• Depression/Anxiety 
• Miscarriage  
• Cushing’s Syndrome 
• Candida Infection 
• Pneumonia  
• Other Autoimmune Disease 
• Haematological Malignancy 
• Solid Tumour Malignancy 
 
Bleeding Events: (yes/no, date)  
• Cutaneous bleeds  
• Bleeds from the oral cavity  
• Epistaxis  
• Uterine bleeds  
• Haematuria  
• Gastrointestinal bleeds  
• Intracranial haemorrhage  
• Muscle bleeds  
• Joint bleeds  
• Subconjunctival bleeds 
• Retinal bleeds 
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Table A4-7: Participant Data for Extraction-III 
Biochemical Fields (Levels at Diagnosis) [Re-/Registration Only] 
• Alanine Transaminase (ALT) 
• Aspartate Transaminase (AST) 
• Alkaline Phosphatase  (ALP) 
• Bilirubin  
 
Haematological Fields [Re-/Registration Form Except Haemoglobin & Neutrophils] 
• Haemoglobin (Levels at Diagnosis & Last Follow-Up)  
• Neutrophils (Levels at Diagnosis & Last Follow-Up) 
• White Blood Cells  
• Red Blood Cells  
• Mean Platelet Volume (MPV)  
• Blood Group (A, B, AB & O; Rh Positive/Negative) 
• Direct Agglutination Test (Yes/No; Positive/Negative) 
• Marrow Aspirate (Yes/No; Conclusions) 
• Trephine Biopsy (Yes/No; Conclusions) 
 
Immunological Fields (Levels at Diagnosis) [Re-/Registration Form Only] 
• Immunoglobulin  
o IgG 
o IgM 
o IgA 
• Anti-Nuclear Antibodies  
 
Coagulatory Fields (Levels at Diagnosis) [Re-/Registration Form Only] 
• Prothrombin Ratio (PT) 
• Activated Partial Prothrombin Time (APPT) 
• Lupus Anticoagulant (LA) 
• IgG-Anticardiolipin Antibody (aCL) 
• IgG-Anticardiolipin Antibody (aCL) 
• Reticulocyte Percentage  
 
Indium Scanning (t80%/t30 minutes spleen/liver ratio; date)  
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7.6   Study Advisory Committee 
The study advisory committee will consist of the following individuals serving in the capacities 
specified. Progress updates will be submitted to the study advisory committee quarterly.   
 
a) Dr. Dimitri Bennett (GSK)- administration, finance, planning & epidemiology  
 
b) Dr. Mike Colopy (GSK)- biostatistics 
 
c) Dr. Drew Provan (RLH)- administration, finance, planning & medicine  
   
d) Professor Adrian Newland (RLH)- planning & medicine 
 
f) Mr. Ameet Sarpatwari (Cambridge)- administration, finance, planning & epidemiology* 
         
7.7   Study reporting and publications 
The information contained in the study reports will be of interest to clinical haematologists, 
ITP patients, and the general public health community, presenting the potential for multiple 
conference presentations and peer-review manuscripts for publication. The principal investigator 
will be free to publish, present, and use study data as deemed fit, provided the provision of at least 
thirty-days for GSK to review and comment prior to submissions for third-party publication.  
As reports stemming from this study will not specifically detail safety information regarding 
GSK marketed products, their inclusion in the Clinical Trial Registry is not mandated but will 
rather be at the discretion of the WWEpi oncology division.  
 
7.8 Resourcing needs 
The resources required to tackle this project are fully documented in Table A4-8. In brief, the 
undertaking will necessitate the full-time employment of one study coordinator and one data 
manager. The part-time services of a a database consultant, a web programmer, a statistical 
analyst, and a clinical specialist will additionally be enlisted. The remaining resources required 
consistute communications services, information technology (IT) products, and overhead 
expenditures. The total estimated cost for this project is £312,875.   
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Table A4-8: Resourcing Needs 
Adult ITP Initiative Budget Proposal Cost Source 
PI   
Conferences 2,000 Not Applicable 
Travel   
Year 1 1,000 Not Applicable 
Year 2 (5% Inflation Adjustment) 1,050 Not Applicable 
Year 3 ((5% Inflation Adjustment) 1,103 Not Applicable 
Study Coordinator   
PhD & Maintenance Expenses   
Year 1   
University Composition Fee 11,571 University of Cambridge 
College Fee 2,001 University of Cambridge 
Maintenance 14,300 Queen Mary University of London 
Year 2 (5% Inflation Adjustment)   
University Composition Fee 12,149 University of Cambridge 
College Fee 2,100 University of Cambridge 
Maintenance 15,015 Queen Mary University of London 
Year 3 (5% Inflation Adjustment)   
University Composition Fee 12,758 University of Cambridge 
College Fee 2,205 University of Cambridge 
Maintenance 15,765 Queen Mary University of London 
Travel   
Year 1: Inter-UK Transport 500 Not Applicable 
Year 2: Inter-UK Transport (5% Inflation Adjustment) 525 Not Applicable 
Year 3: Inter-UK Transport (5% Inflation Adjustment) 551 Not Applicable 
Year 2: International Conference Transport & Accommodation 500 Not Applicable 
Year 3: As Above (5% Inflation Adjustment) 525 Not Applicable 
Data Manager   
Salary   
Year 1 31,739 Queen Mary University of London 
Year 2 (5% Inflation Adjustment) 33,326 Queen Mary University of London 
Year 3 (5% Inflation Adjustment) 34,992 Queen Mary University of London 
Travel   
Year 2: Inter-UK Transport 250 Not Applicable 
Year 3: Inter-UK Transport (5% Inflation Adjustment) 263 Not Applicable 
Year 2: International Conference Transport & Accommodation 500 Not Applicable 
Year 3: As Above (5% Inflation Adjustment) 525 Not Applicable 
Skills Development   
Year 2 500 Not Applicable 
Year 3 500 Not Applicable 
Mailing   
Stationary & Envelopes 2,500 Not Applicable 
Postage 2,500 Not Applicable 
Data Extraction   
Student Workers (£10 pounds/hours*10/hours/week*40 weeks*4 16,000 Not Applicable 
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students) 
Extraction Training 1,000 Not Applicable 
Validation Study   
Independent Expert Clinical Analysis (£75/hour*40 hours*2 weeks) 6,000 Not Applicable 
IT Services   
Database Services   
Remote Server & Front Page Design 15,000 Dendrite Ltd. 
Annual Maintenance   
Year 2 1,500 Dendrite Ltd. 
Year 3 1,500 Dendrite Ltd. 
Miscellaneous Database Services   
Year 1 (50 pounds per hour * 40 hours * 1 weeks) 2,000 Dendrite Ltd. 
Year 2 (5% Inflation Adjustment) 2,100 Dendrite Ltd. 
Web Design Services   
Web Construction (30 pounds per hour * 40 hours * 2 weeks) 2,400 
Association of Technology Staffing Companies: Freelance 
Web Designer 
Troubleshooting   
Year 2 (30 pounds per hour * 40 hours * 2 weeks) 2,400 
Association of Technology Staffing Companies: Freelance 
Web Designer 
Year 3 (5% Inflation Adjustment) 2,520 
Association of Technology Staffing Companies: Freelance 
Web Designer 
Analytical/Statistical Services (£30/hour * 40 hours * 
2 Weeks) 
2,400 Yoh Index of Technology Wages 2006: SAS Programmer 
Hardware   
Desktop-1 750 Dell 
Desktop-2 750 Dell 
Laptop 750 Dell 
Multi-Function Colour Laserjet: Printer, Scanner, Phone, Fax 500 HP 
Black & White Laser Printer (2x) 750 HP 
Toners &  Ink Cartridges 2,500 Not Applicable 
Software   
SAS 400 Single User License-Queen Mary University of London 
Various Software Site Licenses 1,000 Queen Mary University of London 
Miscellaneous Office Equipment   
Year 1 2,000 Not Applicable 
Year 2 2,000 Not Applicable 
Year 3 2,000 Not Applicable 
Publicity & Advertisement 5,000 Not Applicable 
Overhead 36,038 Queen Mary University of London 
Miscellaneous 404 Not Applicable 
 312,875  
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8. APPENDICES 
Appendix A4-A1: Analysis Plan (Page 1 of 8) 
 
 
Descriptive & Basic Analyses Report (Items I-IV)†‡ 
I. Baseline Demographics 
a. summary: demographics at presentation   
b. output: referral status (proportion & 95% confidence interval [CI]); gender (proportion & 95% CI); age-
continuous at presentation (median & range); age-group at presentation (proportion & 95% CI); platelet 
count-continuous at presentation (median & range); platelet count-categories at presentation (proportion & 
95% CI); initial ITP treatment within one month of presentation (proportion & 95% CI); wet bleeding at 
presentation (proportion & 95% CI); period prevalence of 24 co-morbid conditions at presentation 
(proportion & 95% CI) 
c. stratifying variables:  (1) none; (2) referral status; (3) referral status + gender (for all outputs except referral 
status & gender); (4) referral status + platelet count-categories at presentation (for all outputs except referral 
status & platelet count-categories at presentation) (5) referral status + age-dichotomous at presentation (for 
all outputs except referral status, age-continuous & age-categories at presentation); (6) referral status + 
gender + age-dichotomous at presentation (for all outputs except referral status, gender, age-continuous & 
age-group at presentation) 
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Appendix A4-A1: Analysis Plan (Page 2 of 8) 
II. Platelet Progression  
a. summary: platelet count v. time graphs  and documentation of platelet response (relative change of mean 
platelet count§) and disease relapse at 12 & 24 months post-diagnosis  
b. output: platelet count v. time graphs,  response (proportion & 95% CI) & disease relapse (proportion & 95% 
CI) 
c. stratifying variables: (1) none; (2) referral status; (3) referral status + gender; (4) referral status + age-
dichotomous at presentation; (5) referral status + ethnicity (6) referral status + common ITP treatment; (7) 
referral status + gender + age-dichotomous at presentation (for platelet count v. time graphs only); (8) 
referral status + gender + common ITP treatment (for platelet count v. time graphs only); (9) referral status 
+ age-dichotomous at presentation + common ITP treatment (for platelet count v. time graphs only); (10) 
referral status + gender + age-dichotomous at presentation + common ITP treatment (for platelet count v. 
time graphs only) 
 
III. Treatment Patterns  
a. summary: ITP treatment frequency (initial ITP treatment; cumulative ITP treatment-modality; and cumulative 
ITP treatment-number)  
b. output: initial ITP treatment-dichotomous within one month of presentation (proportion & 95% CI); common 
ITP treatment-categories (proportion & 95% CI); cumulative number of ITP treatments utilised by individual 
study participants (median & range)  
c. stratifying variables: (1) none; (2) referral status; (3) referral status + gender; (4) referral status + age 
 
IV. Co-Morbid Incidence** 
a. summary: post-presentation & common ITP treatment incidence of co-morbid conditions 
b. output: Incidence & 95% CI. Incidence will be provided using different time intervals (i.e., 1-90 days; 1-180 
days; 91-180 days; 181-360 days; 1-360 days; 1-2 years; Day 1- study end/follow up end).  Assuming Index 
Date (D) stands for time of diagnosis and Index Date (T) stands for treatment start date, there may be Index 
Date(s) (T[A-Z]), where A-Z stand for each respective type of treatment (i.e., IVIg, corticosteroids, 
splenectomy, and anti-D). Incidence will be provided as cumulative incidence (denominator is people: x out of 
y people, proportion & 95% CI) and incidence rates (denominator is person time, expressed per 10,000 
person years & 95% CI). As this study is descriptive and exploratory in nature, there will be no formal 
hypothesis testing, rendering power calculations unnecessary. Precision of point estimates for co-morbid 
events will be calculated via 95% CIs. Statistical modeling may further be conducted for the purpose of 
hypothesis generation. 
c. stratifying variables: (1) none; (2) referral status; (3) referral status + gender; (4) referral status + disease 
severity at presentation; (5) referral status + age-dichotomous at presentation; (6) referral status + common 
ITP treatment-dichotomous (for post-presentation only)  
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Appendix A4-A1: Analysis Plan (Page 3 of 8) 
Modelling 
Disease Progression Report (Items V & VI) 
V. Multivariable Model for Determining the Likelihood of Major Bleeding Events††‡‡ 
a. summary: development of prognostic model to a build risk score for major bleeding events 
b. epidemiological category: disease progression 
c. model(s): logistic regression 
d. response variable: major bleeding events  
e. predictor variables§§: age-continuous at presentation, gender, count-categories at presentation, wet bleeding 
at presentation, antinuclear antibodies at presentation, time since onset of disease, number of prior ITP 
treatments, splenectomy-status (other possible predictor variables maybe explored) 
 
VI. Multivariable Model for the Risk of Thromboembolic Events***††† 
a. summary: test of the relationship of thromboembolic events with (i) antiphospholipid antibodies at 
presentation  (ii) co-morbid conditions, (iii) common ITP treatment and (iv) platelet count-categories at 
presentation for the time interval 0-24 months post-diagnosis  
b. epidemiological category: co-morbid burden 
c. model(s): Cox proportional hazards (or) Poisson Regression 
d. response variable: thromboembolic events 
e. predictor variables: gender, antiphospholipid antibodies at presentation, corticosteroid treatment, IVIg 
treatment, anti-D treatment, splenectomy status, hypertension, diabetes, chronic renal failure, prior TE, 
count-categories at presentation, age-continuous at presentation, mean platelet count- one month prior to 
thromboembolic event, haematological malignancy, solid tumour malignancy, smoking, inflammatory bowel 
disease (other possible predictor variables may be explored)  
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Appendix A4-A1: Analysis Plan (Page 4 of 8) 
Treatment Effectiveness Report (Item VII) 
VII. Multivariable Model for Determining the Likelihood of Success from Splenectomy‡‡‡  
a. summary: tests of the relationship between (a) autologous 111In-labelled platelet sequestration pattern 
and (b) complete response at (i) 1-3 months (ii) 6-12 months and (iii) last follow-up post-splenectomy 
b. epidemiological category: treatment effectiveness; prognostic model 
c. model(s):  Multivariable logistic regression (exploration of absolute & relative risk) 
d. response variable: complete response (i) 1-3 months (ii) 6-12 months and (iii) last follow-up post-
splenectomy  
e. predictor variables: autologous 111In-labelled platelet sequestration pattern, gender, age-continuous at 
splenectomy (other possible predictor variables maybe explored)  
 
Note: Consultants of patients not undergoing splenectomy will be queried as to the reason(s) the 
procedure was not performed. Responses will be grouped into one of the following categories: test result, 
asymptomatic or mildly asymptomatic disease, patient choice, remission, co-morbid contraindication, other, 
and unspecified. Treatment usage among splenectomised and non-splenectomised patients at last follow-up 
will be compared. Fisher’s Exact Test will be used to evaluate differences in the proportion of patients 
undergoing splenectomy within autologous 111In-labelled platelet sequestration pattern strata and of males v. 
females lost and not-lost to follow-up as well as spenectomized and non-splenectomized patients. Student’s T 
Test will be used to inspect age differences between patients lost and not-lost to follow-up as well as 
spenectomized and non-splenectomized patients.   
Prospective Investigation 
 
Note: In addition to a “Descriptive and Basic Analyses Report-II,” the UK Adult ITP Team will work with 
GSK to develop two further study hypotheses in the second quarter of 2010, which will be addressed in 
deliverables “Disease Progression Report-II” and “Treatment Effectiveness Report-II.” All three of these 
phase II reports will incorporate both retrospective and prospective data (annual prospective follow-up of 
patients enrolled in the Registry).  
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Appendix A4-A1: Analysis Plan (Page 5 of 8) 
 
Table A1-1: Definition of Variables 
 
Age-continuous  0-99 years 
Age-dichotomous  0. < 50 years  
1. " 50 years  
Age-group A. 16-39 years 
B. 40-49 years  
C. 50-59 years 
D. 60-69 years 
E. 70-79 years 
F. " 80   years  
Anti-D treatment 0. no 
1. yes 
Antiphospholipid antibodies explanation: anticardiolipin (IgG or IgM) or 
lupus anticoagulant antibodies 
0. no 
1. yes 
Autologous 111In-labelled platelet 
sequestration pattern 
explanation: spleen:liver ratio at time of 80% 
destruction over spleen:liver ratio at time of 30 
minutes post-labelling; x ! 0.8 hepatic, 0.8 < x 
! 1.4 mixed; 1.4 < x ! 2.0 predominant 
splenic; x > 2.0 purely splenic 
0. purely splenic & predominant splenic 
1. mixed & hepatic 
Bleeding events A. cutaneous 
B. oral cavity 
C. epistaxis 
D. uterine 
E. haematuria 
F. gastrointestinal 
G. intracranial haemorrhage  
H. muscle  
I. subconjunctival 
J. retinal 
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Appendix A4-A1: Analysis Plan (Page 6 of 8) 
 
Co-morbid conditions§§§ A. cataracts 
B. peptic ulcer 
C. H. pylori infection 
D. renal failure or impairment 
E. chronic liver disease 
F. diabetes 
G. hypertension 
H. myocardial infarction 
I. ischaemic stroke 
J. transient ischaemic attack  
K. unstable angina 
L. deep vein thrombosis 
M. pulmonary embolism 
N. portal vein thrombosis 
O. hyperthyroidism 
P. hypothyroidism 
Q. systemic lupus erythematosus  
R. Cushing’s syndrome 
S. Candida infection 
T. haematological malignancy 
U. solid tumour malignancy 
V. phototoxicity 
W. splenomegaly 
X. anaemia 
Y. death 
Common ITP treatment-dichotomous 0. no 
1. yes 
Common ITP treatment-categories A. none 
B. corticosteroids 
C. intravenous immunoglobulin (IVIg) 
D. anti-D 
E. splenectomy 
Complete response explanation: count above 100 ! 109/L 
(NB: use of random-effects, repeated measures 
modelling may be explored)  
0. no 
1. yes 
Corticosteroid treatment 0. no 
1. yes 
Chronic renal failure 0. no 
1. yes 
Cumulative ITP treatment  0-10 treatments 
Diabetes 0. no 
1. yes 
Disease relapse count < 50 ! 109/L for " 2 weeks (with or 
without bleeding/rescue) or < 50 ! 109/L < 
2 weeks with bleeding or rescue. 
0. no 
1. yes 
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Appendix A4-A1: Analysis Plan (Page 7 of 8) 
Ethnicity A. black 
B. east Asian 
C. mixed 
D. south Asian 
E. white 
F. other 
Follow-up time (continuous) 0-360 person-months 
Gender  0. no 
1. yes 
Haematological malignancy-dichotomous 0. no 
1. yes 
Haematological malignancy-categories A. acute myeloid leukaemia  
B. chronic lymphocytic leukaemia 
C. chronic myeloid leukaemia 
D. hairy cell leukaemia 
E. non-Hodgkin's lymphoma 
F. Hodgkin's lymphoma 
G. myeloma 
Hypertension! 0. no 
1. yes 
Inflammatory bowel disease! 0. no 
1. yes 
Initial ITP treatment-dichotomous 0. no 
1. yes 
Initial ITP treatment-categories A. none 
B. corticosteroids 
C. IVIg 
D. anti-D 
ITP treatment A. none 
B. prednisolone 
C. IVIg 
D. splenectomy 
E. anti-D 
F. methylprednisolone 
G. dexamethasone 
H. danazol 
I. dapsone 
J. azathioprine 
K. rituximab 
L. cyclophosphamide   
M. vinca alkaloids 
N. mycopehnolate 
O. cyclosporine 
P. platelet transfusion 
Q. plasmapheresis 
R. protein A immunoadsortion 
S. interferon 
T. H. pylori eradication (triple-therapy) 
U. eltrombopag 
V. romiplostim 
IVIg treatment 0. no 
1. yes 
Major bleeding events explanation: Common Terminology Criteria for 
Adverse Events (CTCAE)-v4 grade 3 or higher 
bleed 
0. no 
1. yes 
! CONFIDENTIAL  
GlaxoSmithKline Research and Development – Worldwide Epidemiology 
203!
!
 
Appendix A4-A1: Analysis Plan (Page 8 of 8) 
Platelet count-continuous 1-1,500 ! 109/L 
Platelet count-categories 0. < 10 ! 109/L 
1. 10 ! 109/L ! X < 20 ! 109/L 
2. 20 ! 109/L ! X < 30 ! 109 /L 
3. 30 ! 109/L ! X < 50 ! 109/L  
4. 50 ! 109/L ! X < 150 ! 109/L 
5. 150 ! 109/L ! X < 400 ! 109/L 
6. " 400 ! 109/L 
Platelet count-response explanation: count  " 30 and at least doubling of 
the baseline count  
(NB: use of random-effects, repeated measures 
modelling may be explored)  
0. no 
1. yes 
Referral status  0. general practitioner referred  
1. haematologist referred 
Solid Tumour Malignancy-dichotomous 0. no 
1. yes 
Solid Tumour Malignancy-categories A. lip, oral cavity and pharynx 
B. digestive organs 
C. respiratory & intrathoracic organs 
D. bone & articular cartilage 
E. skin 
F. connective and soft tissue 
G. breast & female genital organs 
H. male genital organs 
I. urinary organs 
J. nervous system 
K. endocrine glands & related structures 
Smoking 0. no 
1. yes 
Splenectomy status 0. no 
1. yes 
Thromboembolic events (TE) A. none 
B. arterial TE 
i. myocardial infarction 
ii. ischemic stroke 
iii. transient ischemic attack 
iv. unstable angina 
v. other arterial TE 
C. venous TE 
i. pulmonary embolism 
ii. deep vein thrombosis 
iii. portal vein thrombosis 
D. other venous TE 
Wet bleeding 0. no 
1. yes 
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Appendix A4-A2: Study Informed Consent Agreement 
UK Adult ITP Registry 
Please initial boxes. 
1. I confirm that I have read and understand the Prospective Participant Overview of the 
UK Adult ITP Registry dated 20.08.09 (version 2.6) and have had the opportunity to 
address any questions or concerns that I had concerning the study.  
 
2. I understand that my participation is voluntary and that I am free to withdraw from the 
study at any time without giving any reason and without my medical care or legal rights 
being affected.  
 
3. I understand that ITP-related information from my medical notes may be extracted by 
responsible individuals comprising my clinical care team or the chief investigator’s study 
team. I give permission for these individuals to have access to my hospital records.  
 
4. I allow the study coordinator for the UK Adult ITP Registry to share fully-anonymised 
data with GlaxoSmithKline Research Ltd. and the Paediatric and Adult Intercontinental 
Registry on Chronic ITP (PARC-ITP) Study annually during the investigation. I understand 
that, as part of these collaborations, data will be shared with researchers in non-
European Economic Area (EEA) countries which may not have laws protecting patient 
privacy to the same extent as the UK Data Protection Act or European Law. Within 
these constraints, I am aware that study personnel will take all reasonable steps to 
protect my privacy.   
 
5. I agree to take part in the U.K. Adult ITP Registry  
 
 
 
      _____________________ _       __________              _____________________ _        
                Name of Patient                                   Date                                            Signature        
       _____________________ _       __________              _____________________ _        
        Name of Person Taking Consent                   Date                                            Signature      
           (if different from researcher) 
      _____________________ _       __________              _____________________ _            
            Name of Researcher                              Date                                            Signature      
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Appendix A4-A3: Subsequent Tissue Usage Informed Consent Agreement 
 
UK Adult ITP Registry 
Please initial boxes. 
 
1. I consent to the storage of my blood or saliva in a research tissue bank for use in future 
studies.  
 
2. I agree that the blood or saliva I have supplied may be used for future genetic research 
but not for research involving cloning or for the testing of inherited diseases without my 
express consent. 
 
3. I am aware that I am free to withdraw my consent for the subsequent storage and use of 
my blood or saliva at any time.  
 
If you have any preferences or exclusions for use of your donated blood, or any other comments, please 
include them here: 
 
 
 
 
 
 
 
      _____________________ _       __________              _____________________ _        
                Name of Patient                                   Date                                            Signature        
       _____________________ _       __________              _____________________ _        
        Name of Person Taking Consent                   Date                                            Signature      
           (if different from researcher) 
      _____________________ _       __________              _____________________ _            
            Name of Researcher                              Date                                            Signature      
 
 
 
 
 
 
